ORFeom Phagen Display des Darm Mikrobioms zur Identifizierung von Biomarkern entzündlicher Darmerkrankungen by Zantow, Jonas Max
 
 
 
 
 
 
ORFeome phage display to identify microbiome-derived biomarker 
candidates in the context of inflammatory disorders of the gut 
 
 
 
Von der Fakultät für Lebenswissenschaften 
 
der Technischen Universität Carolo-Wilhelmina zu Braunschweig 
 
zur Erlangung des Grades eines 
 
Doktors der Naturwissenschaften 
 
(Dr. rer. nat.) 
 
genehmigte 
 
D i s s e r t a t i o n 
 
 
 
 
 
 
 
 
 
 
 
von Jonas Max Zantow 
aus Filderstadt 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Referent: apl. Professor Dr. Michael Hust 
2. Referent: Professor Dr. Stefan Dübel 
3. Referentin: Professorin Dr. Susanne Engelmann 
eingereicht am: 13.07.2016 
mündliche Prüfung (Disputation) am: 24.10.2016 
 
Druckjahr 2016 
  
Vorveröffentlichungen der Dissertation 
 
Teilergebnisse aus dieser Arbeit wurden mit Genehmigung der Fakultät für 
Lebenswissenschaften, vertreten durch den Mentor der Arbeit,  
in folgenden Beiträgen vorab veröffentlicht: 
 
 
Publikationen 
 
Zantow, J., Just, S., Lagkouvardos, I., Kisling, S., Dübel, S., Lepage, P., Clavel, T. and 
Hust, M. (2016). Mining gut microbiome oligopeptides by functional metaproteome 
display. Sci Rep 6, 34337  
 
Zantow, J., Moreira, G.M.S.G., Dübel, S., Hust, M. (2016). ORFeome phage display. 
(eingereicht) 
 
 
Tagungsbeiträge 
 
Zantow, J. and Hust, M.: A vaccine pipeline - phage display for biomarker identification 
and generation of human antibodies for diagnostics and therapy. (Vortrag). BIT’s 8th 
Annual World Congress of Vaccine, Dalian, China (2016). 
 
Zantow, J., Just, S., Sokol, H., Haller, D., Lepage, P, Clavel, T. and Hust, M.: Functional 
Metaproteome Display - Applying phage display to discover novel serologic biomarkers 
for Inflammtory Bowel Disease. (Vortrag und Poster). 
4th Inflammatory and Immunological Biomarkers Summit, San Diego, USA (2015). 
 
Zantow, J., Just, S., Sokol, H., Haller, D., Lepage, P., Clavel, T. and Hust, M.: 
Metaproteome Display: A novel approach for biomarker discovery in Inflammatory Bowel 
Disease. (Vortrag). 2nd World Congress on Targeting Microbiota, Paris, Frankreich 
(2014). 
 
 
  

Table of Contents 
I 
 
Table of Contents  
Abbreviations .................................................................................................................. IV 
1  Introduction ............................................................................................................... 1 
1.1  Biomarkers ......................................................................................................... 1 
1.2  Biomarker discovery tools and their limitations ................................................... 1 
1.2.1  Classical proteomics .................................................................................... 1 
1.2.2  Protein and peptide arrays ........................................................................... 2 
1.2.3  Serologic expression cloning ....................................................................... 2 
1.2.4  E. coli display ............................................................................................... 3 
1.3  Phage display ..................................................................................................... 3 
1.3.1  Enrichment of open reading frames in phage display libraries ..................... 4 
1.3.2  Applications of ORFeome phage display ..................................................... 8 
1.4  Inflammatory bowel disease ............................................................................... 8 
1.4.1  Biomarkers in IBD ...................................................................................... 10 
1.4.2  IBD mouse models ..................................................................................... 12 
1.5  Objectives ......................................................................................................... 12 
2  Materials and Methods ........................................................................................... 13 
2.1  Material ............................................................................................................. 13 
2.1.1  Equipment .................................................................................................. 13 
2.1.2  Consumables ............................................................................................. 15 
2.1.3  Chemicals .................................................................................................. 15 
2.1.4  Enzymes and buffers ................................................................................. 16 
2.1.5  Antibodies .................................................................................................. 17 
2.1.6  Commercial kits and markers ..................................................................... 17 
2.1.7  Bacterial strains and bacteriophages ......................................................... 18 
Table of Contents 
II 
 
2.1.8  Murine specimens ...................................................................................... 18 
2.1.9  Human specimens ..................................................................................... 20 
2.1.10  Plasmids and oligonucleotides ............................................................... 21 
2.1.11  Peptides .................................................................................................. 23 
2.1.12  Media and supplements .......................................................................... 24 
2.1.13  Buffers and solutions .............................................................................. 25 
2.1.14  Software and databases ......................................................................... 27 
2.2  Methods ............................................................................................................ 28 
2.2.1  Bacterial cultivation techniques .................................................................. 28 
2.2.2  Transformation of bacteria ......................................................................... 28 
2.2.3  Phage handling .......................................................................................... 29 
2.2.4  Molecular biological methods ..................................................................... 32 
2.2.5  Panning of metaproteome phage display libraries ..................................... 38 
2.2.6  Recombinant protein expression ................................................................ 39 
2.2.7  Immunological methods ............................................................................. 42 
3  Results ................................................................................................................... 46 
3.1  Metaproteome display in experimental ileitis (TNF∆ARE/+ mouse model) ........... 46 
3.1.1  Construction of gut metaproteome phage display libraries ........................ 46 
3.1.2  NGS analysis of metaproteome phage display libraries ............................. 48 
3.1.3  Selection of immunogenic oligopeptides from metaproteome phage display 
libraries ................................................................................................................... 50 
3.1.4  Validation of oligopeptide immunogenicity by immunoblot ......................... 50 
3.1.5  Validation of TNF∆ARE/+ specific immune responses by ELISA ................... 52 
3.1.6  Time dependent occurrence of biomarker candidates ............................... 55 
3.2  Metaproteome display in inflammatory bowel disease (clinical IBD samples) .. 56 
3.2.1  Construction of gut metaproteome phage display libraries ........................ 57 
Table of Contents 
III 
 
3.2.2  Selection of immunogenic oligopeptides from metaproteome phage display 
libraries ................................................................................................................... 59 
3.2.3  Validation of IBD specific immune responses by ELISA ............................ 64 
3.2.4  Recombinant production of biomarker candidates ..................................... 67 
3.2.5  Assessment of diagnostic performance of a biomarker panel (peptide/ 
recombinant protein) ............................................................................................... 68 
4  Discussion .............................................................................................................. 71 
5  Outlook ................................................................................................................... 78 
6  Summary ................................................................................................................ 79 
7  Acknowledgements ................................................................................................ 80 
8  List of Figures ......................................................................................................... 82 
9  List of Tables .......................................................................................................... 83 
10  References .......................................................................................................... 85 
11  Supplemental Information .................................................................................... 96 
11.1  Supplementary tables ................................................................................... 96 
11.2  Supplementary figures .................................................................................. 98 
11.3  Sequences .................................................................................................. 100 
11.3.1  Mouse approach ................................................................................... 100 
11.3.2  Human approach .................................................................................. 100 
11.4  Sequence alignments .................................................................................. 100 
11.4.1  JOZ191-G8 ........................................................................................... 100 
11.4.2  JOZ241-A4 ........................................................................................... 103 
11.4.3  JOZ241-C4 ........................................................................................... 107 
11.4.4  JOZ242-C9 ........................................................................................... 111 
 
  
Abbreviations 
IV 
 
Abbreviations 
 
% Percent 
+ Wildtype, positive 
°C Degree celsius 
µg Microgram(s) 
µL Microliter(s) 
µM Micromolar 
ACCA Anti-chitobioside 
antibodies 
ALCA Anti-laminaribioside 
antibodies 
AMCA Anti-mannobioside 
antibodies 
ANCA Anti-neutrophil 
cytoplasmic antibodies 
APS Ammonium persulfate 
ARE AU-rich elements 
ASCA Anti-Saccharomyces 
cerevisiae antibodies 
AUC Area under curve 
BLAST Basic Local Alignment 
Search Tool 
bp Basepair(s) 
BSA Bovine serum albumine 
CD Crohn’s disease 
cDNA Complementary DNA 
cfu Colony forming unit(s) 
conc. Concentration 
conv. Conventional 
CRP C-reactive protein 
DAB 3,3′-Diaminobenzidine 
DNA Deoxyribonucleic acid 
E. coli Escherichia coli 
EDTA Ethylenediaminetetra-
acetic acid 
ELISA Enzyme-linked 
immunosorbent assay 
ESR Erythrocyte sedimentation 
rate 
FACS Fluorescence-activated 
cell sorting 
FMT Fecal microbiota 
transplantation 
Fwd. Forward 
g Gram(s), earth 
acceleration 
Gbp Gigabasepair(s) 
gDNA Genomic DNA 
gIII M13 minor coat protein III 
gene 
GM-CSF Granulocyte macrophage 
colony-stimulating factor 
GP2 Glycoprotein 2 
h Hour(s) 
HPLC High performance liquid 
chromatography 
HRP Horseradish peroxidase 
IBD Inflammatory bowel 
disease 
Abbreviations 
V 
 
IgA Immunoglobulin A 
IgG Immunoglobulin G 
IgM Immunoglobulin M 
IMAC Immobilized metal ion 
affinity chromatography 
IPTG Isopropyl-β-D-
thiogalactopyranosid 
kb Kilobase(s) 
kDa Kilodalton(s) 
kV Kilovolt(s) 
M Molar 
mA Milliampere(s) 
MDA Multiple displacement 
amplification 
min Minute(s) 
mL Milliliter(s) 
mM Millimolar 
mRNA Messenger RNA 
MS Mass spectrometry 
MTP Microtiter plate 
MW Molecular weight 
MWCO Molecular weight cut-off 
MyD88 Myeloid differentiation 
primary response protein 
88 
ng Nanogram(s) 
NGS Next generation 
sequencing 
nm Nanometer(s) 
nt Nucleotide(s) 
OD600 Optical density at wave 
length 600 nm 
OmpC Outer membrane protein 
C 
OmpW TonB-linked outer 
membrane protein 
ORF Open reading frame 
PAB Anti-pancreas antibodies 
PAGE Polyacrylamide 
gelelectrophoresis 
pANCA Atypical perinuclear 
antineutrophilic 
cytoplasmic antibodies 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction
pelB Pectate lyase B leader 
sequence 
pIII M13 minor coat protein III 
pVIII M13 major coat protein 
VIII 
Rev. Reverse 
RNA Ribonucleic acid 
Rpm Rounds per minute 
rRNA Ribosomal RNA 
s Second(s) 
SAICAR Phosphoribosylamino-
imidazolesuccino-
carboxamide 
SDS Sodium dodecyl sulfate 
SEREX Serologic expression 
cloning 
SPF Specific pathogen free 
TEMED N,N,N',N'-
Tetramethylethylendiamin 
Abbreviations 
VI 
 
tetR Tetracycline repressor 
TNF Tumor necrosis factor 
U Unit(s) 
UC Ulcerative colitis 
UV Ultra-violet 
V Volt(s) 
v/v Volume per volume 
w/v Weight per volume 
wt Wildtype 
Δ Delta, deletion 
λ Phage lambda, wave 
length 
3’ UTR 3’ untranslated region 
Introduction 
 
1 
 
1 Introduction 
1.1 Biomarkers 
Biomarkers are indispensable tools for diagnostics and clinical disease management and 
can be measured in different body fluids. Due to the ease of collection, blood serum is the 
most convenient source for biomarker measurements, it circulates through all body 
regions and tissues and contains numerous proteins that can be measured for diagnostic 
purposes. Immunoglobulins in particular comprise a group of serum proteins which can 
be indicative of specific diseases. Countless diagnostic ELISAs and other assays rely on 
the detection of specific immunoglobulins. Technological advances such as protein 
microarrays, peptide microarrays or Luminex multiplex assays today also allow fast and 
cost-efficient measurement of complex patterns of antibody responses (I. H. Khan et al., 
2011; Ravindran et al., 2014; Robinson et al., 2002; Schirwitz et al., 2012; van den Berg 
et al., 2011). However, the identification of the antigens that trigger these specific systemic 
antibody responses is still difficult and limits the application of these technologies. 
1.2 Biomarker discovery tools and their limitations 
In order to develop efficient diagnostics and identify target structures of specific antibody 
responses indicative for disease or inflammatory disorders, several technologies have 
been developed for biomarker discovery but are limited in one or the other way. 
1.2.1 Classical proteomics 
Classical proteomic studies to identify pathogen proteins for diagnostic applications 
typically rely on the cultivation of the pathogen followed by 2D-PAGE and immunoblot of 
the proteome using patient sera and protein identification by mass spectrometry (MS) 
(Delvecchio et al., 2006; Jacobsen, Meens, Baltes, & Gerlach, 2005; LaFrentz, LaPatra, 
Call, Wiens, & Cain, 2011). But proteome analysis after in vitro cultivation does not allow 
the identification of proteins that are only expressed during host-pathogen interactions. To 
identify immunogenic proteins that are specifically important in pathogenesis, the 
pathogen has to be cultivated in direct contact with the host to ensure gene expression 
patterns reflecting the true pathogenicity situation. While this approach has been applied 
with some success, its inherent problem is that the pathogen proteome will most likely be 
overwhelmed by that of the host (Zhang, Chromy, & McCutchen-Maloney, 2005). Further, 
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two other groups of potential biomarkers also usually fail to be identified by classical 
proteome analysis. Proteins with a molecular mass smaller than 10 kDa or weakly 
expressed proteins may not be identified by 2D-PAGE/MS (Beranova-Giorgianni, 2003; 
Rabilloud, Chevallet, Luche, & Lelong, 2010; Urquhart, Cordwell, & Humphery-Smith, 
1998). 
1.2.2 Protein and peptide arrays 
As an alternative, arrays with several hundred proteins spotted on glass slides and 
subsequently incubated with patient sera have been used for biomarker discovery. 
Immunogenic proteins from pathogens (Danckert, Hoppe, Bier, & von Nickisch-Rosenegk, 
2014; Hoppe, Bier, & von Nickisch-Rosenegk, 2013; Kunnath-Velayudhan et al., 2010), 
E. coli-derived biomarkers for inflammatory bowel disease (IBD) (C. S. Chen et al., 2009), 
and exposure related antibody responses to proteins from Plasmodium falciparum (Helb 
et al., 2015) were identified by protein arrays. Even though microarrays allow the 
screening of several hundred target proteins at a time, the technology is laborious and 
expensive as each protein must be produced in a recombinant manner. Peptide 
microarrays can be produced with potentially millions of individual sequences (Schirwitz 
et al., 2012) allowing to cover entire proteomes, but they are still limited to only detect 
antibodies binding to short linear epitopes. 
1.2.3 Serologic expression cloning 
Gene library based screening technologies potentially offer a workaround for the above 
limitations. Serologic expression cloning (SEREX), a technology developed in the 1990s, 
relies on the expression of cDNA libraries in E. coli using lytic phage vectors (Y. T. Chen, 
Gure, & Scanlan, 2005). The cells are then plated and produce cDNA library encoded 
proteins intracellularly. The λ phage causes cell lysis and the resulting plaques containing 
the expressed proteins are transferred to a membrane that is stained using patient sera. 
The SEREX technology was initially developed for serologic analysis of tumor cDNA 
expression libraries (Türeci, Sahin, & Pfreundschuh, 1997), but was also used to identify 
bacterial flagellin as a dominant antigen associated with Crohn's disease using an 
expression library constructed from metagenomic DNA of the caecum of a transgenic 
mouse model for experimental colitis (Lodes et al., 2004). However, handling of lytic 
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phage, maintenance of the phage library, and laborious screening procedures are major 
drawbacks of this technology. 
1.2.4 E. coli display 
Instead of cytoplasmic expression of recombinant proteins and release by cell lysis, large 
libraries may also be screened by displaying peptides or proteins on the surface of 
selectable particles. Random peptide libraries displayed on E. coli cells were enriched for 
displayed epitopes specifically reactive with sera from celiac disease patients using 
fluorescent activating cell sorting (FACS). Subsequent directed peptide evolution and 
further sorting steps revealed biomarker candidates for the disease (Ballew et al., 2013). 
However, working with sera and E. coli cells as display chassis requires additional 
subtraction steps using control immunoglobulins, since antibodies reactive towards E. coli 
proteins usually are present. This drawback may be especially problematic for the 
identification of bacterial antigens in the context of gut-related diseases. 
1.3 Phage display 
The biomarker discovery approach of the present study depends on phage display, a 
technology initially invented by G.P. Smith in 1985 (Smith, 1985). To allow the display of 
heterologous proteins on the surface of phage particles, they are fused to a structural M13 
phage protein whereas the corresponding coding DNA sequence of the heterologous 
protein is packaged in the same phage particle.  
Phage display can be used to identify protein interaction partners based on the binding 
characteristics of the presented heterologous protein. Therefore, the desired interaction 
partner is immobilized on a solid surface and subsequently incubated with the protein 
displaying phage particles. Stringent washing removes non-bound phage particles and 
the phage displaying proteins that specifically bind to the immobilized interaction partners 
are enriched at the solid surface. Elution of bound phage particles allows infection of 
E. coli to provide the coding DNA of the selected proteins for DNA sequencing. 
The main application of phage display is the selection of human antibodies from antibody 
gene libraries (Breitling, Dübel, Seehaus, Klewinghaus, & Little, 1991; Hoogenboom, 
2005; McCafferty, Griffiths, Winter, & Chiswell, 1990) and was used to generate antibodies 
for diagnostics (Fuchs et al., 2014), therapy (Mazumdar, 2009) as well as detection 
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reagents for basic research (Bradbury, Sidhu, Dübel, & McCafferty, 2011; Dübel, 
Stoevesandt, Taussig, & Hust, 2010).  
However, phage display has also been used for epitope mapping of antibodies (Blüthner, 
Bautz, & Bautz, 1996; Zhou et al., 2013). Here, the antigen cDNA is randomly fragmented 
and cloned into a phage display vector. Based on the protein interaction between the 
antibodies and the displayed peptides, the DNA fragments coding for the epitope can be 
selected. 
The phage display technology was further used for the identification of allergens (Crameri 
& Walter, 1999; Kodzius et al., 2003; Rhyner et al., 2004) and the identification of 
immunogenic proteins of pathogens, e.g. Mycobacterium tuberculosis (Liu et al., 2011), 
Mycoplasma mycoides (Miltiadou, Mather, Vilei, & Du Plessis, 2009), the rickettsia 
Cowdria ruminantium (Fehrsen & du Plessis, 1999) or the eukaryotic pathogen Taenia 
solium (Gonzalez et al., 2010) by cloning cDNA or whole genome fragments. However, 
non-directional cloning of cDNA or whole genome fragments into phage display vectors 
result in the majority of sequences not encoding any protein. 
1.3.1 Enrichment of open reading frames in phage display libraries 
Only one out of eighteen randomly cloned DNA fragments statistically result in correct 
open reading frames (ORFs). This means, only fragments cloned in the correct 
orientation, correct reading frame and fragments with the correct length do not lead to 
frameshifts. Additional stop codon containing “junk” sequences originate from non-coding 
DNA like gene regulatory elements. The “junk” content in libraries derived from eukaryotic 
genomic DNA is even more increased as introns account for a large portion of the 
eukaryotic genome. The propagation of phage without inserts or out-of-frame insert is 
more favored and in consequence affecting phage library composition and complexity as 
well as the proportion of protein displaying particles which dramatically hampers the 
panning success (Hust et al., 2006; Stratmann & Kang, 2005). Therefore, decreasing the 
portion of DNA fragments in the library that do not code for a correct protein sequence 
substantially increases the chance to eventually identify specific protein interactions. 
To address this problem, the DNA libraries should be enriched for ORFs. Cloning cDNA 
upstream of a selection marker (e.g. β-lactamase conferring ampicillin resistance) in an 
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E. coli vector allows the enrichment of ORFs as only DNA fragments without stop codons 
and cloned in-frame with the β-lactamase gene allow the expression of β-lactamase and 
the corresponding E. coli clone can grow in selection medium supplemented with 
ampicillin (Seehaus, Breitling, Dübel, Klewinghaus, & Little, 1992). However, this method 
is tedious, too, since the inserts have to be subcloned into a phage display vector after 
ORF enrichment to allow selection of protein interaction partners (Faix et al., 2004). 
For phage display, the protein of interest is displayed by fusion to an M13 phage coat 
protein, typically minor coat protein 3 (pIII). A phage particle has about five pIII copies and 
this protein provides the initial binding of the phage to the E. coli F pilus to initiate infection. 
Consequently, a phage particle without pIII is non-infectious and cannot be amplified. Due 
to their independent replication and regulation, phage display vectors are usually 
phagemids, i.e. plasmids that can be packaged into phage particles and contain the 
coding DNA for the foreign protein fused to the pIII gene but no other phage proteins. In 
order to complement the missing phage proteins like major coat protein pVIII and other 
necessary non-structural proteins, the E. coli cells have to be infected with a helperphage. 
Different antibiotics resistances and origins of replication (ori) allow the coexistence of 
phagemid and helperphage genome in the same E. coli cell and an attenuated packaging 
signal in the helperphage genome ensures that the phagemid is preferably packaged into 
the phage particle. 
The enrichment for correct ORFs and subsequent functional selection using phage display 
without any further cloning steps was enabled by a special helperphage (Figure 1-1), 
referred to as “Hyperphage” (M13K07ΔgIII) (Rondot, Koch, Breitling, & Dübel, 2001; 
Soltes et al., 2007). 
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Figure 1-1: Schematic illustration of an oligopeptide phage, phagemid library vector and ORF enrichment using 
“Hyperphage”. Phage display links genotype and phenotype, as the genetic information coding for the 
displayed protein or oligopeptide is contained on the phagemid packaged in the same phage particle. Non-
directional cloning of DNA fragments only lead to a minor fraction of insert encoding proteins. When using a 
special helperphage (“Hyperphage”, deleted pIII gene), the phagemid encoded pIII fusion protein is the only pIII 
source. Infectious phage particles are only assembled if the cloned DNA sequence is in-frame with the pIII gene 
and does not contain any stop codon leading to an enrichment of ORFs in a library. At the same time, the 
encoded protein is displayed on the phage particle as fusion protein with minor coat protein III (pIII). 
“Hyperphage” is a unique helperphage as it has a deletion in the pIII gene (genotype pIII-) 
but carries functional pIII proteins and therefore is infectious (phenotype pIII+). Infection 
of E. coli provides it with all phage proteins except from pIII and consequently does not 
result in the production of infectious helperphage particles. Infection with “Hyperphage” 
allows the enrichment of ORFs encoded in suitable phagemids, as the phagemid is the 
only pIII source and is only produced if the randomly fragmented DNA cloned upstream 
of the pIII gene is in-frame with the pIII gene and without stop codon (Figure 1-1) ORF 
enriched phage display libraries (ORFeome phage display) can directly be used to select 
immunogenic proteins in a panning using patient sera (Figure 1-2). Specifically bound 
proteins or oligopeptides are usually enriched over 2-3 rounds of panning and 
immunogenic proteins as potential biomarker candidates are finally identified by 
monoclonal ELISA and DNA sequencing. 
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Figure 1-2: Schematic illustration of a panning procedure. ORF-enriched phage display library is applied to 
serum antibodies immobilized on a solid surface. Stringent washing removes non-bound oligopeptides. Elution 
and reinfection of E. coli allows the amplification of bound oligopeptide phage after coinfection with a 
helperphage. Monoclonal screening by ELISA identifies immune-reactive oligopeptides and the biomarker 
candidate is subsequently identified by DNA sequencing. 
Thus, ORFeome phage display combines the positive selection of ORFs from whole 
genomes and metagenomes with the functional display of protein fragments coded by 
these sequences. 
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1.3.2 Applications of ORFeome phage display 
The ORFeome phage display technology was used to identify novel immunogenic 
proteins from two different Mycoplasma species (Kügler et al., 2008; Naseem et al., 2010), 
Salmonella Typhimurium (Meyer et al., 2012) and Neisseria gonorrhoeae (Connor, 
Zantow, Hust, Bier, & von Nickisch-Rosenegk, 2016). The technology was also validated 
to work with eukaryotic cDNA, as immunogenic saliva proteins involved in tick feed were 
identified from Ixodes scapularis (Becker et al., 2015). 
Despite ORFeome phage display can overcome certain limitations of other biomarker 
discovery technologies, proteins have to be able to be expressed in E. coli and displayed 
on phage particles. Further, ORFeome phage display usually only displays protein 
domains or oligopeptides and not whole proteins on the surface. 
However, as ORFeome phage display is independent of cultivation and does not rely on 
sequenced or annotated genomes, it can be applied on complex microbial communities. 
In a recent study, a ruminal metasecretome was analyzed using phage display (Ciric et 
al., 2014). The authors cloned a rumen bacterial metagenome library in a phage display 
vector and enriched the library for secreted proteins by packaging with a pIII deficient 
helper phage (VCSM13d3, (Rakonjac, Jovanovic, & Model, 1997)). Only cloned gene 
fragments coding for endogenous signal peptides resulted in a pIII fusion protein and 
functional phage particles were sarkosyl resistant. The enriched metasecretome library 
was subsequently analyzed by next generation sequencing. The logical next step and aim 
of the present work was the use of metagenomic DNA for a functional metaproteome 
display applying the ORFeome phage display technology and selection of biomarker 
candidates based on protein-protein interactions. 
1.4 Inflammatory bowel disease 
Inflammatory bowel diseases (IBD) are idiopathic chronic relapsing inflammatory 
disorders of the gastro-intestinal tract characterized by bloody diarrhea and abdominal 
pain. The two major phenotypes of IBD are Crohn’s disease (CD) and ulcerative colitis 
(UC). CD is characterized by a patchy transmural inflammation in ileum and colon 
whereas UC only affects the colon and rectum with continuous proximal moving mucosal 
inflammation. 
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IBD is a global burden with highest incidence in developed countries (Cosnes, Gower-
Rousseau, Seksik, & Cortot, 2011; Molodecky et al., 2012). Estimated 2.5 - 3 million 
Europeans (Burisch, Jess, Martinato, & Lakatos, 2013), 233,000 Canadians (Rocchi et 
al., 2012) and 1.2 million individuals in the US (Kappelman, Moore, Allen, & Cook, 2013) 
are affected. The economic burden in 2014 was estimated to range between 14.6 and 
31.6 billion USD in the US alone (Mehta, 2016). 
Despite the etiology of IBD is not fully understood, it is believed to result from an aberrant 
immune response towards the gut microbiota in a genetically susceptible host. Genetic 
predisposition markers comprise mutations in genes associated with microbial sensing 
(Duerr et al., 2006; Hugot et al., 2001; Jostins et al., 2012). Moreover, shifts in microbiota 
composition are associated with IBD (Gevers et al., 2014; Manichanh et al., 2006), 
highlighting the crucial role of the microbiome in IBD pathogenesis. 
The treatment of CD and UC is as individual-specific as the disease. Surgery in CD may 
become necessary to treat complications and colectomy can cure intestinal symptoms in 
UC but a cure without removing large parts of the intestines is not available. IBD 
management is mostly limited to treat the symptoms and to induce and maintain disease 
remission using chemical immunosuppressive and anti-inflammatory drugs (Bernstein, 
2015; Triantafillidis, Merikas, & Georgopoulos, 2011) as well as biologicals such as the 
monoclonal anti-TNF antibodies infliximab, adalimumab and certolizumab pegol (Danese 
et al., 2014; Peyrin-Biroulet, 2010; Peyrin-Biroulet et al., 2008). Another monoclonal 
antibody, vendolizumab, was approved by FDA and EMA in 2014 for CD and UC 
treatment. Vendolizumab blocks α-integrins and prevents leukocytes to migrate into the 
intestinal mucosa (Raine, 2014). But biologicals are expensive and good biomarkers to 
identify drug responders and non-responders are needed. 
With respect to the gut microbiome, antibiotics treatment was reported to have beneficial 
effects on disease activity in CD and UC (K. J. Khan et al., 2011). Addressing a pathogenic 
dysbiosis of the gut microbiome in IBD, the experimental treatment of fecal microbiota 
transplantation (FMT) has gained attention in the last years. A recent study reported FMT 
to induce remission in UC patients (Moayyedi et al., 2015) but more randomized trials are 
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needed to evaluate the efficacy of FMT for IBD treatment (Colman & Rubin, 2014; 
Moayyedi, 2016; Rossen et al., 2015). 
1.4.1 Biomarkers in IBD 
Biomarkers in IBD comprise different fecal markers such as lactoferrin and calprotectin as 
well as serologic markers like C-reactive protein (CRP) and erythrocyte sedimentation 
rate (ESR). Besides CRP and ESR to assess an inflammatory state, specific humoral 
immune responses have been associated with IBD (Iskandar & Ciorba, 2012). These IgG 
and IgA responses comprise autoantibodies and a broad panel of antibodies against 
microbial antigens such as carbohydrate structures of yeast and bacterial proteins which 
were identified using different biomarker discovery approaches (Table 1-1). 
The use of antibodies as diagnostic, prognostic or predictive biomarkers in IBD has 
extensively been reviewed (Bonneau et al., 2015; Ferrante et al., 2007; Peyrin-Biroulet, 
Standaert-Vitse, Branche, & Chamaillard, 2007; Prideaux, De Cruz, Ng, & Kamm, 2012) 
concluding that despite a broad panel of IBD-associated immune responses was 
published in the last decade (Table 1-1), their clinical usability is still very limited.  
Alone serologic assessment of pANCA and ASCA has found clinical application to aid 
distinguishing CD and UC patients with ASCA+/pANCA- being indicative for CD and 
ASCA-/pANCA+ for UC. According to a meta-analysis of 60 studies with 7860 IBD 
subjects, CD patients can be distinguished from UC patients with 55 % sensitivity and 
93 % specificity (Reese et al., 2006). In a recently published study referring to a 
commercial diagnostic test (Prometheus® IBD sgi™) the combination of serologic, genetic 
and inflammatory markers enhanced the diagnostic performance over single markers or 
the serologic marker panel alone (Plevy et al., 2013). Moreover, increased antibody titers 
were associated with a more complicated disease course in CD (Dubinsky et al., 2008; 
Ferrante et al., 2007; Mow et al., 2004; Tamboli, Doman, & Patel, 2011) and lower 
response to anti-TNF treatment in UC (Kevans et al., 2015; Nguyen, Nguyen, & Bechtold, 
2015). 
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Table 1-1: Summary of published IBD antibody biomarkers 
Marker Description Discovery approach Reference 
Autoantibodies 
ANCA 
pANCA 
Anti-neutrophil 
cytoplasmic antibody 
Immunofluorescence, fixed 
cell ELISA 
(Rump et al., 1990; 
Saxon, Shanahan, 
Landers, Ganz, & 
Targan, 1990) 
PAB 
Anti-GP2 
Anti-pancreas 
antibodies 
(glycoprotein 2) 
Immunofluorescence using a 
panel of tissues and IBD 
sera, antigen identification by 
2D-Immunoblot and MALDI-
TOF MS 
(Roggenbuck et al., 
2009; Stöcker et al., 
1987) 
Anti-GM-CSF 
Antibodies against 
granulocyte-
macrophage colony-
stimulating factor 
(GM-CSF) 
ELISA (Han et al., 2009) 
Antibodies against glycans 
ASCA 
Anti- Saccharomyces 
cerevisiae antibodies 
(mannan) 
ELISA against S. cerevisiae 
preparations (Main et al., 1988) 
Anti-L 
Anti-C 
ALCA 
ACCA 
AMCA 
Antibodies against 
laminarin, chitin, 
laminaribioside, 
chitobioside and 
mannobioside 
Glycan array using CD 
serum samples 
(I. Dotan et al., 
2006; Dotan, 
Altstock, Schwarz, & 
Dukler, 2006; Seow 
et al., 2009) 
Antibodies against bacterial proteins 
Anti-OmpC 
Antibodies against E. 
coli outer membrane 
protein C 
Cross-reactivity of 
monoclonal pANCA with 
colonic bacteria using 
immunoblot 
(Cohavy et al., 
2000) 
Anti-Cbir1, 
Anti-A4-Fla2 
and Anti-FlaX 
Antibodies against 
bacterial flagellin 
SEREX using caecal 
metagenomic DNA of 
C3H/HeJBir mice 
(Duck et al., 2007; 
Lodes et al., 2004) 
Anti-I2 
Antibodies against 
protein I2 protein 
sequence (tetR 
homologue) of 
Pseudomonas 
fluorescens, 
Subtractive cloning in lamina 
propria mononuclear cells 
from the colonic mucosa of 
IBD patients 
(Sutton, Kim, et al., 
2000) 
TCP-353 Antibodies against 8 aa peptide TCP-353 
T7 phage display using 
cDNA of Caco-2 cells and 
CD patient serum 
(Mitsuyama et al., 
2011) 
Anti-OmpW 
Antibodies against a 
TonB-linked outer 
membrane protein of 
Bacteroides caccae 
Cross-reactivity of 
monoclonal pANCA with 
colonic bacteria using 
immunoblot, SEREX using a 
B. caccae genomic 
expression library 
(Cohavy et al., 
2000; Wei et al., 
2001) 
Introduction 
 
12 
 
Consequently, serologic markers have the potential to improve IBD diagnostics and 
disease management but cannot be used as a stand-alone diagnostic tool. Due to the low 
prevalence of known IBD-associated antibody responses, there is an urgent need for 
additional serologic markers in particular to classify subtypes of IBD and to predict disease 
course and drug response. 
1.4.2 IBD mouse models 
Numerous mouse models have been established to study molecular mechanisms 
underlying IBD and can mainly be grouped in three categories with defects in (1) epithelial 
barrier integrity, (2) innate immune mechanisms and (3) adaptive immune mechanisms. 
The use of IBD mouse models has recently been reviewed (Goyal, Rana, Ahlawat, Bijjem, 
& Kumar, 2014; Hörmannsperger, Schaubeck, & Haller, 2015; Wirtz & Neurath, 2007). 
The model used in this work, transgenic TNFΔARE/+ mice, comprises a 69 bp deletion of 
the AU-rich elements (ARE) in the 3’ UTR region of the TNFα gene conferring increased 
TNFα mRNA stability followed by elevated TNF levels (Kontoyiannis, Pasparakis, Pizarro, 
Cominelli, & Kollias, 1999). TNFΔARE/+ mice spontaneously develop inflammation of the 
terminal ileum. Ileal inflammation in this model was recently shown to be triggered by the 
gut microbiota, as germ-free mice did not develop inflammation (Schaubeck et al., 2015) 
and mice deficient in MyD88 (an adaptor protein essential for innate recognition of gut 
microbes) demonstrated attenuated signs of inflammation (Roulis et al., 2015). Moreover, 
shifts in the microbiota composition associated with inflammation were able to induce ileal 
inflammation when transferred to germ-free animals (Schaubeck et al., 2015). The 
involvement of both TNF and the gut microbiota are shared features between TNFΔARE/+ 
mice and human CD suggesting mechanistic similarities in the pathophysiology and 
making this mouse model well-suited to study host-microbiome interactions. 
1.5 Objectives 
The objective of this work was to develop a functional metaproteome display based on 
the ORFeome phage display technology and to identify novel gut microbiome-derived 
biomarker candidates for inflammatory bowel disease. After first providing the proof-of-
concept in the transgenic TNFΔARE/+ mouse model of Crohn’s like ileitis, novel biomarker 
candidates should be identified using clinical relevant IBD samples.  
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2 Materials and Methods 
2.1 Material 
2.1.1 Equipment 
The equipment used in this study is listed in the following table: 
Table 2-1: List of equipment used in the study 
Equipment Model Manufacturer 
96-well pipette VIAFLO96 INTEGRA Biosciences, Zizers, Switzerland  
Balances Sartorius Analytic Sartorius, Göttingen, Germany 
Balances Sartorius excellence Sartorius, Göttingen, Germany 
Blotting Machine Trans-Blot SD Bio-Rad Laboratories, München, Germany 
Blotting Machine Trans-Blot Turbo Bio-Rad Laboratories, München, Germany 
Bluetooth music streaming 
device Soundweaver Bluetooth 4.0 EasyAcc, Hong Kong, HKG 
Capillary electrophoresis QIAxcel Advance Qiagen, Hilden, Germany 
Centrifuges 5415 D Eppendorf, Hamburg, Germany 
Centrifuges Sorvall RC6 Plus Thermo Scientific, Dreieich, Germany 
Electrophoresis chamber Biotechnology Model 40-0708 Peqlab, Erlangen, Germany 
Electrophoresis chamber Mini Protean III for SDS PAGE 
Bio-Rad Laboratories, München, 
Germany 
Electroporation device MicroPulser™ Bio-Rad Laboratories, München, Germany 
ELISA Reader Sunrise Tecan, Crailsheim, Germany 
ELISA Reader Epoch BioTek Germany, Bad Friedrichshall, Germany 
ELISA Washer Columbus Pro Tecan, Crailsheim, Germany 
ELISA Washer Columbus Plus Tecan, Crailsheim, Germany 
ELISA Washer EL405 BioTek Germany, Bad Friedrichshall, Germany 
Gel Documentation ChemiDoc MP Bio-Rad Laboratories, München, Germany 
Incubators BE 400 Memmert, Schwabach, Germany 
Incubators Vortemp 56 Labnet International, Edison, NJ USA 
Incubators Infors HT Infors, Leipzig, Germany 
Lab automation QIAcube Qiagen, Hilden, Germany 
Laminar flow benches Hera safe Heraeus, Hanau, Germany 
Laminar flow benches MSCAdvantage Thermo Scientific, Dreieich, Germany 
Liquid handlig system EL406 BioTek Germany, Bad Friedrichshall, Germany 
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Equipment Model Manufacturer 
Microplate stacker Biostack 3  
BioTek Germany, Bad 
Friedrichshall, Germany 
Microplate stacker Biostack 4 BioTek Germany, Bad Friedrichshall, Germany 
Photometer NanoDrop ND1000 PeqLab, Erlangen, Germany 
Photometer Libra S11 Biochrom, Holliston, USA 
Pipettes Research Eppendorf, Hamburg, Germany 
Pipettes Pipetman Gilson, Middleton, USA 
Pipettes Biohit eLine e1200 Sartorius, Göttingen, Germany 
Power Supplies Electrophoresis Power Supply 301 
Amersham Bioscience, Freiburg, 
Germany 
Power Supplies Electrophoresis Power Supply 601 
Amersham Bioscience, Freiburg, 
Germany 
Power Supplies Electrophoresis Power Supply EPS-301 
Amersham Bioscience, Freiburg, 
Germany 
Power Supplies PowerPac HC Bio-Rad Laboratories, München, Germany 
Rocker GFL 3013 Omnilab Laborzentrum, Bremen, Germany 
Rotors SLA-300 Thermo Scientific, Dreieich, Germany 
Rotors SS34 Thermo Scientific, Dreieich, Germany 
Rotors F9S-4x1000y Thermo Scientific, Dreieich, Germany 
Rotors A-4-81 Eppendorf, Hamburg, Germany 
Thermocycler DNAEngine Bio-Rad Laboratories, München, Germany 
Thermocycler S1000 ThermalCycler Bio-Rad Laboratories, München, Germany 
Thermomixer Compact Eppendorf, Hamburg, Germany 
Thermomixer Comfort Eppendorf, Hamburg, Germany 
Water Installation Arium 611 Sartorius, Göttingen, Germany 
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2.1.2 Consumables 
The consumables used in this study are listed in the following table: 
Table 2-2: List of consumables used in this study 
Material Manufacturer 
Air-o-Seal hydrophobic Gas permeable seal 4titude, Dorking, UK 
Amicon Ultra-0.5 mLCentrifugal Filters 30K  Merck Millipore, Darmstadt, Germany 
Chelating Sepharose™ Fast Flow GE Healthcare UK Ltd, Buckinghamshire, UK 
Costar disposable serological pipettes 
(2 mL/5 mL/10 mL/25 mL) Corning Inc., NY, USA 
Costar MTP 96 Well Polystyrole plates Corning Inc., Corning, NY, USA 
Disposable Cuvettes Brand, Wertheim, Germany 
Electroporation cuvettes, GenePulser 0.1 cm Bio-Rad Laboratories, München, Germany 
Inoculation loops VWR, Darmstadt, Germany 
Microplate seal 4titude, Dorking, UK  
MTP 384 Well Polystyrole Greiner Bio-One, Frickenhausen, Germany 
MTP 96 Well Polypropylene, U-shaped Greiner-Bio-One, Frickenhausen, Germany 
MTP cover foil AeraSeal Excel Scientific, Victorville, CA, USA 
MTP cover foil Sealplate Excel Scientific, Victorville, CA, USA 
Multiply-µStrip Pro 8-strip Sarstedt, Nümbrecht, Germany 
Petri dishes (7 cm, 15 cm) Greiner Bio-One, Frickenhausen, Germany 
Pipette tips Sarstedt, Nümbrecht, Germany 
Pipette tips, filtered Greiner Bio-One, Frickenhausen, Germany 
Pipette tips, filtered Nerbe plus, Winsen, Germany 
Polypropylene Centrifugation Tubes Corning Inc., NY, USA 
Polypropylene Columns Qiagen, Hilden, Germany 
PVDF membrane Carl Roth, Karlsruhe, Germany 
Reaction tube (1.5 mL, 2 mL) Sarstedt, Nümbrecht, Germany 
Reaction tube (15 mL, 50 mL) Greiner Bio-One, Frickenhausen, Germany 
Screw-top micro caps Sarstedt, Nümbrecht, Germany 
Spatulas VWR, Darmstadt, Germany 
Sterile filter (0.2 µm, 0.45 µm) Sartorius, Göttingen, Germany 
 
2.1.3 Chemicals 
If not noted differently, all chemicals were obtained from the following companies: Carl 
Roth GmbH (Karlsruhe, Germany), Sigma-Aldrich Chemie GmbH (Steinheim, Germany), 
Merck KGaA (Darmstadt, Germany), ApplChem GmbH (Darmstadt, Germany), Roche 
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Diagnostics GmbH (Penzberg, Germany) and SERVA Electrophoresis GmbH 
(Heidelberg, Germany). 
For all solutions, media and buffers prepared, cleaned and completely desalted water was 
used (Arium 611, Sartorius AG). 
2.1.4 Enzymes and buffers 
The enzymes and the corresponding buffers used in this study are listed in the following 
table: 
Table 2-3: Enzymes and corresponding buffers used in this study 
Enzyme Manufacturer 
DNA Polymerases 
GoTaq® G2 DNA polymerase Promega, Madison, USA 
5x Green GoTaq® Flexi Buffer Promega, Madison, USA 
MgCl2 (25 mM) Promega, Madison, USA 
Phusion® High-Fidelity DNA Polymerase Thermo Scientific, Dreieich, Germany 
5x Phusion® HF Buffer Thermo Scientific, Dreieich, Germany 
Endonucleases 
NcoI-HF New England BioLabs, Frankfurt a. M., Germany 
NdeI New England BioLabs, Frankfurt a. M., Germany 
NheI-HF New England BioLabs, Frankfurt a. M., Germany 
NotI-HF New England BioLabs, Frankfurt a. M., Germany 
PmeI New England BioLabs, Frankfurt a. M., Germany 
CutSmart® Buffer New England BioLabs, Frankfurt a. M., Germany 
NEBuffer 3 New England BioLabs, Frankfurt a. M., Germany 
Phosphatases 
Alkaline Phosphatase, Calf Intestinal (CIP) New England BioLabs, Frankfurt a. M., Germany 
DNA Ligases 
T4 DNA ligase Promega, Madison, USA 
Proteases
Trypsin Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
 
Materials and Methods 
 
17 
 
2.1.5 Antibodies 
Antibodies were used as detecting reagents for ELISA and immunoblots as well as 
capture antibodies in ELISA. Secondary detection reagents were conjugated with 
horseradish peroxidase (HRP). The antibodies used in this study and the working dilutions 
are listed in the following table: 
Table 2-4: Antibodies and working dilutions used in this study 
Antibody Conjugate Dilution Manufacturer 
  ELISA Immunostain  
Mouse anti-M13 
(pVIII specific) - 
1:1,000 
(capture) - Progen, 61097 
Rabbit anti-M13 (pVIII 
specific) - 
1:5,000 
(capture) - 
Pierce Biotechnology, 
PA1-46334 
Goat anti-human 
(IgA, IgG, IgM) - 
1:500 
(capture) - 
Dianova, 109-005-
064 
Goat anti-human 
(IgA, IgG, IgM) HRP 
1: 5,000 
(detection) - 
Dianova, 109-036-
064 
Goat anti-mouse 
(IgA, IgG, IgM) - 
1:1,000 
(capture) - 
Antikoerper-online, 
ABIN376851 
Goat anti-mouse 
(IgA, IgG, IgM) HRP 
1:8,000 
(detection) 1:4,000 
Antikoerper-online, 
ABIN376237 
Mouse anti-M13 
(pVIII specific) HRP 
1:40,000 
(detection)  GE, 27-9421-01 
 
2.1.6 Commercial kits and markers 
Commercial kits were used for the extraction and purification of nucleic acids (Table 2-5). 
Table 2-5: Kits used for nucleic acid purification 
Kit Manufacturer 
NucleoSpin Gel and PCR Clean-Up Macherey-Nagel, Düren, Germany 
peqGOLD MINIprep Kit I Peqlab, Erlangen, Germany 
 
DNA and protein markers were used as reference agarose gel- and capillary 
electrophoresis as well as in SDS-PAGE and immunoblots (Table 2-6). 
Table 2-6:DNA and protein size standards used in this study 
Marker Manufacturer 
DNA 
GeneRuler 1 kb Plus Ladder Thermo Scientific, Dreieich, Germany 
QX DNA Size Marker 100 bp - 2.5 kb Qiagen, Hilden, Germany 
QX Alignment Marker 15 bp/3 kb Qiagen, Hilden, Germany 
Protein 
Precision Plus Protein All Blue Bio-Rad, München, Germany 
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Enzymatic kits were used for DNA amplification (MDA) and blunting/phosphorylation of 
DNA fragments (Table 2-7). 
Table 2-7: Enzymatic kits used in this study 
Kit Manufacturer 
Illustra RTG GenomiPhi V3 GE Healthcare UK Ltd, Buckinghamshire, UK 
Fast DNA End Repair Kit Thermo Scientific, Dreieich, Germany 
 
2.1.7 Bacterial strains and bacteriophages 
Bacterial strains and bacteriophages used in this study are listed below: 
Table 2-8: List of bacterial strains and bacteriophages used in this study 
Strain Genotype Application Source 
E. coli XL1-Blue-MRF’ 
Δ(mcrA)183 Δ(mcrCB-
hsdSMR-mrr)173 endA1 
supE44 thi-1 recA1 
gyrA96 relA1 lac [F′ 
proAB lacIqZΔM15 Tn10 
(Tetr)] 
Cloning Stratagene, La Jolla, CA, USA 
E. coli TOP10F’ 
F'[lacIq Tn10(tetR)] mcrA 
Δ(mrr-hsdRMS-mcrBC) 
φ80lacZΔM15 ΔlacX74 
deoR nupG recA1 
araD139 Δ(ara-leu)7697 
galU galK rpsL(StrR) 
endA1 λ- 
Library 
construction, 
panning 
Invitrogen, Carlsbad, 
CA, USA 
E. coli SS320 
(MC1061 F‘) 
F'[proAB+lacIqlacZΔM15 
Tn10 (tetr)]hsdR mcrB 
araD139 Δ(araABC-
leu)7679 ΔlacX74 
galUgalK rpsL thi 
Library 
construction 
Lucigen, Middleton, 
WI USA 
E. coli BLR(DE3) 
F- ompT hsdSB(rB- mB-) 
gal dcm (DE3) Δ(srl-
recA)306::Tn10 (TetR) 
Protein 
expression 
Merck Biosciences 
Ltd, Nottingham, UK 
(former Novagen) 
Hyperphage 
M13K07ΔgIII - Phage production (Rondot et al., 2001) 
M13K07 - Serum preclearance 
(Vieira & Messing, 
1987) 
 
2.1.8 Murine specimens 
All murine samples used in this work were provided by Dr. Thomas Clavel (TU München, 
Germany) and derived from following mouse strains: 
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Table 2-9: List of mouse strains used in this study 
Mouse strain Description Reference 
C57BL/6N Wildtype  
TNFΔARE/+ 
Mouse model of experimental 
ileitis, 69 bp deletion of AU-
rich elements in 3’ UTR of 
TNFα gene 
(Kontoyiannis et al., 1999) 
 
Animal use was approved by “Landratsamt Freising” (animal welfare authorization 
no. 32 568), following the guidelines of the “Deutsches Tierschutzgesetz” (German Animal 
Welfare Act) and the “Deutsche Tierschutz-Versuchstierverordnung” (German Animal 
Welfare of Experimental Animals Regulation) under supervision of a veterinarian and an 
animal welfare officer. Mice were sacrificed for scientific purposes only and were not 
included in any specific treatment protocols. 
All mice were housed in the mouse facility at the Life Sciences faculty of the Technische 
Universität München under conventional or specific pathogen free (SPF) conditions with 
a 12 h light/dark cycle at 24-26 °C. All mice were fed a standard diet (R/M-H, Ssniff, Soest, 
Germany) ad libitum and were sacrificed by CO2 inhalation at the indicated age 
(4 to 18 weeks). 
Histologic scoring was performed using formalin fixed and paraffin embedded tissue 
sections of the distal ileum and proximal colon from TNFΔARE/+ and WT mice stained with 
hematoxylin and eosin (H&E) and scored in a blinded manner by assessing lamina propria 
mononuclear cell infiltration, crypt hyperplasia, goblet cell depletion and architectural 
distortion. Gut inflammation was assessed by scoring from 0 (non-inflamed) to 12 (highly 
inflamed) per section as described previously (Katakura et al., 2005). 
2.1.8.1 Metagenomic DNA 
Metagenomic DNA was isolated from the caecal content of TNFΔARE/+ mice (Technische 
Universität München). Samples were stored at -20 °C. 
Table 2-10: Gut microbiome-derived metagenomic DNA from mice for library construction 
Mouse ID Library Genotype Housing Age (weeks) 
4643 1 TNFΔARE/+ Conv. 8 
4647 2 TNFΔARE/+ Conv. 8 
4651 3 TNFΔARE/+ Conv. 8 
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2.1.8.2 Blood samples 
Blood was collected from the vena cava of sacrificed mice using tubes containing EDTA. 
The cells were separated by centrifugation and plasma (Table 2-11) stored at -80 °C for 
long-term or short-term storage at 4 °C. 
Table 2-11: Mouse blood samples used in this study 
Mouse/Cohort n of samples Genotype Housing Age 
4643 1 TNFΔARE/+ Conv. 8 
4647 1 TNFΔARE/+ Conv. 8 
4651 1 TNFΔARE/+ Conv. 8 
Candidate 
validation 17 TNFΔARE/+ Conv. 18 
Candidate 
validation 19 wildtype Conv. 18 
Reactivity SPF 20 TNFΔARE/+ SPF 18 
Reactivity SPF 20 wildtype SPF 18 
Time series 50 (10 of each age) TNFΔARE/+ Conv. 4, 6, 8, 12, 18 
Time series 
49 (10 of each 
age, 9 at 18 
weeks) 
wildtype Conv. 4, 6, 8, 12, 18 
 
2.1.9 Human specimens 
2.1.9.1 Metagenomic DNA 
Human gut metagenomic DNA was provided from different sources (Table 2-12). 
Table 2-12: Gut microbiome-derived metagenomic DNA from IBD patients for library construction 
Library Source Provided by 
1 CD, Colon, lumen, non-inflamed Patricia Lepage, INRA, Joey-en-Josas, France 
2 CD, Colon, lumen, non-inflamed  
3 CD, Caecum, lumen, non-inflamed  
4 CD, remission, fecal sample 
Dr. Harry Sokol, St. 
Antoine Hospital, Paris, 
France 
5 CD, remission, fecal sample  
6 UC, remission, fecal sample  
7 UC, remission, fecal sample  
 
2.1.9.2 Blood samples 
Human sera used in this study was provided from different sources (Table 2-13). Storage 
was at -80 °C for long-term of 4 °C for short-term.  
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Table 2-13: Human blood samples used in this study 
Cohort n of samples Phenotype Description Provided by 
IBD cohort 50 25 CD/25 UC 
Serum of IBD 
patients. Unknown 
ASCA/ANCA 
status. 
Dr. Harry 
Sokol, St. 
Antoine 
Hospital, Paris, 
France 
Preliminary 
control cohort 9 healthy 
Healthy males. 
Exclusion criteria: 
among others 
chronic diseases 
(e.g. inflammatory 
bowel diseases) 
(Lagkouvardos et 
al., 2015) 
Dr. Thomas 
Clavel, TU 
München, 
Germany 
Control cohort 55 healthy 
Age matched 
control sera. 
Exclusion criteria: 
any history of 
gastrointestinal 
disorder 
Sampled for the 
VID (Virtuelles 
Institut Diabetes) 
study 
Prof. Dr. Hans 
Hauner and 
Dr. Thomas 
Skurk, TU 
München, 
Germany 
 
2.1.10 Plasmids and oligonucleotides 
In this study, different plasmids were used as backbones for phage display library 
construction or recombinant protein expression and are listed in the following table: 
Table 2-14: Plasmid used in this study 
Plasmid Description Reference 
pHORF3 
Phagemid, coding for oligopeptide:pIII fusion 
protein, library vector for metaproteome phage 
display libraries 
(Kügler et al., 2008) 
pET21a(+) E. coli expression vector for cytoplasmic protein expression (T7 promoter) 
Merck Biosciences Ltd, 
Nottingham, UK (former 
Novagen) 
pET21a(+)-
pelB 
E. coli expression vector for periplasmic protein 
expression (T7 promoter) 
TU Braunschweig, Dep. 
of Biotechnology, 
Braunschweig, Germany
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Oligonucleotides were used for colony PCR or PCR primers to amplify coding sequences. 
Oligonucleotide use this work are listed in the following table: 
Table 2-15: Oligonucleotide used in this study 
ID DNA sequence (5’3’) Fwd./rev. Description 
125 GGCTCGTATGTTGTGTGG Fwd. CPCR pHORF3 Sequencing pHORF3
11 CTAAAGTTTTGTCGTCTTTCC Rev. CPCR pHORF3 
152 GAGCGGATAACAATTCCCC Fwd. 
CPCR pET21a(+), 
pET21a(+)-pelB 
Sequencing 
pET21a(+), 
pET21a(+)-pelB 
153 GCAGCCAACTCAGCTTCC Rev 
CPCR pET21a(+), 
pET21a(+)-pelB 
Sequencing 
pET21a(+), 
pET21a(+)-pelB 
2421 X-GCTCAGCCGGCGATGG Fwd. NGS pHORF3 
2422 X-CAGCTCTGATATCTTTGGATCCC Rev. NGS pHORF3 
2976 GATCCCATGGCTTGGAAGCCTGATCCGTCTTAC Fwd. JOZ240-H2 domain, NcoI 
2977 GATCGCGGCCGCCTTGTATCTTCCCGCTGTTCTAC Rev. 
JOZ240-H2 domain, 
NotI 
2978 GATCCCATGGCTGATTCCCAGTCTATGAACGG Fwd. JOZ241-A4 domain, NcoI 
2979 GATCGCGGCCGCGGGAATATCCGCGATTG Rev. JOZ241-A4 domain, NotI 
2980 GATCCCATGGCTATTTTGGCAACAGATGAAGATC Fwd. JOZ241-C4 domain, NcoI 
2981 GATCGCGGCCGCCGCTTTTTTGCCCACTTC Rev. JOZ241-C4 domain, NotI 
2982 GATCCCATGGCTTGGGATGCCGTGGCC Fwd. JOZ242-C9 domain, NcoI 
2983 GATCGCGGCCGCAAAATAGAACGGCCTGCGAC Rev. JOZ242-C9 domain, NotI 
2984 GATCCCATGGCTTCCAGGGACTCCTTGAGGAG Fwd. JOZ242-G4 domain, NcoI 
2985 ATCGCGGCCGCTGCCGCCAAGAAGGC Rev. JOZ242-G4 domain, NotI 
2986 GACTCCATGGCTTTGTCCAACATATCTCGGGATG Fwd. JOZ243-E9 domain, NcoI 
2987 GATCGCGGCCGCACTGGGAATATCCGCGATTG Rev. JOZ243-E9 domain, NotI 
2988 GATCCCATGGCTATGGCAACTGAGAACGATGATTC Fwd. 
JOZ241-A4 full-
length, NcoI 
2989 GATCGCGGCCGCTTCGCCAGCAGTACCTGTATCTG Rev. 
JOZ241-A4 full-
length, NotI 
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ID DNA sequence (5’3’) Fwd./rev. Description 
2990 GATCCATATGGCAACTGAGAACGATGATTC Fwd. JOZ241-A4 full-length, NdeI 
2991 GATCCCATGGCTATGAAAACACTCATTAAAAATGTGC Fwd. 
JOZ241-C4 full-
length, NcoI 
2992 GATCGCGGCCGCGAGAGCAGCTCTTTTTTTAGCTTC Rev. 
JOZ241-C4 full-
length, NotI 
2993 GATCCATATGAAAACACTCATTAAAAATGTGC Fwd. JOZ241-C4 full-length, NdeI 
2994 GATCGCTAGCATGTGCAGGAGATTCGCG Fwd. JOZ242-C9 full-length, NheI 
2995 GATCGCGGCCGCAAACAGACGCATGGGTTCG Rev. JOZ42-C9 full-length, NotI 
2996 GATCCATATGTGCAGGAGATTCGCGC Fwd. JOZ242-C9 full-length, NdeI 
3001 GATCCCATGGCTATGGTTAAATTACCGCCGCTG Fwd. JOZ191-G8 full-length, NcoI 
3002 GATCGCGGCCGCCTCAGCCAGAAAAAGCTCCAG Rev JOZ191-G8 full-length, NotI 
3003 GATCCATATGGTTAAATTACCGCCGCTG Fwd. JOZ191-G8 full-length, NdeI 
3026 GATCCCATGGCTATGCAGGATATTGCGATTGAGG Fwd.  JOZ243-F9, NcoI 
3027 GATCGCGGCCGCTACCGTTTCCGGCAGC Rev. JOZ243-F9 domain, NotI 
3028 GATCGCGGCCGCCTTCACCCACTTTTGAGCGTTC Rev. JOZ243-F9 full-length, NotI 
3085 GATCCCATGGCTTGGAAGCCTGATCCGTCTTAC Fwd. JOZ240-H2 domain, NdeI 
3086 GATCCATATGGATTCCCAGTCTATGAACGG Fwd. JOZ241-A4 domain, NdeI 
3087 GATCCATATGATTTTGGCAACAGATGAAGATC Fwd. JOZ241-C4 domain, NdeI 
3088 GATCCATATGTGGGATGCCGTGGCC Fwd. JOZ242-C9 domain, NdeI 
3096 GATCCATATGTCCAGGGACTCCTTGAGGAGCG Fwd. JOZ242-G4 domain, NdeI 
3090 GATCCATATGTTGTCCAACATATCTCGGGATG Fwd. JOZ243-E9 domain, NdeI 
3100 GATCCATATGCAGGATATTGCGATTGAGG Fwd. JOZ243-F9 domain, NdeI 
 
2.1.11 Peptides 
All peptides used in this study (Table 2-16) were purchased from Peps4LS (Heidelberg, 
Germany) either as raw product or HPLC purified. N-terminal biotinylated peptides were 
purchased with a short PEG-spacer (eBio) and glycine-serine linker.  
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Table 2-16: Peptides used in this study 
Peptide Sequence Purification 
JOZ156-H5 eBio-GGSGGS-WDFMGNFWNFNSYRDFDFPR Raw product 
JOZ158-E11 eBio-GGSGGS-VFWPADGYEPGHGQPSFDKQFARDWLKENDGHDWTLPQEIVE Raw product 
JOZ158-G8 eBio-GGSGGS-VSNDLNALLETNISAGTRTTQVSMSYFGEMLMSHIADNEFLSGSEDEKAAHANALA Raw product 
JOZ191-E5 eBio-GGSGGS-FSGPSHRTAPVPSGGWGTQVTQGR Raw product 
JOZ191-G8 eBio-GGSGGS-IEPNTLFGSRPPVLPDDDALWDIFEQGHQLLTA Raw product 
JOZ191-G8 IEPNTLFGSRPPVLPDDDALWDIFEQGHQLLTC HPLC 
JOZ192-A10 eBio-GGSGGS-YIVSAPSGAGKSSLIQALLKTQ Raw product 
JOZ193-A9 eBio-GGSGGS-VVEGTSGSTKPVLGANVK Raw product 
JOZ240-H2 WKPDPSYLCTCSEYAASSAPMPASCASTSSACRTAGRYKC Raw product 
JOZ243-F12 SALTAAASAERC HPLC 
JOZ243-F9 MQDIAIEDTPSSFAATVDDVQNSSNSMPDNPNATLPETVC HPLC 
 
2.1.12 Media and supplements 
If not noted otherwise, E. coli was generally cultured in fully buffered two times yeast-
tryptone media (2xYT) (Table 2-17). For solid media 12 g agar per liter was added. 
Table 2-17: Recipe for 2x YT medium 
2x YT medium  
Bacto-Yeast Extract 1.0 % (w/v) 
Bacto-Tryptone 1.6 % (w/v) 
NaCl 0.5 % (w/v) 
SOC medium (Table 2-18) was used for regeneration of E. coli cells after transformation. 
Table 2-18: Recipe for SOC medium 
SOC medium  
Bacto-Yeast Extract 0.5 % (w/v) 
Bacto-Tryptone 2.0 % (w/v) 
NaCl 0.05 % (w/v) 
Glucose 1.8 % (w/v) 
 
All media were sterilized by autoclaving (121°C, 20 min and excess pressure 1 bar). For 
solid media Agar-Agar was added before autoclaving. 
Media supplements (Table 2-19) were prepared as concentrated stock solutions and 
autoclaved or filter sterilized (0.2 µm pore size) if heat sensitive. Addition of supplements 
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to the media was performed under sterile conditions. For solid media supplements were 
added after media had reached a temperature below 55°C. 
Table 2-19: Medium supplements used in this study 
Supplement Stock solution Final concentration 
Ampicillin 100 mg/mL 100 µg/mL 
Kanamycin 50 mg/mL 50 µg/mL 
Tetracycline 10 mg/mL 20 µg/mL 
Glucose 2 M 100 mM 
IPTG 1 M 1 mM 
 
Supplemented 2xYT media used in this study are listed in the following table: 
Table 2-20: List of media used in this study 
Medium Supplements 
2x YT-A 100 µg/mL ampicillin 
2x YT-GA 100 mM glucose, 100 µg/mL ampicillin 
2x YT-AK 100 µg/mL ampicillin, 50 µg/mL kanamycin 
2x YT-T 20 µg/mL tetracycline 
 
2.1.13 Buffers and solutions 
Buffers used in this studies are given in the following table: 
Table 2-21: List and composition of buffers and solutions used in this study 
3,3-diaminobenzidine (DAB) stock solution 
3,3’-diaminobenzidine 2.5
 
% 
 
(w/v) 
 
in PBS 
Acrylamide Mix 
Acrylamide 
Bisacrylamide 
30
0.8
 
% 
% 
 
(w/v) 
(w/v) 
 
Agarose Gel 
Agarose 1.0
 
% 
 
(w/v) 
in TAE 
Buffer 
Ammonium persulfate (APS-) Solution 
APS 10
 
% 
 
(w/v) 
 
Blotting Buffer 
Tris 
Glycine 
25
192
 
mM 
mM 
  
 
BPBST 
Bovine serum albumin (BSA) 2
 
% 
 
(w/v) 
 
in PBST 
(0.1 %) 
Coomassie blue destaining solution 
Acetic acid 10
 
% 
 
(v/v) 
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Coomassie blue staining solution 
Coomassie Brilliant Blue R250  
Acetic acid 
2-Propanol 
0.05
10
2.5
 
% 
% 
% 
 
(w/v) 
(v/v) 
(v/v) 
 
DAB substrate solution 
CoCl2 
DAB 
Hydrogen peroxide 
0.02
0.05
0.03
 
% 
% 
% 
 
(w/v) 
(w/v) 
 
In PBS 
ELISA washing buffer 
Tween20 0.05
 
% 
 
(w/v) 
 
in H2O 
Ethidium Bromide Solution 
Ethidium Bromide 0.1
 
% 
 
(w/v) 
 
IMAC binding buffer 
Na2HPO4 
NaH2PO4 
NaCl 
Imidazole 
20
20
500
10
 
mM 
mM 
mM 
mM 
  
IMAC Elution buffer 
EDTA 100
 
mM 
  
in PBS 
MPBS 
Skim Milk Powder 2
 
% 
 
(w/v) 
 
in PBS 
MPBST 
Skim Milk Powder 2
 
% 
 
(w/v) 
 
in PBST 
(0.1 %) 
OS buffer 
MgSO4 5
 
mM 
  
PBST (0.05 - 0.1 %) 
Tween20 0.05 - 0.1
 
% 
 
(v/v) 
 
in PBS 
PE buffer, pH 8.0 
Sucrose 
Tris 
EDTA 
20
50
1
 
% 
mM 
mM 
 
(w/v) 
 
Phage dilution buffer 
Tris-HCl pH7.5 
NaCl 
EDTA 
10
20
2
 
mM 
mM 
mM 
  
Phage elution buffer 
Trypsin 10
 
µg/mL 
  
in PBS 
Phage precipitation buffer 
PEG 6000 
NaCl 
20
2.5
 
% 
M 
 
(w/v) 
 
Phosphate buffered saline (PBS) 
NaCl 
KCl 
Na2HPO4 x 2 H2O 
KH2HPO4 
0.8
0.02
0.144
0.024
 
% 
% 
% 
% 
 
(w/v) 
(w/v) 
(w/v) 
(w/v) 
 
SDS sample (Laemmli) buffer (5x) 
SDS 
Glycerol 
Bromophenol Blue 
β-Mercaptoethanol 
10
50
0.02
15
 
% 
% 
% 
% 
 
(w/v) 
(w/v) 
(w/v) 
(v/v) 
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SDS Solution 
SDS 10
 
% 
 
(w/v) 
 
SDS-PAGE Running Buffer 
Tris 
Glycine 
SDS 
25
192
0.1
 
mM 
mM 
% 
 
 
 
(w/v) 
 
TAE Buffer 
Tris-HCl 
Acetic acid 
EDTA 
4
2
1
 
mM 
mM 
mM 
  
TMB Reagent (20A:1B) 
Solution A, pH 4.1 
Potassium Citrate 
Citric acid 
Solution B 
3,3’,5,5’-Tetramethylbenzidine 
Acetone 
Ethanol 
Hydrogen peroxide 
30
50
1
10
90
0.3
 
 
mM 
mM 
 
mM 
% 
% 
% 
 
 
 
 
 
 
(v/v) 
(v/v) 
(v/v) 
 
 
2.1.14 Software and databases 
The software and databases used for this work are listed in the following table: 
Table 2-22: Software and databases used in this study 
Software/database Application Manufacturer/Source 
Vector NTI Advance 
11.5 
Vector maps 
DNA and protein alignments 
DNA sequence processing 
Invitrogen, Carlsbad, CA, US 
Geneious 4.8.5 
Vector maps 
DNA and protein alignments 
In silico cloning 
Biomatters Ltd, Auckland, New 
Zealand 
NCBI 
Literature research, 
sequence comparisons 
(BLAST), gene and protein 
sequence information 
http://www.ncbi.nlm.nih.gov/ 
UniProt Protein sequence database http://www.uniprot.org/ 
Graphpad Prism Data presentation and statistical analysis  
QIAxcel ScreenGel Capillary electrophoresis analysis Qiagen, Hilden, Germany 
ImageLab Documentation of gelelectrophoresis Bio-Rad 
Illustrator Figure illustration Adobe 
Endnote Literature database Citing tool Thomson Reuters, NYC, USA 
Gen5 2.08 Readout of ELISA plates BioTek Instruments, USA 
Liquid Handling 
Control 2.17 
Controlling of liquid handling 
system EL406 BioTek Instruments, USA 
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2.2 Methods 
2.2.1 Bacterial cultivation techniques 
2.2.1.1 Plating 
After transformation or phage infection of E. coli, cell suspensions were plated on a 
2xYT agar plates supplemented with 0.1 M glucose and the respective antibiotic with a 
spatula or glass beads. Incubation was performed at 37°C overnight. 
2.2.1.2 Liquid cultures 
Starter cultures were prepared in 5 mL or 30 mL scale in 2x YT media supplemented with 
the respective antibiotic and optional 0.1 M glucose. Inoculation was performed either 
from a single colony taken from a plate or directly from a glycerol stock. Cultures were 
incubated at 37 °C and 250 rpm for 16 to 18 h. 
Main cultures of volumes between 30 and 400 mL were inoculated from the starter culture 
with OD600 adjusted to 0.05 to 0.1. Composition of the medium was generally set up as 
for the starter culture. Incubation of main cultures was performed at 37 °C and 250 rpm in 
a shaking incubator logarithmic growth (OD600 = 0.5) was reached. 
2.2.1.3 Storage of microbial cultures 
Bacterial cultures were stored short-term on solid media for up to two weeks at 4 °C. For 
long-term storage of bacterial cultures, liquid cultures were supplemented with 20 % (v/v) 
glycerol and stored at -80 °C. 
2.2.2 Transformation of bacteria 
2.2.2.1 Transformation by heat shock 
For the transformation of E. coli cells after ligation, 20 µL of frozen chemically competent 
cells were carefully thawed on ice. The cells were mixed with 10 µL of the ligation and 
incubated on ice for 20 min. The cells were incubated at exactly 42 °C for 60 s and 
subsequently chilled for 2 min on ice. 1 mL pre-warmed SOC media was added and the 
cells were incubated for 1 h at 37 °C and 650 rpm. The cells were pelleted for 30 s at 
16,100 xg and resuspended in 100 µL supernatant. The cell suspension was plated on 
2x YT-G supplemented with the appropriate antibiotic and incubated at 37 °C overnight. 
Materials and Methods 
 
29 
 
2.2.2.2 Transformation by electroporation 
Electroporation was used for the transformation of electro-competent E. coli cells for 
metaproteome phage display library construction and recombinant protein expression. 
When transforming cells using a previous ligation reaction, a buffer exchange of the DNA 
was performed 4 times with 500 µL H2O using Amicon Ultra Centrifugal Filters (30K) 
(Merck Millipore). 
Frozen electro-competent E. coli cells were thawed on ice and mixed with the DNA. The 
cell/DNA mixture was transferred to pre-chilled (-20 °C) electroporation cuvettes and 
transformation was performed at 1.7 kV (E.coli BLR(DE3)) or 1.8 kV (E. coli TOP10F’ and 
SS320) (MicroPulser™, BioRad). Immediately after the electroporation pulse, 1 mL of 
pre-warmed (37 °C) SOC was added. After 60 min of incubation at 37 °C and 600 rpm the 
cells were plated on 2x YT agar containing the appropriate supplements. 
2.2.2.3 Preparation of plasmid DNA from E. coli 
Preparation of plasmid DNA was performed using the peqGOLD MINIprep Kit I (Peqlab, 
Erlangen) following the manufacturer’s instructions. E. coli carrying the plasmid of interest 
was cultured in 5 mL 2xYT GA medium at 37°C and 250 rpm overnight. The cells were 
harvested by centrifugation at 16,100 xg for 10 min and plasmid DNA was isolated 
according to the supplier’s instructions. 
2.2.3 Phage handling 
2.2.3.1 Production of phage particles 
2.2.3.1.1 400 mL scale (oligopeptide phage libraries) 
Glycerol stocks of the metaproteome phage display libraries (2.2.4.6) were thawed 
completely and used to inoculate 400 mL 2x YT-GA medium (OD600 < 0.1). The cells were 
cultivated at 37 °C and 250 rpm (Infors HT) until logarithmic growth (OD600 = 0.5) was 
reached. In order to complement the missing coat proteins and ensure enrichment of 
ORFs, 25 mL of the culture were infected with a 20-fold excess (2.5x 1011 colony forming 
units (cfu) of the M13K07ΔgIII helperphage “Hyperphage“ for 30 min at 37 °C. The infected 
cells were incubated for another 30 min at 37 °C and 250 rpm (Infors HT) to express 
antibiotic resistance. The cells were pelleted (3,220 xg, 10 min) and subsequently 
resuspended in 400 mL 2x YT-AK. 
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Oligopeptide phage particles were produced for 24 h at 30 °C and 250 rpm (Infors HT). 
The cells were pelleted and phage particles were precipitated from the supernatant at 
4 °C overnight after adding 1/5 volume phage precipitation buffer. The precipitated phage 
particles were pelleted for 1 h at 12,000 xg and 4 °C (Sorval Centrifuge RC5B Plus, Rotor 
F9S) and resuspended in 10 mL phage dilution buffer. In order to confer higher purity, the 
resuspended phage were filtered (Whatman syringe filter, 0.45 µm) and a second 
precipitation step was performed for 2 h at 4 °C with 1/5 volume phage precipitation buffer. 
The phage particles were pelleted for 30 min at 20,000 xg and 4 °C (Sorval Centrifuge 
RC5B Plus, Rotor SS34) and resuspended in 1 mL fresh phage dilution buffer. Remaining 
bacteria were pelleted for 2 min at 16,100 xg and supernatants containing the oligopeptide 
phage libraries were collected and stored at 4 °C. 
2.2.3.1.2 30 mL scale (oligoclonal phage or monoclonal phage) 
The production of 30 mL scale phage production was performed during phage 
amplification between panning rounds (2.2.5.5) or the production of monoclonal phage for 
characterization in immunoblot and ELISA (2.2.7.1 and 2.2.7.2.2). 
Thirty mL of 2x YT-GA were inoculated (OD600 < 0.1) and cultivated at 37 °C and 250 rpm 
(Infors HT) until logarithmic growth phase (OD600 = 0.5) was reached. Helperphage 
infection was performed for 30 min at 37 °C using 5 mL of the culture and a 20-fold excess 
(5x 1010 cfu) of the M13K07ΔgIII helperphage “Hyperphage”. The infected cells were 
incubated at for another 30 min at 37 °C and 250 rpm (Infors HT) to express antibiotics 
resistance. The cells were pelleted (3,220 xg, 10 min) and subsequently resuspended in 
30 mL 2x YT-AK following phage production at 30 °C and 250 rpm overnight. 
Amplified phage were precipitated (1 h on ice) after adding 1/5 volume phage precipitation 
buffer. After pelleting (1 h at 4 °C, 3,220 xg), the oligopeptide phage were resuspended in 
500 µL phage dilution buffer. Remaining bacteria were pelleted for 2 min at 16,100 xg, the 
amplified oligopeptide phage containing supernatant was collected and stored at 4 °C until 
used. 
2.2.3.1.3 MTP scale (monoclonal phage) 
For the screening of monoclonal phage after panning (2.2.7.2.1), phage particles were 
produced in 96-well microtiter plate (MTP) scale. 
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A 96-well MTP was supplemented with 180 µL 2x YT-GA medium, inoculated with single 
colonies bearing a phagemid and incubated at 34 °C and 800 rpm (Labnet Vortemp 56) 
overnight. For phage production, 175 µL 2x YT-GA per well were inoculated with 10 µL of 
the overnight culture and incubated for 2 h at 37 °C and 800 rpm to reach logarithmic 
growth. The cells were infected with 5 x 109 cfu “Hyperphage” (M13K07∆gIII) for 30 min 
at 37 °C. To ensure antibiotic resistance, the cells were incubated for another 30 min at 
37 °C and 800 rpm. In order to change the medium for phage production, the cells were 
pelleted for 10 min at 3,220 xg and resuspended in 180 µL 2x YT-AK followed by phage 
production at 30 °C and 800 rpm overnight. The cells were pelleted and the phage were 
precipitated (1 h on ice) after adding 40 µL phage precipitation buffer to 150 µL phage 
containing supernatant. The phage particles were pelleted for 1 h at 3,220 xg an 4 °C, the 
supernatant was discarded and the phage were resuspended in 150 µL phage dilution 
buffer. Remaining bacteria were pelleted for 10 min at 3,220 xg. 
2.2.3.2 Determination of phage titers 
Phage titers were determined for preparation of oligopeptide phage libraries and produced 
monoclonal oligopeptide phage as well as to monitor panning output. 
Phage titers were determined by infection of E. coli cells. Ten-fold serial dilutions of the 
phage were prepared in PBS. For infection, 50 µL of an E. coli XL1 Blue MRF’ or E. coli 
TOP10F’ culture at logarithmic growth (OD600 = 0.5 in 2xYT-T) was briefly mixed with 
10 µL of a phage dilution and incubated for 30 min at 37°C. After the infection, 3x 10 µL 
of each dilution were spotted on 2x YT-GA agar plates. The plates were incubated at 
37 °C overnight and the colonies were counted the next day. 
To exclude phage contamination of the used PBS, a control with 50 µL E. coli culture and 
PBS was treated equally to the infection with phage. Also, the used PBS and E. coli culture 
alone was spotted on 2x YT-GA agar plates to exclude bacterial contamination of the PBS 
or ampicillin resistance of the E. coli culture. Another 50 µL of the E. coli culture were 
infected with 10 µL of a phage solution with known titer as a positive control. 
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2.2.4 Molecular biological methods 
2.2.4.1 Polymerase chain reaction (PCR) 
2.2.4.1.1 Colony-PCR 
Colony-PCR war used to determine insert rates and mean insert size of metaproteome 
phage display libraries and to confirm the correct insert size after cloning.  
Table 2-23: Combinations of oligonucleotide primers for colony PCR 
Plasmid Oligonucleotide primer (fwd./rev.) 
pHORF3 125/11 
pET21a(+) 152/153 
pET21a(+)-pelB 152/153 
 
The composition of the PCR reaction (Table 2-24) and the temperature profile (Table 2-25) 
for colony PCRs are listed in the following tables. 
Table 2-24: Standard composition of a colony PCR 
Component Volume (µl) Final conc. 
Template (Cell material from one colony) -  
Primer forward [10 µM] 0.5 500 nM 
Primer reverse [10 µM] 0.5 500 nM 
dNTP mix [10 mM] 0.2 200 µM 
5x Green GoTaq Reaction Buffer 2 1 x 
MgCl2 [25mM] 0.8 2 mM 
GoTaq DNA polymerase (5 U/µL) 0.05 0.025 U/µL 
dH2O 5.95  
Total volume 10  
 
Table 2-25: Temperature profile of a colony PCR (GoTaq®) 
Step Temperature (°C) Time (s) Cycles 
Initial Denaturation 95 120 1x 
Denaturation 95 15 
25x Annealing x 20 
Elongation 72 Dependent on insert size (1 min/kb) 
Final elongation 72 600 1x 
Soak 16 ∞  
 
2.2.4.1.2 Gene amplification 
The genes coding for the protein domains and full-length proteins of selected biomarker 
candidates were amplified by PCR using as template plasmid DNA containing the coding 
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sequence and amplified metagenomic DNA, respectively (Table 2-26). For cloning into 
the destination vectors pET21a(+) and pET21a(+)-pelB, the appropriate restrictions sites 
were introduced into the genes by PCR. 
Table 2-26: Combination of oligonucleotide primers for the amplification of coding sequences 
Clone Destination vector 
Oligonucleotide 
primer (fwd./rev.) 
Annealing temp. 
(°C) 
JOZ191-G8 full-length pET21a(+) 3003/3002 53 pET21a(+)-pelB 3001/3002 53 
JOZ240-H2 domain pET21a(+) 3085/2977 55 pET21a(+)-pelB 2976/2977 51 
JOZ241-A4 domain pET21a(+) 3086/2977 55 pET21a(+)-pelB 2978/2979 51 
JOZ241-A4 full-length pET21a(+) 2990/2989 52 pET21a(+)-pelB 2988/2989 52 
JOZ241-C4 domain pET21a(+) 3087/2981 55 pET21a(+)-pelB 2980/2981 51 
JOZ241-C4 full-length pET21a(+) 2993/2992 52 pET21a(+)-pelB 2991/2992 52 
JOZ242-C9 domain pET21a(+) 3088/2983 55 pET21a(+)-pelB 2982/2983 51 
JOZ242-C9 full-length pET21a(+) 2996/2995 52 pET21a(+)-pelB 2994/2995 52 
JOZ242-G4 domain pET21a(+) 3096/2985 55 pET21a(+)-pelB 2984/2985 51 
JOZ243-E9 domain pET21a(+) 3090/2987 52 pET21a(+)-pelB 2986/2987 52 
JOZ243-F9 domain pET21a(+) 3100/3027 55 pET21a(+)-pelB 3026/3027 51 
JOZ243-F9 full length pET21a(+) 3100/3028 55 pET21a(+)-pelB 3026/3028 51 
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The composition of PCR reactions (Table 2-27) and the temperature profile (Table 2-28) 
for gene amplification using Phusion® high-fidelity polymerase are listed in the following 
tables 
Table 2-27: Standard composition of a PCR for gene amplification (Phusion®) 
Component Volume (µl) Final conc. 
Template 
Metagenomic DNA 
Plasmid DNA 
 
x 
x 
 
3000-5000 ng/mL 
40 ng/mL 
Primer forward [10 µM] 0.5 100 nM 
Primer reverse [10 µM] 0.5 100 nM 
dNTP mix [10 mM] 1 200 µM 
5x Phusion® HF Buffer 10 1 x 
Phusion® High-Fidelity DNA 
Polymerase (2 U/µL) 0.5 0.02 U/µL 
dH2O 37.5-x  
Total volume 50  
 
Table 2-28: Temperature profile of a standard PCR for gene amplification 
Step Temperature (°C) Time (s) Cycles 
Initial Denaturation 95 120 1x 
Denaturation 95 15 
30x Annealing 56 15 
Elongation 72 Dependent on insert size (15-20 s/kb) 
Final elongation 72 600 1x 
Soak 16 ∞  
 
The PCR product was purified directly or after gel extraction using the NucleoSpin Gel 
and PCR Clean-Up (Macherey-Nagel). 
2.2.4.2 Multiple displacement amplification (MDA) 
Metagenomic DNA was amplified by multiple displacement amplification according to the 
manufacturer's instructions (illustra RTG GenomiPhi V3 DNA Amplification Kit, GE 
Healthcare). Briefly, 100 ng metagenomic template DNA was used per 20 µL reaction. 
The template DNA was denatured for 3 min at 95 °C in denaturation buffer and 
subsequently chilled to 4 °C. The template DNA was transferred to the lyophilized reaction 
cake and incubated for 2 h at 30°C. Each amplification was performed in triplicates and 
the amplified DNA was pooled. Amplified DNA concentration was measured using a 
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spectrophotometer with a control reaction as reference. Integrity of amplified DNA was 
analyzed on a 1 % (w/v) agarose gel. 
2.2.4.3 Electrophoresis 
2.2.4.3.1 Agarose gel electrophoresis 
Agarose gels (1 % (w/v)) were supplemented with 10 µL ethidium bromide solution per 
40 mL of gel and the separation was performed at a constant voltage of 130 V for 20 min 
in TAE buffer. Documentation of the DNA fragments was performed under UV radiation 
(λ = 312 nm) using a camera system (ChemiDoc MP, Bio-Rad). 
2.2.4.3.2 Capillary electrophoresis 
Colony PCR analysis to determine insert rates and mean insert sizes of constructed 
libraries was performed by capillary electrophoresis (QIAxcel Advance) using a QIAxcel 
DNA Fast Analysis cartridge. Capillary electrophoresis was analyzed using the QIAxcel 
ScreenGel software and exported as virtual gel image. Minimal volumes of 15 µL were 
used. If PCR was performed in smaller volumes, the volume was increased to 15 µL by 
diluting with QX DNA Dilution Buffer (Qiagen). 
2.2.4.4 DNA sequencing 
2.2.4.4.1 Sanger sequencing 
All DNA sequences were obtained from GATC Biotech GmbH (Konstanz, Germany) or 
Seqlab Sequence Laboratories GmbH (Göttingen, Germany) after providing purified 
plasmid DNA or an E. coli liquid culture containing the plasmid DNA. 
2.2.4.4.2 Next generation sequencing (NGS) 
NGS analysis was performed at the sequencing facility of ZIEL, TU München and raw 
data processing was performed by Dr. Ilias Lagkouvardos (TU München, Germany). 
Briefly, nucleotide libraries were constructed by PCR (25 cycles) adding adaptor and 
barcode sequences using primer 2421 and 2422 (Table 2-15). They were purified and 
sequenced in paired-modus using a MiSeq Illumina sequencer. Reads were merged, 
cleaned from primer and vector sequences, and those with more than 0.1 % expected 
error rate were discarded using USEARCH v8.1.18 (Edgar, 2010). When different 
samples or replicates were compared, sequences were first dereplicated to allow 
comparison of unique reads across samples.  
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2.2.4.5 DNA Cloning 
2.2.4.5.1 DNA fragmentation for library cloning 
DNA was diluted in 2 mL H2O and fragmented by sonication (6x 2 min, 50 % intensity, 
MS72 sonotrode, HD2200 Sonopuls). Fragmented DNA was analyzed on 1 % agarose 
gels to ensure fragment sizes between 200 and 1500 bp. The fragmented DNA was 
concentrated using Amicon Ultra Centrifugal Filters (30K) (Merck Millipore). 
2.2.4.5.2 Removal of cohesive ends and DNA phosphorylation 
Cohesive ends were blunted and blunt ends were phosphorylated according to 
manufacturer's instructions (Fast DNA End Repair Kit, Thermo Scientific). Briefly, 5 µg 
fragmented DNA in a total reaction volume of 50 µL were incubated for 16 min at 20 °C. 
The DNA was then purified using a spin column according to the manufacturer's 
instructions (NucleoSpin Gel and PCR Clean-UP Kit, Macherey-Nagel). 
2.2.4.5.3 Endonuclease digest 
Library vector pHORF3 was digested in one batch and used for all library constructions. 
Plasmid DNA was linearized using 5 U PmeI/µg plasmid DNA in CutSmart buffer (New 
England Biolabs) and a total reaction volume of 200 µL for 1h at 37 °C.  
PCR fragments and plasmid DNA for the construction of expression vectors were digested 
with the appropriate enzymes using the buffer recommended by the manufacturer. 
Restriction digest was performed in 20-50 µL reaction volumes using up to 3 µg DNA and 
20 U endonuclease per reaction. If available, NEB high fidelity (HF) enzymes were used. 
All reactions were performed at 37 °C for 1-2 h. 
2.2.4.5.4 Dephosphorylation of linearized vector DNA 
Vector DNA was dephosphorylated in order to prevent religation events. 
Dephosphorylation was usually performed in parallel with endonuclease digest by adding 
2x 5U CIP (New England Biolabs) to the restriction digest and incubation for 30 min at 
37°C each. 
In order to increase dephosphorylation efficiency of blunt end linearized pHORF3 library 
plasmid, purified linearized plasmid DNA was incubated with 2 U CIP/µg DNA at a DNA 
concentration of 60 ng/µL using NEB3 buffer (New England Biolabs) and a total reaction 
volume of 150 µL for 1h at 50 °C. 
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2.2.4.5.5 Purification of DNA fragments 
DNA fragments and PCR products were purified either directly or after extraction from 
agarose gels using the NucleoSpin Gel and PCR Clean-Up (Macherey-Nagel) according 
to the manufacturer’s instructions. 
2.2.4.5.6 Spectrophotometric determination of DNA concentrations 
DNA concentrations were determined using a spectrophotometer (NanoDrop ND1000, 
λ = 260 nm). 
2.2.4.6 Construction of metaproteome phage display libraries 
The libraries were constructed using 1,400 ng fragmented, blunted and phosphorylated 
metagenomic DNA and 1000 ng PmeI (New England Biolabs) linearized and 
dephosphorylated pHORF3 library vector. The ligation was performed in a total reaction 
volume of 100 µL using 10 U T4 DNA Ligase (Promega) for 16 h at 16 °C and ligase was 
heat inactivated for 10 min at 65 °C. After buffer exchange, the ligation was split into 
4 separate transformations and 25 µL of electro-competent E. coli (TOP10F’ or SS320) 
were transformed by electroporation as described above (2.2.2.2). Transformation rates 
were determined by plating dilutions on 2 x YT-GA agar. Remaining cells were plated on 
2 x YT-GA agar plates (25 x 25 cm) and incubated at 37 °C overnight. The cells were 
scraped using 20 mL of 2 x YT medium, flash frozen in liquid nitrogen and stored at -80 °C 
in 20 % (v/v) glycerol. Insert rates and mean insert sizes were determined by colony PCR 
(2.2.4.1.1).and capillary electrophoresis (2.2.4.3.2) of randomly analyzed colonies (n = 20 
per transformation)  
ORF enrichment and phage packaging of the libraries was performed as described above 
(2.2.3.1.1) 
2.2.4.7 Construction of expression vectors for recombinant protein expression 
Construction of the expression vectors for recombinant protein expression was performed 
using ligation reactions of 50 ng of linearized and dephosphorylated vector (pET21a(+) or 
pET21a(+)-pelB) and 3-5-fold molecular excess of insert.  
ܫ݊ݏ݁ݎݐ	ሾ݊݃ሿ ൌ ݊݃	ܸ݁ܿݐ݋ݎ ൈ ܾ݇	ܫ݊ݏ݁ݎݐܾ݇	ܸ݁ܿݐ݋ݎ ൈ n	ሺെfold	excess	of	insertሻ 
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Ligations were performed in total volumes of 10 µL using 1 U of T4 DNA Ligase 
(Promega). The samples were incubated for 16 h at 16 °C and inactivated for 10 min at 
65°C. 
The ligation reaction was used to transform chemically competent E. coli XL1 Blue MRF’ 
by heat shock transformation. 
2.2.5 Panning of metaproteome phage display libraries 
2.2.5.1 Preclearance of serum from phage binders 
Panning allows the selection of displayed oligopeptides based on specific affinity binding 
to serum antibodies. In order to reduce background signals, the serum used for panning 
was precleared from antibodies reactive with phage particles alone. Therefore, two wells 
of a 96-well ELISA plate (Costar MTP 96 Well Polystyrole, Corning) were coated with 
4x 1010 cfu Hyperphage in 300 µL PBS. The wells were blocked with 350 µL MPBST per 
well. The blocking solution was removed and the sera (1:500 dilution in 300 µL MPBST) 
were incubated for 2x 1 h on immobilized Hyperphage to preclear anti-phage serum 
antibodies. 
2.2.5.2 Immobilization of serum antibodies 
The precleared serum was transferred into 2 blocked wells (150 µL each) previously 
coated with goat anti-mouse (IgA, IgG, IgM) (antikoerper-online, ABIN376851, 1:1,000 in 
PBS)) and goat anti-human (IgA, IgG, IgM) (109-005-064, Dianova, 1:500 in PBS) 
antibody, respectively, and incubated for 2 h at room temperature). Excess serum 
antibodies and other serum proteins were removed by washing 3 times with PBST 
(0.05%). 
2.2.5.3 Preclearance of oligopeptide phage library from undesired clones 
(optional) 
An optional preclearance step of the libraries to remove universal immunoglobulin-binding 
proteins and proteins non-specific to IBD (matched panning approach, human) was 
partially included. The libraries were incubated on control serum antibodies previously 
captured using an immobilized goat anti-human (IgA, IgG, IgM) antibody (1:500 in 
PBS,109-005-064, Dianova) for 2 h at room temperature. 
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2.2.5.4 Selection of specifically bound oligopeptides 
For the selection of specifically bound oligopeptides, two to three rounds of panning were 
performed using 2x 1010 cfu oligopeptide phage library (in 150 µL MPBST) as input phage 
in round one and 100 µL of amplified oligopeptide phage (accounting for 3x 1011 cfu) as 
input in round two and three. 
The oligopeptide phage were incubated with the immobilized serum antibodies for 2 h at 
room temperature and unbound oligopeptide phage were removed by stringent washing 
(10, 20, 30 times with PBST (0.05 %) according to the panning round). Bound oligopeptide 
phage particles were eluted with 200 µL phage elution buffer per well for 30 min at 37 °C. 
The eluted phage titer was determined using 10 µL of the elution and a 10-fold dilution 
series. 
2.2.5.5 Amplification of eluted phage 
Eluted phage were amplified to use as input phage for the next panning round. The 
remaining 390 µL of the elution (see above) were used to infect 5 mL of an E. coli TOP10F' 
culture (OD600 = 0.5) for 30 min at 37 °C. Cells were plated on 15 cm 2x YT-GA agar 
plates and incubated at 37 °C overnight in order to allow amplification of eluted phage for 
the next panning round. The cells were scraped using 5 mL 2x YT-GA and used to 
inoculate a culture for phage amplification or was supplemented with 20 % (v/v) glycerol 
and stored at -80 °C. Phage amplification was performed in 30 mL scale as described 
above (2.2.3.1.2). 
2.2.5.6 Screening of monoclonal oligopeptide phage 
After the second and third panning round, respectively, 10-fold dilutions of eluted phage 
were used to infect 50 µL E. coli TOP10F' (OD600 = 0.5). The cells were plated on 
2x YT-GA agar plates and incubated at 37°C overnight in order to obtain single colonies 
that allow screening of monoclonal oligopeptide phage. The monoclonal oligopeptide 
phage were produced in MTP scale (2.2.3.1.3) and analyzed for their reactivity with serum 
antibodies by monoclonal screening ELISA (2.2.7.2.1). 
2.2.6 Recombinant protein expression 
Recombinant protein expression was performed using E. coli BLR(DE), an E. coli strain 
bearing an IPTG inducible T7 polymerase gene. Expression of the recombinant proteins 
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was controlled by a T7 promoter using the expression vectors pET21a(+) for cytoplasmic 
and pET21a(+)-pelB for periplasmic expression. 
Electro-competent E. coli BLR(DE3) were transformed with the respective expression 
vector as described above (2.2.2.2). As a starter culture, 30 mL of 2xYT-GA were 
inoculated with the transformed cells and incubated over night at 37 °C and 250 rpm 
(Infors HT). For protein production, 300 mL 2xYT-GA were inoculated (OD600 = 0.1) and 
cultivated at 37 °C and 250 rpm until logarithmic growth phase was reached (OD600 = 0.5). 
To induce protein expression, the cells were pelleted for 15 min at 4,000 xg (Sorval 
Centrifuge RC5B Plus, Rotor F9S), the supernatant was discarded and the cells were 
resuspended in 300 mL 2x YT-A supplemented with 1 mM IPTG. Recombinant protein 
expression followed for 6 h at 22 °C and 200 rpm (Infors HT). The cells were pelleted for 
15 min at 4,000 xg and 4 °C (Sorval Centrifuge RC5B Plus, Rotor F9S) and the 
recombinant proteins were subsequently isolated form the periplasm or cytoplasm. 
2.2.6.1 Periplasmic protein isolation 
For periplasmic protein isolation, the cells were resuspended in 15 mL cold PE buffer and 
incubated for 20 min on ice thoroughly vortexing every 5 min. The cells were pelleted for 
20 min at 4,000 xg (Sorval Centrifuge RC5B Plus, Rotor SLA-3000) and the periplasmic 
preparation (supernatant) was collected. The cells were resuspended in 15 mL cold OS 
buffer and incubated for 20 min on ice thoroughly vortexing every 5 min. The cells were 
pelleted for 20 min at 4,000 xg (Sorval Centrifuge RC5B Plus, Rotor SLA-3000) and the 
osmotic shock fraction (supernatant) was collected. If not used immediately for affinity 
chromatography, the fractions were stored at 4 °C. 
2.2.6.2 Cytoplasmic protein isolation 
For cytoplasmic protein isolation, the cells were resuspended in 15 mL cold IMAC binding 
buffer. Cells were disrupted using sonication (5x 30 s, 50 % intensity, MS72 sonotrode, 
Sonopuls 2200). The cell debris were pelleted for 20 min at 10,000 xg and 4 °C (Sorval 
Centrifuge RC5B Plus, Rotor SLA-3000) and the protein containing supernatant was 
transferred to a fresh tube and subject to affinity chromatography. If not used immediately 
the supernatant was stored at 4 °C. 
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2.2.6.3 Immobilized metal ion affinity chromatography (IMAC) 
Recombinant proteins were purified using immobilized metal ion affinity chromatography 
(IMAC). Supernatant from cytoplasmic protein isolation was directly mixed with 
1 mL Ni-sepharose and incubated for 45 min constantly mixing by inverting. The fraction 
from periplasmic protein isolation were combined and mixed with the same volume of 
IMAC binding buffer. Thirty mL were mixed each with 1 mL Ni-sepharose (Chelating 
Sepharose Fast Flow, GE Healthcare) and incubated for 45 min constantly mixing by 
inverting. 
Sepharose with bound protein was pelleted for 10 min and 500 xg (Eppendorf centrifuge) 
and the supernatant was discarded. The sepharose was transferred and to flow column 
and washed with 25 mL IMAC binding buffer (supplemented with 10-50 mM imidazole). 
Proteins were eluted twice with 1 mL IMAC elution buffer each. 
In order to remove EDTA from the protein elution, the proteins were dialyzed against PBS 
at 4 °C overnight (MWCO 3.5 - 14 kDa, according to protein MW). 
2.2.6.4 Spectrophotometric determination of protein concentrations 
Protein concentrations were determined using a spectrophotometer (NanoDrop ND1000, 
λ = 280 nm) applying the calculated molecular weight and molar extinction coefficient 
(according to Vector NTI Advance 11.5 or Geneious 4.8.5). 
2.2.6.5 SDS-PAGE 
The discontinuous SDS-PAGE was performed as outlined by Laemmli (Laemmli, 1970) 
using a stacking gel to focus the proteins with a subsequent separation in a separating 
gel. The composition of the stacking (Table 2-29) and separating gel (Table 2-30) is 
summarized in the following tables: 
Table 2-29: Recipe for a stacking polyacrylamide gel 
Component Volume 
dH2O 1.00 mL 
Acrylamide Mix 0.26 mL 
1 M Tris-HCl, pH 6.8 0.20 mL 
SDS solution 15 µL 
APS solution 15 µL 
TEMED 2 µL 
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Table 2-30: Recipe for a separating polyacrylamide gel 
Component Volume 12 % Volume 15 %  
dH2O 1.3 0.9 mL 
Acrylamide Mix 1.6 2.0 mL 
1.5 M Tris-HCl, pH 8.8 1.0 1.0 mL 
SDS solution 40 40 µL 
APS solution 40 40 µL 
TEMED 2 2 µL 
 
The protein samples were mixed with SDS sample buffer (+ 2-mercaptoethanol) followed 
by incubation at 95°C for 10 min. The electrophoresis was performed at 200 V and 
25 mA/gel for 45-60 min. After SDS-PAGE the gels were either stain with a Coomassie 
staining solution or blotted on a PVDF membrane. 
2.2.6.6 Coomassie staining of polyacrylamide gels 
For Coomassie staining, the polyacrylamide gels were incubated in Coomassie staining 
solution. The gels were microwave heated and incubated until the gel was completely 
stained. The staining solution was removed and the gel was washed with dH20. The 
following destaining was performed by microwave heating of the gel in destaining solution 
and incubation with pieces of cotton tissue until the gel was destained und the protein 
bands were visible. 
2.2.7 Immunological methods 
2.2.7.1 Immunoblot of phage particles 
The oligopeptide phage (4x 108 - 6x 109 cfu) proteins were separated on a 12 % 
polyacrylamide gel and blotted (20 V, 770 mA, 35 min) onto PVDF membranes. 
Membranes were blocked by incubating in MPBS at 4 °C overnight. Sera of fifteen 
18 week-old TNFΔARE/+ and 19 C57BL/6N wt male mice were pooled. These pools and the 
reference sera used for selection (1:200 in MPBS containing 1.5 x 1010 cfu/mL M13K07 
wildtype phage for competition) were incubated at 4 °C overnight. Membranes were 
stained with the sera for 2.5 h at room temperature and excess serum antibodies were 
removed by using washing buffer PBST (0.1 %). Bound serum antibodies were detected 
with a goat anti-mouse (IgA, IgG, IgM) antibody conjugated with HRP (antikoerper-online, 
ABIN376237, 1:4,000 in MPBS) for 1.5 h at room temperature. Immunoblots were 
developed using diaminobenzidine (DAB) substrate. 
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2.2.7.2 Enzyme-linked immunosorbent assay (ELISA) 
ELISA was performed in 96-well (Costar MTP 96 Well Polystyrole, Corning) and 384-well 
(MTP 384 Well Polystyrole, Greiner Bio-One) scale using 100 µL/well and 30 µL/well total 
volume, respectively. 
2.2.7.2.1 Monoclonal screening ELISA 
In order to screen the clones after panning, monoclonal oligopeptide phage were 
produced as described above (2.2.3.1.2) and binding of serum antibodies was detected 
by ELISA. 
To capture the oligopeptide phage in a screening setup with mouse serum, a rabbit anti-
M13 antibody (pVIII specific, 1:5,000 in PBS, PA1-46334, Pierce Biotechnology) was 
immobilized on an ELISA plate at 4 °C overnight. 
For a screening setup using human sera, a mouse anti-M13 antibody (pVIII specific, 
1:1,000 in PBS, 61097, Progen) was immobilized at 4 °C overnight. 
Wells were completely saturated with MPBST for 1 h at room temperature. The plates 
were washed 3 times with ELISA washing buffer before adding the monoclonal phage 
(40 µL in 100 µL MPBST). Phage particles were captured for 2 h at room temperature 
(50 µL precipitated phage in 100 µL MPBST). Remaining monoclonal phage were 
removed by 3 washing steps with ELISA washing buffer and the sera (1:500-1:1,000 in 
MPBST) were transferred to the wells containing immobilized oligopeptide phage particles 
and incubated for 2 h at room temperature. Excess serum antibodies were removed by 
3 washing steps with ELISA washing buffer. 
Bound murine serum antibodies were detected using a goat anti-mouse (IgA, IgG, IgM) 
antibody conjugated with horseradish peroxidase (HRP) (antikoerper-online, 
ABIN376237, 1:8,000 in MPBST) for 1.5 h at room temperature. 
Bound human serum antibodies were detected using a goat anti-human (IgA, IgG, IgM) 
antibody conjugated with HRP (Dianova, 109-036-064, 1:5,000 in MPBST) for 1 h at room 
temperature. 
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Excess detection antibody was removed by 3 washing steps and the ELISA was 
developed with TMB substrate solution for up to 10 min. Signals were detected using an 
ELISA reader (450 nm, reference 620 nm). 
2.2.7.2.2 ELISA based measurement of antibody response 
2.2.7.2.2.1 96-well scale 
The reactivity of mice sera with the selected oligopeptides was performed in 96-well 
format. Serum reactivity with the peptides was measured in doublets. The measured 
background binding to streptavidin was subtracted from the mean serum reactivity to 
compensate inter-individual differences in streptavidin background binding. 
The 96-well ELISA plates were coated with 200 ng/well streptavidin at 4 °C overnight and 
the whole wells were blocked with BPBST. After three washing steps with ELISA washing 
buffer, 200 ng/well of synthetic biotinylated peptide was immobilized for 2 h at room 
temperature. Excess peptide was removed by three washing steps with ELISA washing 
buffer. The sera (1:100 dilution in MPBST) and incubated with the immobilized peptides 
and the streptavidin controls for 2.5 h at room temperature. Unbound serum antibodies 
were removed by three washing steps with ELISA washing buffer. The bound serum 
antibodies were detected with goat anti-mouse (IgA, IgG, IgM) antibodies conjugated with 
HRP (antikoerper-online, ABIN376237, 1:8,000 in MPBST) for 1.5 h at room temperature 
and the ELISA was developed with TMB substrate solution as described above and 
signals were detected using an ELISA reader (450 nm, reference 620 nm). 
2.2.7.2.2.2 384-well scale 
The reactivity of human sera with the selected oligopeptides and full-length proteins 
(oligopeptide phage or synthetic peptide) was performed in 384-well scale. Serum 
reactivity with the peptides was measured in triplicates. The measured mean background 
binding to M13K07ΔgIII Hyperphage (oligopeptide phage) or system background in 
blocked wells (synthetic peptides) was subtracted from the mean serum reactivity to 
compensate inter-individual differences in background binding. 
For ELISA using oligopeptide phage, the 384-well ELISA plates were coated with mouse 
anti-M13 (pVIII specific) (1:1,000 in PBS, 61097, Progen) at 4 °C overnight and the wells 
were blocked with MPBST for 1 h at room temperature. After three washing steps with 
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ELISA washing buffer, 2.5x 107 cfu oligopeptide phage and M13K07ΔgIII Hyperphage 
was immobilized for 1.5 h at room temperature. Excess phage was removed by three 
washing steps with ELISA washing buffer. 
For ELISA using recombinant protein and synthetic peptide, 30 ng/well (in PBS) were 
immobilized at 4 °C overnight. Control wells were filled with only PBS. The wells were 
blocked for 1 h at room temperature and washed 3 times using ELISA washing buffer. 
The sera (1:500 dilution in MPBST) were transferred to the ELISA plates (Viaflo96, 
Integra) and incubated for 1.5 h at room temperature with the immobilized oligopeptide 
phage and proteins/peptides, respectively. Unbound serum antibodies were removed by 
three washing steps with ELISA washing buffer. The bound serum antibodies were 
detected with a goat anti-human (IgA, IgG, IgM) antibody conjugated with HRP (Dianova, 
109-036-064, 1:5,000 in MPBST) for 1.5 h at room temperature and the ELISA was 
developed with TMB substrate solution as described above and signals were detected 
using an ELISA reader (450 nm, reference 620 nm). 
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3 Results 
3.1 Metaproteome display in experimental ileitis (TNF∆ARE/+ mouse model) 
3.1.1 Construction of gut metaproteome phage display libraries 
Three individual metaproteome phage display libraries were constructed from 
metagenomic DNA isolated from the caecum of three 8-week-old TNFΔARE/+ mice (the 
metagenomic DNA was a kind gift from Dr. Thomas Clavel, TU München, Germany) 
(Table 3-1). To increase starting material quantity, the metagenomic DNA was 
isothermally amplified by multiple displacement amplification (MDA) a suggested method 
for whole genome amplification (Taupp, Mewis, & Hallam, 2011). Whereas metagenomic 
DNA generally appears as a rather distinct band with approx. 5-10 kb when analyzed by 
agarose gelelectrophoresis, DNA after MDA resulted in branched DNA (Spits et al., 2006) 
strands that appeared as a smear in the range of 1 to 10 kb in an agarose gel 
(Figure 3-1).  
The amplified gDNA was randomly fragmented by sonication yielding DNA fragments in 
the range of 100 bp - 1 kb (Figure 3-1). The DNA fragments were cloned into the phage 
display vector pHORF3 in a non-directional manner. Based on transformation rates, the 
Figure 3-1: Agarose gel presenting the different levels of DNA preparation. (Templ. DNA = metagenomic 
template DNA for MDA, Ampl. DNA = MDA product, Frag. DNA = fragmented DNA by sonication) 
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initial library diversities were 5.9x107, 1.9x107 and 2.5x107 independent clones with mean 
insert sizes of 335 bp, 284 bp and 354 bp, respectively. Insert rates were >85 % for all 
three libraries as analyzed by colony PCR (Figure 3-2).  
Library quality was further enhanced by the enrichment of open reading frames (ORF) 
coupled to the display of the corresponding oligopeptides on phage particles. Inserts rates 
were 100% as analyzed by colony PCR, ORF enrichment was verified by Sanger DNA 
sequencing and ranged from 50 % to 80 %, the mean insert size was decreased after 
ORF enrichment with 92 bp – 117 bp (Figure 3-2). 
Table 3-1: Summary of constructed metaproteome phage display libraries 
Library 1 2 3 
Approach Mouse model 
Source Caecum TNFΔARE/+ Caecum TNFΔARE/+ Caecum TNFΔARE/+
Initial library size (x107) 5.9 1.9 2.5 
Before ORF 
enrichment 
Mean insert 
size (bp) 335 284 354 
Insert rate 
(%) 90 85 85 
After ORF 
enrichment 
Mean insert 
size (bp) 92 102 117 
Insert rate 
(%) 100 100 100 
ORF rate 
(%) 75 50 80 
 
Figure 3-2: Representative PCR of single colonies before and after ORF enrichment. PCR products were
analyzed on a Qiaxcel Advance capillary electrophoresis machine. (Ctr = empty library vector pHORF3). 
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3.1.2 NGS analysis of metaproteome phage display libraries 
To obtain an overview of the starting oligonucleotide diversity prior to panning and 
reproducibility of library packaging, triplicate phage libraries of each of the three donor 
mice were sequenced. An average of 193,500 total reads and 122,000 unique reads were 
obtained per mouse per replicate (NGS and raw data processing was performed by 
Dr. Ilias Lagkouvardos, TU München, Germany). NGS analysis of the ORF enriched 
libraries revealed a size distribution ranging from 8 to 476 nt, with a mean sequence length 
of 65.8 ± 4.3 to 84.8 ± 1.9 nt (size limit due to sequencing specifications was approximately 
500 nucleotides) Mean sequence length was comparable to the mean sequence length 
obtained from a small sample (19 – 20 clones) by Sanger sequencing and represents a 
decrease in insert sizes compared to the initial libraries before ORF enrichment. 
 
Random fragmentation of DNA for library construction results in DNA fragments with sizes 
of 3n, 3n+1 and 3n+2 nucleotides. Sequences with a length of 3n+1 were enriched over 
sequences with 3n+2 and 3n nucleotides (70.3 % vs. 27.3 % vs. 2.4 % of unique reads) 
(Figure 3-3). Due to the vector design (Suppl. Figure 1), only inserts with 3n+1 nucleotides 
can result in ORFs with phage pIII. Hence, NGS data strongly supported efficacy of the 
Figure 3-3: Size distribution histogram of ORF enriched oligopeptide phage library determined by NGS analysis. 
Sequences with 3n+1 nucleotides (nt) were enriched over sequences with 3n+2 and 3n nt. The histogram was
trimmed at 300 nt but sequences with up to 476 nt were detected. 
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ORF enrichment and was comparable to the ORF rate obtained from Sanger sequencing 
of a small sample of randomly analyzed clones (19 – 20 clones). 
Approximately 30 % of the reads (54,000 of 176,000, represented on average by 30,000 
peptides) corresponded to redundant peptides (i.e., those with more than one copy; 
median copy number was 2, showing that most of the redundant peptides had low copy 
numbers; maximum copy number ranged between 44 and 163, depending on the library). 
The 20 most abundant clones represented less than 0.5 % of total reads. 
Across different library preparations from the same sample, only 8-10 % of the sequences 
were shared between all three replicates and another 6-8 % between each of the replicate 
pairs (overlap between duplicates was 18-23 %) (Figure 3-4) (data was provided by 
Dr. Ilias Lagkouvardos and Dr. Thomas Clavel, TU München, Germany).  
 
Figure 3-4: Venn’s diagram showing the percentage of oligonucleotides that are shared between or unique to 
the ORFeome phage display library replicates. The percentages refer to a total number of approximately 265,000 
oligonucleotide reads. (Data was provided by Dr. Ilias Lagkouvardos and Dr. Thomas Clavel, TU München, 
Germany.) 
These findings suggest that the total diversity of oligonucleotides existing in the libraries 
was not covered by either the individual library preparation or more likely by the 
sequencing depth, and it exceeded 265,000 detected sequences per library. Therefore, a 
final statement about reproducibility of library packaging is not possible. But these data 
show that the constructed library displayed a high degree of diversity (unique peptides 
dominated the libraries), which demonstrates their suitability as starting materials for 
peptide selection. 
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3.1.3 Selection of immunogenic oligopeptides from metaproteome phage display 
libraries 
For the selection of microbiota-derived immunogenic oligopeptides from metaproteome 
phage display libraries, three independent pannings, one for each mouse, using 
immobilized serum antibodies (IgA, IgG and IgM in combination) were performed. 
Matched samples (i.e. one individual library constructed from a given mouse gut content 
and the corresponding serum sample) were used. After three consecutive rounds of 
panning, 92 clones from each panning were screened by monoclonal phage ELISA for an 
antibody response of the designated serum specific towards the displayed oligopeptide 
(data not shown). In total, 16 individual clones reactive with the designated mouse serum 
were selected (Table 3-2). 
Some selected clones were found in multiple copies among the 276 screened clones. In 
particular, clone JOZ156-A6 was dominantly enriched during the panning procedure, but 
was later found to be a universal immunoglobulin binding protein (data not shown). The 
other selected fragments ranged from 31 to 328 bp in size and originated from unknown 
sequences. Blastn did not return any annotation for the selected clones except from clone 
JOZ158-E11 which was found to have 84 % identity with an annotated sequence from 
Roseburia hominis. Protein homologies (blastp) were only found for clones JOZ157-E1 
and JOZ158-E11. Clone JOZ156-A6, JOZ156-A8, JOZ156-F7, and JOZ157-C10 were 
annotated as predicted proteins from Blautia species. 
3.1.4 Validation of oligopeptide immunogenicity by immunoblot 
Blotted proteins of the selected oligopeptide phage particles were incubated with pools of 
each 15 TNFARE/+ and 19 wt C57BL/6N mouse sera at the age of 18 weeks. All TNFARE/+ 
mice were inflamed in the distal ileum and proximal colon, as confirmed by histological 
scoring (3.9 ± 1.3 vs. 0.03 ± 0.08 (distal ileum) and 4.3 ± 1.7 vs. 0.05 ± 0.13 (proximal 
colon)) (histological scoring was performed by Dr. Sigrid Kisling, TU München, Germany).  
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Table 3-2: Summary of selected clones 
Clone Insert size (bp) Redundancy Origin (blastn) Protein homology (blastp) 
GenBank 
Accession 
JOZ156-A3 43 1 Unknown - - 
JOZ156-A6 298 32 Unknown Predicted protein (Blautia sp.) (E-value 7e-24, 66 % identity) n.d. 
JOZ156-A8 319 1 Unknown Predicted protein (Blautia sp.) (E-value 3e-27, 57 % identity) n.d. 
JOZ156-B11 58 6 Unknown - - 
JOZ156-F7 328 1 Unknown Predicted protein (Blautia sp.) (E-value 3e-29, 58 % identity) n.d. 
JOZ156-G7 85 2 Unknown - - 
JOZ156-H5 58 1 Unknown - - 
JOZ157-C10 211 3 Unknown Predicted protein (Blautia sp.) (E-value 7e-18, 72 % identity) n.d. 
JOZ157-E1 202 1 Unknown 
ABC transporter permease 
(Eubacterium sp. ER2) 
(E-value 2e-21, 62 % identity) 
WP_033126529 
JOZ157-G6 58 1 Unknown - - 
JOZ158-C11 76 1 Unknown - - 
JOZ158-C12 46 1 Unknown - - 
JOZ158-D10 31 2 Unknown - - 
JOZ158-E11 121 2 Roseburia hominis (E-value 3e-9, 84 % identity) 
Phosphoribosylaminoimidazole-
succinocarboxamide synthase 
(Blautia sp.) 
(E-value 4e-20, 100 % identity) 
CDA05871.1 
JOZ158-G8 163 1 Unknown - - 
JOZ158-H8 52 1 Unknown - - 
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Detection of bound serum antibodies resulted in a stronger staining of the 
oligopeptide::pIII fusion protein for three of the 16 candidate oligopeptide phage clones 
(Figure 3-5). These peptides (JOZ156-H5, JOZ158-E11, and JOZ158-G8) were 
considered to be the most promising candidates for detection of specific circulating 
antibodies in TNFARE/+ mice and were synthesized as biotinylated peptides.  
3.1.5 Validation of TNF∆ARE/+ specific immune responses by ELISA 
3.1.5.1 Conventional housing 
Even though immunogenicity was validated using oligopeptide phage and serum pools, 
further characterization was performed using synthetic peptides and individual sera of the 
TNFARE/+ and control cohorts. Peptides were immobilized via streptavidin coupling and 
incubated with the individual sera. Bound anti-peptide serum antibodies were detected by 
ELISA using a secondary anti-mouse antibody. Some sera of mostly the TNFARE/+ cohort 
reacted with streptavidin alone and competition with streptavidin in solution did not 
decrease the background binding of streptavidin. Therefore, a background subtraction 
step was implemented to exclude false positive reactive sera. The measured antibody 
Figure 3-5: Immunoblot of oligopeptide phage particles stained with mouse serum. Oligopeptide:pIII fusion 
protein was stained with serum pools (1:200 dilution) from TNFΔARE/+ and wildtype mice. Bound antibodies were 
detected with an anti-mouse (IgA, IgG, IgM) secondary antibody. 
Results 
 
53 
 
responses against all three peptides were significantly higher in TNFARE/+ mice compared 
to the wildtype, despite marked inter-individual differences (Figure 3-6). 
 
Figure 3-6: Specific reactivity of TNFARE/+ cohort from conventional housing with the selected biomarker 
candidates. Serum response was determined by ELISA and plotted as mean of duplicate measurement. A 
background subtraction of streptavidin binding was included. The median cohort reactivity is indicated by a 
black line. Peptides were immobilized by streptavidin and bound serum antibodies from single sera (1:100 
dilution) were detected with an anti-mouse (IgA, IgG, IgM) antibody. (Non-parametric Mann-Whitney 
test; ** = p < 0.01; *** = p < 0.001) 
Compared to peptide JOZ156-H5, antibody responses against the peptides JOZ158-E11 
and JOZ158-G8 were generally stronger and reactivity of some control sera was 
increased. Nevertheless, the serum reactivity of the TNFARE/+ cohort against both 
peptides (JOZ158-E11 and JOZ158-G8) was significantly stronger compared to the 
control sera (p < 0.01). Consequently, all three isolated peptides were considered as 
biomarker candidates for the TNFARE/+ mouse model. Peptide JOZ158-E11 was identified 
as a peptide from phosphoribosylaminoimidazole-succinocarboxamide synthase 
(SAICAR synthase) of a Blautia species. At the DNA level however (Table 3-2), there was 
only similarity to the DNA sequence of the SAICAR synthase gene from 
Roseburia hominis. The peptides JOZ156-H5 and JOZ158-G5 returned no annotation by 
using both blastn and blastp. 
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3.1.5.2 Specific pathogen free housing (SPF) and human IBD samples 
In order to assess the influence of the gut microbiome on the development of specific 
antibody responses against the selected biomarker candidates, serum response was 
measured by ELISA using samples from TNFARE/+ and matched wildtype mice kept under 
specific pathogen free (SPF) housing conditions. Ileal inflammation in mice kept under 
SPF conditions was generally weaker than in mice kept under conventional housing 
conditions as determined by histological scoring (3.0 ± 2.3 vs. 3.9 ± 1.3) and was absent 
in the proximal colon (0.1 ± 0.3 vs. 4.3 ± 1.7) (histological scoring was performed by 
Dr. Sigrid Kisling, TU München, Germany). Weaker gut inflammation in mice from SPF 
housing compared to conventional housing was reflected by overall weaker serum 
response. Antibody titers against the oligopeptides JOZ156-H5 and JOZ158-E11 were 
increased in TNFARE/+ mice when compared to wildtype controls but was very weak for 
JOZ156-H5 and absent for JOZ158-G8 (Figure 3-7). 
 
Figure 3-7: Reactivity of TNFARE/+ cohort from SPF with the selected biomarker candidates. Serum response 
was determined by ELISA and plotted as mean of duplicate measurement. A background subtraction of 
streptavidin binding was included. The median cohort reactivity is indicated by a black line. Peptides were 
immobilized by streptavidin and bound serum antibodies from single sera (1:100 dilution) were detected with 
an anti-mouse (IgA, IgG, IgM) antibody. (Non-parametric Mann-Whitney test; ** = p < 0.01; *** = p < 0.001) 
The relatively low but specific antibody responses against two out of the three 
oligopeptides may indicate a correlation between intestinal inflammation and antibody 
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response. The lack of specific antibody titers against the peptide JOZ158-G8 suggests 
that the peptide originates from a bacterial species that was not present in SPF housing. 
3.1.6 Time dependent occurrence of biomarker candidates 
TNFARE/+ mice are known to develop intestinal inflammation gradually from the age of 
4-6 weeks on with plateauing around 12 weeks of age (Baur et al., 2011; Kontoyiannis et 
al., 1999). An overall weaker serum response against two out of the three biomarker 
candidates in mice kept under SPF housing conditions and less intestinal inflammation 
suggested a correlation between inflammatory state and specific antibody responses. In 
order to test whether the systemic antibody response towards the three identified gut 
microbiome-derived peptides gradually developed over age and inflammatory state, 
serum reactivity was monitored using ten mice of each genotype sacrificed at week 4, 6, 
8, 12, and 18 of age. Intestinal inflammation was assessed by histopathological scoring 
(histological scoring was performed by Dr. Sigrid Kisling, TU München, Germany) and 
anti-JOZ156-H5, anti-JOZ158-E11, and anti-JOZ158-G8 serum antibody titers were 
measured by ELISA (Figure 3-8). 
Intestinal inflammation was observed by week 6 and the inflammatory state increased with 
older age of the TNFARE/+ mice, whereas no inflammation was observed in wildtype 
controls (Figure 3-8A). Inter-individual differences in serum response were observed for 
all three analyzed oligopeptides. Serum levels of anti-JOZ156-H5 antibodies were 
increased in 4-, 6-, 8-, 12- and 18-week-old TNFARE/+ mice when compared to the 
matched wildtype controls and tended to gradually develop increased antibody titers with 
age and inflammation (Figure 3-8B). Levels of anti-JOZ158-E11 antibodies were relatively 
high in 8-week-old TNFARE/+ mice, but were not further increased thereafter and were not 
abundant in the serum of 18-week-old mice (Figure 3-8C). Anti-JOZ158-G8 antibodies 
were only present in a fraction of TNFARE/+ samples and there was only a trend towards 
increased response from week 8 on (Figure 3-8D). There was no clear evidence of a direct 
correlation of increased intestinal inflammation and serum response against the selected 
biomarker candidates although there was a trend of increased serum response with 
increased intestinal inflammation. Overall serum response in the measured cohorts was 
very heterogeneous and specific antibody titers were not measured in the same 
individuals over time but in different individuals at different time points. 
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Figure 3-8: Time-course of ileal inflammation and serum response against the selected biomarker candidates. 
Serum response of mice sacrificed at life week 4, 6, 8, 12 and 18 was determined by ELISA and plotted as mean 
of duplicate measurement. A background subtraction of streptavidin binding was included. The median cohort 
reactivity is indicated by a black line. Peptides were immobilized by streptavidin and bound serum antibodies 
from single sera (1:100 dilution) were detected with an anti-mouse (IgA, IgG, IgM) antibody. (Non-parametric 
Mann-Whitney test; ** = p < 0.01; *** = p < 0.001) (Figure presenting histopathological scores and H&E staining 
was provided by Sarah Just, TU München, Germany) 
Nevertheless, the results from the TNFARE/+ mouse model of experimental ileitis 
represented a proof-of-concept for the selection of gut microbiome-derived oligopeptides 
that have induced specific antibody responses in mice suffering from intestinal 
inflammation. 
3.2 Metaproteome display in inflammatory bowel disease (clinical IBD samples) 
For the selection of potential novel biomarker candidates for IBD, the ORFeome phage 
display technology was applied on human IBD samples following two different strategies. 
The selections were performed using an unmatched and a matched approach. As 
unmatched approach, metaproteome phage display libraries were construction from gut 
metagenomic DNA of two CD patients and oligopeptides were selected using serum pools 
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of different IBD patients based on disease phenotype. The IBD serum donors were in 
disease remission to only select biomarker candidates that are IBD specific and also 
detectable in remission state. For the matched approach, metaproteome phage display 
libraries were constructed from the gut metagenomic DNA of each two CD and UC 
patients and serum antibodies from the same individuals were used for the selection of 
candidate oligopeptides. 
3.2.1 Construction of gut metaproteome phage display libraries 
The construction of the metaproteome phage display libraries from gut metagenomic DNA 
of IBD patients was performed analogue to the construction of the libraries from the gut 
metagenomic DNA of TNFARE/+ mice. In total, seven metaproteome phage display 
libraries were constructed (Table 3-3). Three libraries were constructed for an unmatched 
panning approach (library 1-3) and four libraries were constructed for a matched panning 
approach (library 4-7). (The metagenomic DNA was a kind gift from Dr. Patricia Lepage, 
INRA, Joey-en-Josas (library 1-3) and Dr. Harry Sokol, St. Antoine Hospital, Paris (library 
4-7)). 
Metagenomic approaches demand for large libraries and in order to further increase the 
library sizes, the construction of library 4-7 was performed using the E. coli SS320 strain 
allowing higher transformation rates compared to the previously used E. coli TOP10F’. 
The E. coli SS320 strain was previously proven to be applicable to the ORFeome phage 
display technology and allowed transformations rates of more than 108 cfu/transformation 
following the same procedure as described in the present work (Felix Pritsch, Master 
thesis, TU Braunschweig, 2015). 
Based on transformation rates, the initial library diversities for the unmatched panning 
approach (1-3) were 6.3x 107, 8.6x 107 and 5.7x 107 independent clones with mean insert 
sizes of 300 bp, 370 bp and 350 bp, respectively. Although the construction of library 4-7 
was performed using an E. coli strain with higher competence, initial library sizes were 
5.3x 107, 1.8x 107, 3.7x 107 and 3.2x 107 with mean insert sizes between 285 bp and 
405 bp and were not increased compared to library 1-3. Notably, insert rates of library 4-7 
were also lower (41 – 75 vs. 90 – 95 %) suggesting a correlation between insert rate and 
transformation rate which was also observed before (data not shown).  
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Table 3-3: Summary of constructed metaproteome phage display library from human gut content 
Library 1 2 3 4 5 6 7 
Approach unmatched matched 
Source Colonic lumen CD 
Colonic 
lumen CD 
Caecal 
lumen CD Stool CD Stool CD Stool UC Stool UC 
Initial library size (x107) 6.3 8.6 5.7 5.3 1.8 3.7 3.2 
Before ORF 
enrichment 
Mean insert size 
(bp) 300 370 350 285 300 365 405 
Insert rate 
(%) 90 95 95 75 41 55 71 
After ORF 
enrichment 
Mean insert size 
(bp) 115 115 - 190 170 205 230 
Insert rate 
(%) 100 100 - 95 100 100 100 
ORF rate 
(%) 61 50 - 55 70 52 61 
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ORF enrichment and production of phage particles resulted in very low phage titers for 
library 3 (at least more than two orders of magnitude lower). DNA sequencing of random 
clones of the initial libraries 1-3 and BLAST analysis revealed that library 3 contained 
>85% human DNA sequences whereas the fraction of human DNA sequences in library 
1 and 2 was 28% and 40% (n = 30), respectively. No human-derived DNA sequences 
were detected in initial libraries 4-7. High content of human DNA sequences in the initial 
libraries may hamper the packaging of oligopeptide phage (accompanied by ORF 
enrichment) due to more intergenic DNA content of eukaryotic DNA sequences. ORF 
enrichment of the remaining metaproteome phage display libraries was verified by Sanger 
sequencing and ranged from 50 – 61 % to 52 – 70 % (library 4-7) with insert rates of 
mostly 100 % demonstrating the successful elimination of empty phagemid constructs 
from the metaproteome phage display libraries. 
The library sizes and quality (insert and ORF rate) of ORF enriched metaproteome phage 
display libraries was comparable to the libraries from the proof-of-concept using the 
TNFARE/+ mouse model and were subsequently used for the selection of candidate 
oligopeptides using patient sera. 
3.2.2 Selection of immunogenic oligopeptides from metaproteome phage display 
libraries 
3.2.2.1 Unmatched samples 
For the selection of candidate biomarker oligopeptides, 25 sera from CD patients and 
25 sera from UC patients were grouped based on localization of intestinal inflammation 
and smoking habits (4 groups from CD patients and 2 from UC patients). (The patient sera 
were a kind gift from Dr. Harry Sokol, St. Antoine Hospital, Paris, France). The grouped 
sera were pooled. Using the immobilized antibodies (IgA, IgG and IgM in combination) 
from these serum pools, six individual pannings were performed. Panning 1-4 was 
performed using sera from CD patients and panning 5-6 was performed with UC patient 
sera. After three consecutive rounds of panning, 92 clones from each panning were 
screened by monoclonal phage ELISA for a specific antibody response of the designated 
serum pool (data not shown). In total, only 6 individual clones reactive with the designated 
serum pool were selected and subsequently identified by DNA sequencing (Table 3-4). 
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Table 3-4: Summary of selected clones applying an unmatched panning approach.  
Clone Panning Insert size (bp) Redundancy Origin (blastn) Protein 
GenBank 
Accession 
JOZ191-E5 3 73 1 Escherichia coli (E value 1e-13) - - 
JOZ191-F12 3 109 1 Bacteroides vulgatus (E value 3e-49) 
Putative LPS biosynthesis 
related UDP-galactopyranose 
mutase 
ALK83393.1 
JOZ191-G8 3 100 1 Escherichia coli (E value 1e-43) Coproporphyrinogen III oxidase ALY14458.1 
JOZ192-A10 4 64 1 Salmonella enterica (E value 4e-24) Guanylate kinase AKF91369.1 
JOZ193-A9 5 55 2 Bacteroides dorei (E value 4e-19) - - 
JOZ194-C4 6 103 1 Escherichia coli (E value 7e-46) 
nicotinate phosphoribosyl 
transferase AIZ86460.1 
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Panning 1 and 2 (CD patient sera) did not reveal any oligopeptides that were specifically 
reactive with the designated serum pools. The coding DNA sequences of the selected 
oligopeptides from panning 3-4 (CD patient sera) and panning 5-6 (UC patient sera) 
ranged from 55 – 109 bp in size and only the oligopeptide JOZ193-A9 was found in 
another copy. A nucleotide BLAST analysis of the selected sequences returned 
annotations from Bacteroides species, E. coli and Salmonella species and except from 
JOZ191-E5 that seemed to be derived from a non-coding plasmid DNA sequence and 
JOZ193-A9 that did not translate in the correct frame to match a protein annotation, all 
selected sequences were linked with a protein annotation in GenBank. 
In order to identify the most promising biomarker candidates, the reactivity of the different 
serum pools with all selected oligopeptides was determined by ELISA, reactivity was 
scored from 0 - 3 and presented as heat map (Table 3-5). Based on the reactivity of the 
different serum pools, the clones JOZ191-F12 and JOZ194-C4 were excluded from the 
panel for further characterization with single IBD sera. 
Table 3-5: Heat map of serum reactivity of different IBD serum pools with the selected biomarker candidates. 
Clones marked with asterisk were further analyzed. 
 Pool 1 (CD) 
Pool 2 
(CD) 
Pool 3 
(CD) 
Pool 4 
(CD) 
Pool 5 
(UC) 
Pool 6 
(UC) 
Control 
pool  
(health) 
JOZ191-E5* 0 0 2 0 0 0 0 
JOZ191-F12 1 0 0 0 0 1 0 
JOZ191-G8* 1 0 3 1 0 0 0 
JOZ192-A10* 1 0 2 2 0 0 0 
JOZ193-A9* 2 0 0 1 3 3 1 
JOZ194-C4 1 0 0 0 0 1 0 
Hyperphage 
control 0 0 0 0 0 0 0 
 
3.2.2.2 Matched samples 
In order to select gut microbiota derived immunogenic oligopeptides in a matched panning 
approach, the ORF enriched libraries were pooled according to their disease phenotype 
(CD, library 4 and 5/UC, library 6 and 7) and four individual pannings were performed 
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using immobilized serum antibodies (IgA, IgG and IgM in combination) from the IBD 
patients that served as donors for the gut metagenomic DNA. 
Previous pannings resulted in enrichment of also universal immunoglobulin binding 
proteins (data not shown) and phage titers suggested a large enrichment of specifically 
bound oligopeptides already in panning round two (Suppl. Figure 2). Therefore, the 
metaproteome phage display libraries were precleared from universal immunoglobulin 
binding oligopeptides and peptides that were not specific for IBD by incubation with 
immobilized serum antibodies from healthy donors. To keep a broader diversity of 
selected oligopeptides, 92 clones from each panning were already screened after the 
second panning round by monoclonal phage ELISA (data not shown). Antibody responses 
were measured with the designated patient serum used for panning and a serum pool of 
healthy donors to exclude universal immunoglobulin binding proteins and oligopeptides 
reactive with sera from healthy individuals. 
In total, 32 individual clones were selected including two universal immunoglobulin binding 
proteins (complete list in Suppl. Table 1). In order to exclude oligopeptides that were only 
reactive with the single patient serum used for the selection, cross-reactivity with the 
4 patient sera used for panning and 6 different IBD serum pools as well as a healthy 
control pool was determined by ELISA. Nine different clones seemed to be specific for 
IBD (Table 3-6). However, clone JOZ241-A4 and JOZ243-E9 were identical overlapping 
clones with JOZ241-A4 having 8 additional N-terminal amino acids and JOZ243-E9 one 
additional C-terminal amino acid. The selected specific sequences ranged from 31 bp to 
349 bp. Clone JOZ243-F9 was not in-frame with phage pIII and therefore should not result 
in functional phage particles. However, the sequence of JOZ243-F9 contained another 
start codon downstream of the pelB leader and translation from this start codon resulted 
in an ORF with phage pIII that also contained an N-terminal signal peptide recognized by 
E. coli as predicted by SignalP 4.1 analysis (Petersen, Brunak, von Heijne, & Nielsen, 
2011). The selection of out-of-frame sequences that contained alternative start codons 
resulting in ORFs with phage pIII and endogenous N-terminal signal peptides was 
described before (Connor et al., 2016). 
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Table 3-6: Selection of candidate oligopeptides with potential IBD specific features 
Clone Panning Insert size (bp) Copies Origin (blastn) Protein 
GenBank 
Accession 
JOZ240-D7 CD 1 181 1 Escherichia coli (E value 3e-88) outer membrane lipoprotein AKK49496.1 
JOZ240-H2 CD 1 121 1 
Bifidobacterium longum 
subsp. Longum 
(E value 3e-55) 
- - 
JOZ241-A4 CD 2 229 1 Bifidobacterium adolescentis (E value 1e-111) glycine-rich cell wall protein AJE06446.1 
JOZ241-C4 CD 2 349 1 Enterococcus faecalis (E value 2e-176) chlorohydrolase family protein AAO81020.1 
JOZ242-C9 UC 1 328 1 Bifidobacterium breve (E value 7e-170) Hypothetical protein ALE13104.1 
JOZ242-G4 UC 1 217 1 Unknown - - 
JOZ243-F12 UC 2 31 3 Unknown - - 
JOZ243-E9 UC 2 208 1 Bifidobacterium adolescentis (E value 5e-100) glycine-rich cell wall protein AJE06446.1 
JOZ243-F9 UC 2 296 1 Bifidobacterium adolescentis (E value 9e-149) 1,4-beta-N-acetylmuramidase AII76920.1 
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Nucleotide BLAST analysis of the selected sequences did not return any annotation for 
the clones JOZ242-G4 and JOZ243-F12 but the remaining sequences were found to 
originate from E. coli, Enterococcus faecalis and Bifidobacterium species.  
3.2.3 Validation of IBD specific immune responses by ELISA 
In order to assess the specificity of the selected oligopeptides, the reactivity of 25 sera 
from CD patients, 25 UC patient sera and 9 healthy control sera was measured by ELISA. 
Reactivity of the oligopeptides of the unmatched panning approach was determined using 
synthetic peptides whereas specific reactivity against oligopeptides from the matched 
panning approach was determined based on oligopeptide phage. 
3.2.3.1 Unmatched samples (synthetic peptides) 
No oligopeptide showed strong serum reactivity specific for one of the IBD phenotypes or 
IBD in general (Figure 3-6). 
 
Figure 3-9: Reactivity of IBD serum cohorts with biomarker candidates selected by an unmatched panning 
approach (synthetic peptides). Serum response was determined by ELISA and plotted as mean of duplicate 
measurement. A background subtraction of streptavidin binding was included. The median cohort reactivity is 
indicated by a black line. Peptides were immobilized by streptavidin and bound serum antibodies from single 
sera (1:500 dilution) were detected with an anti-human (IgA, IgG, IgM) antibody. 
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Notably, the IBD cohorts contained at least one serum that reacted very strongly with the 
respective oligopeptide whereas this sample was part of the pool used for selection. The 
selection of the respective oligopeptides was presumably only due to the very high 
antibody titers in one individual serum of the pool. At least, some IBD sera also reacted 
with the peptide JOZ191-G8 even though it was not significant when compared to the 
healthy control cohort. Applying an unmatched panning approach did not result in the 
selection of oligopeptides that were highly sensitive to the IBD serum cohorts. 
3.2.3.2 Matched samples (oligopeptide phage) 
Selecting immunogenic oligopeptides using serum antibodies and the metaproteome 
phage display library from the same donor did not result in candidate biomarkers that 
reacted with the majority of samples in the IBD serum cohorts (Figure 3-10).  
 
Figure 3-10: Reactivity of IBD serum cohorts with biomarker candidates selected by a matched panning 
approach (oligopeptide phage). Serum response was determined by ELISA and plotted as mean of triplicate 
measurement. A background subtraction of phage binding was included. The median cohort reactivity is 
indicated by a black line. Oligopeptide phage (2.5 x 107 cfu) were immobilized by an anti-M13 antibody and 
bound serum antibodies from single sera (1:500 dilution) were detected with an anti-human (IgA, IgG, IgM) 
antibody. 
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The cohorts contained the sera that were used for the selection and these single sera 
reacted strongly with the respective oligopeptide phage. Only a few other sera of the IBD 
cohorts were also reactive with some of the selected candidate biomarkers. But there was 
no biomarker candidate that suggested promising features for diagnostic performance in 
IBD. 
However, except from oligopeptide JOZ240-D7, sera from the healthy control cohort did 
not react with the candidate biomarkers at all, i.e. serum reactivity was specific to IBD. 
The patterns of serum reactivity differed for the different oligopeptides (different sera were 
reactive with different oligopeptides) suggesting that combining the different candidate 
biomarkers in a panel may increase diagnostic performance as demonstrated by a 
preliminary receiver-operator-characteristics (ROC) excluding JOZ240-D7 (Figure 3-11). 
Whereas the biomarker panel conferred increased diagnostic performance over single 
markers with best combined sensitivity and specificity of 84 % and 66.7 %, discrimination 
between the two phenotypes CD and UC was not possible. 
 
Nevertheless, these results motivated to produce the selected oligopeptides as synthetic 
peptides or recombinant oligopeptides and full-length proteins to verify these preliminary 
findings on recombinant protein level and a larger control cohort. Also, full-length proteins 
would potentially further increase sensitivity due to additional immunogenic epitopes. 
Figure 3-11: Receiver-operator-characteristics for a panel of biomarker candidates (oligopeptide phage). 
Specificity and sensitivity was calculated at thresholds of 1x, 2x, 3x, 5x, 10x and 20x standard deviation of the 
negative cohort. If the serum response of at least one marker was greater than the threshold (i.e. positive), 
the response of the panel was considered positive. 
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3.2.4 Recombinant production of biomarker candidates 
For the recombinant production of the selected oligopeptides and the originating full-
length proteins (if known), the coding DNA sequences were PCR amplified and cloned 
into pET21a(+) and pET21a(+)-pelB for both cytoplasmic and periplasmic expression in 
E. coli. Additionally to the oligopeptides selected applying the matched panning approach, 
clone JOZ191-G8 from the unmatched approach was included in the panel for 
recombinant protein production. PCR amplification of the genes coding for the full-length 
proteins was performed using the amplified metagenomic DNA as template and 
oligonucleotide primers based on the annotations found by blast analysis (Table 3-4 and 
Table 3-6). 
PCR amplification of the genes coding for the full-length protein using metagenomic 
template DNA resulted in PCR products with the expected fragment size. However, as 
determined by DNA sequencing, they did not match the found annotation with 
100 % identity (Suppl. Table 2 and Suppl. information) suggesting a broad variety of 
homologue proteins from various species in the gut metaproteome. Cloning the gene 
coding for the full length protein of JOZ243-F9 (AII76920.1) was not possible at all. 
 
Figure 3-12: Coomassie gel of recombinant biomarker candidate proteins. The full-length protein JOZ191-G8 
precipitated after purification and only minute amount of protein were loaded on the gel. The protein 
preparations of JOZ241-C4 domain and JOZ241-A4 full-length contained marked E. coli protein impurities. 
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The production of the recombinant full-length proteins was only possible for JOZ191-G8, 
JOZ241-C4 and JOZ241-A4 and for the domains JOZ241-C4, JOZ243-E9 and 
JOZ241-A4 (Figure 3-12). 
The full-length protein JOZ191-G8 precipitated after purification and only minute amounts 
of proteins remained in solution when 8 M urea was added (Figure 3-12, lane 1, ~40 kDa 
protein). The protein preparation JOZ241-C4 (domain) and JOZ241-A4 (full-length) 
contained many E. coli protein impurities. The production and purification of the 
oligopeptides or protein domains of JOZ240-H2, JOZ242-C9, JOZ242-G4 and JOZ243-F9 
failed to yield sufficient recombinant protein. Therefore, the oligopeptides JOZ191-G8, 
JOZ240-H2, JOZ243-F9 and JOZ243-F12 were chemically synthesized as peptides and 
the clones JOZ242-C9 and JOZ242-G4 had to be excluded from the panel. The resulting 
panel for further validation as recombinant protein or synthetic peptide is summarized in 
Table 3-7. 
Table 3-7: Summary of biomarker candidates available as recombinant protein or synthetic peptide 
Clone Oligopeptide/ domain Full-length protein 
JOZ191-G8 synthetic recombinant 
JOZ240-H2 synthetic - 
JOZ241-A4 recombinant recombinant 
JOZ241-C4 recombinant recombinant 
JOZ242-C9 failed failed 
JOZ242-G4 failed - 
JOZ243-F12 synthetic - 
JOZ243-E9 recombinant failed 
JOZ243-F9 synthetic failed 
 
3.2.5 Assessment of diagnostic performance of a biomarker panel (peptide/ 
recombinant protein) 
For the validation of the selected biomarker candidates on recombinant protein level, 
reactivity of the IBD sera (see above) and healthy control sera was determined by ELISA 
(Figure 3-13). Additionally to the nine healthy control sera used previously, a larger cohort 
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of 55 appropriate matched control sera was included (healthy control sera were a kind gift 
from Dr. Thomas Skurk, TU München, Germany). 
 
Figure 3-13: Reactivity of IBD serum cohorts with biomarker candidates selected by a matched panning 
approach (recombinant protein and synthetic peptide). Serum response was determined by ELISA and plotted 
as mean of triplicated measurement. A background subtraction step was included. The median cohort reactivity 
is indicated by a black line. Reactivity of the serum (or samples of serum pool) used for candidate selection are 
highlighted in red; healthy control sera are highlighted in orange. Recombinant proteins and peptides were 
directly immobilized and bound serum antibodies from single sera (1:500 dilution) were detected with an anti-
human (IgA, IgG, IgM) antibody.  
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The validation of the biomarker candidates on the level of recombinant proteins or 
synthetic peptides failed. Although some sera of the IBD cohort were reactive with the 
recombinant proteins and synthetic peptides, an equal portion of sera from the control 
cohort also reacted with the selected biomarker candidates. 
The protein preparations from JOZ191-G8 (full-length), JOZ241-A4 (full-length) and 
JOZ241-C4 (domain) were most reactive with all sera considered as background and most 
likely resulted from the high amount of E. coli protein impurities in the sample. Background 
in the remaining samples was decreased especially for the synthetic peptides purified by 
HPLC. 
The serum used for the selection of the biomarker candidates was always (except from 
JOZ240-H2) among the sera most reactive with the corresponding protein or peptide 
(Figure 3-13, marked in red) demonstrating the selection was indeed based on the specific 
interaction of serum antibodies and displayed oligopeptide. Notably, all healthy control 
sera of the initial validation on oligopeptide phage level were among the least reactive 
sera (Figure 3-13, marked in orange) recapitulating initial findings that sera from healthy 
individuals did not react with the biomarker candidates. Nevertheless, these findings were 
not confirmed with a larger cohort of control sera and consequently the selected biomarker 
candidates were not specific to IBD. 
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4 Discussion 
The present work describes a biomarker discovery approach based on functional 
proteomics using the phage display technology (ORFeome phage display). Whereas 
previous studies successfully identified biomarkers of single pathogens using the 
ORFeome phage display technology (Becker et al., 2015; Connor et al., 2016; Kügler et 
al., 2008; Meyer et al., 2012; Naseem et al., 2010), in the present study, the technology 
was applied for the first time in a metagenomic context. The goal was to identify novel gut 
microbiome-derived biomarker candidates for inflammatory bowel disease, a chronic 
inflammatory disorder of the gut that results from an aberrant immune reaction against the 
gut microbiome in genetically susceptible hosts. 
First, as a proof-of-concept, the technology was applied using a mouse model. Therefore, 
three metaproteome phage display libraries were constructed from gut microbiome-
derived metagenomic DNA of TNFARE/+ mice, a mouse model for Crohn’s disease-like 
ileitis. Successfully identifying three novel immunogenic oligopeptides that had specifically 
induced an immune response in inflamed mice prove the ORFeome phage display 
technology to be applicable in a metagenomic context. However, compared to phage 
display libraries covering genomes of one species, metagenomic approaches require 
larger libraries. Estimating the necessary total library diversity to cover whole 
metagenomes is very difficult as the gut microbiome composition and relative abundance 
of the different species is not completely known. The human gut microbiome harbors 
several hundred different bacterial species (Human Microbiome Project, 2012) with more 
than 10 million genes (Li et al., 2014; Qin et al., 2010) and although the libraries contained 
more than 107 clones and up to 20 Gbp, they presumably still did not cover the entire 
metagenome. Especially genes from species with low abundance may have been 
underrepresented. Additionally, the metagenomic DNA used for library construction may 
have also contained DNA of other microorganisms such as fungi and protozoa as well as 
viruses, host and food-derived DNA. In a previous study, however, serological expression 
cloning (SEREX) of randomly fragmented metagenomic DNA from the caecum of 
C3H/HeJBir mice and screening of 6x 105 pfu of the lambda expression libraries was 
sufficient to identify bacterial flagellin as immunogenic protein (Lodes et al., 2004). The 
metaproteome phage display libraries constructed in the present work contained more 
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than 107 individual clones and exceeded the library size from the study by Lodes et al. at 
least 20-fold. Moreover, similar to the ORFeome phage display technology, SEREX relies 
on non-directional cloning of randomly fragmented DNA, so only a small fraction (typically 
less than 6 %) of inserts usually result in open reading frames. Employing non-lytic M13 
phage and a special helperphage with deleted gIII (“Hyperphage”) (Rondot et al., 2001; 
Soltes et al., 2007), the ORFeome phage display technology not only allows the screening 
by monoclonal ELISA but also an ORF enrichment (Hust et al., 2006) prior to selection. 
The metaproteome phage display libraries of the present work contained up to 80 % open 
reading frames based on Sanger DNA sequencing of 20 clones. Hence, ORFeome phage 
display libraries contain a much lower number of junk fragments which can hamper 
functional selection due to a propagation bias of these fragments (Hust et al., 2006). 
Although the constructed metaproteome phage libraries did most likely not cover the full 
gut metagenome, they still had a substantial degree of diversity that allowed their use as 
starting materials for peptide selection. Moreover, the ability to perform culture-
independent proteomic studies is one of the superior characteristics of the technology, 
clearly demonstrated as in the gut microbiome only 56 and 70 % of 16S rRNA reads 
detected by sequencing have been related to cultivated bacteria at the species and genus 
level, respectively (Goodman et al., 2011). 
The present study provides the first analysis of ORFeome phage display libraries based 
on NGS data and revealed that only few clones were overrepresented in the libraries but 
the majority of sequences were equally distributed. In another NGS study analyzing a 
commercial peptide phage library (Ph.D.™-12) after amplification, the authors acquired 
2x 107 reads to analyze a library of 106 unique sequences (Matochko et al., 2012). This is 
about the 50-fold sequencing depth compared to the present study suggesting that the 
full library diversity of the present study was not covered especially considering that only 
10 % of sequences were shared between triplicate library preparations. Nevertheless, 
sequencing depth was sufficient to gain insights into the size distribution and relative 
abundance of individual clones in the libraries. Analyzing the Ph.D.™-12 peptide phage 
library, the authors reported a strong bias towards 150 clones that dominated 20 % of the 
library (with 20 clones accounting for 8 %) (Matochko et al., 2012). The broad size 
distribution ranging from 8 to 476 bp would suggest an even stronger bias in the ORFeome 
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phage display libraries due to different inserts having different impact on cell growth. 
However, the 20 most abundant clones accounted for less than 0.5 % of total reads, 
indicating the lack of a respective bias in the ORFeome phage display libraries. Moreover, 
the size distribution of nucleotide inserts revealed a strong enrichment (70.3 % of total 
sequences) of clones with inserts of 3n+1 nucleotides representing again a strong 
enrichment of ORFs as only insert with 3n+1 nucleotides can result in ORFs. The degree 
of enrichment reflected the ORF enrichment based on small sample DNA sequencing and 
is in line with previously reported ORF enrichment using the ORFeome phage display 
technology (Connor et al., 2016; Hust et al., 2006). In the packaged ORFeome phage 
display libraries remained about 30 % inserts which were not in frame with the pIII and in 
theory they should not result in infective phage particles. But functionally displayed 
oligopeptides derived from inserts with frameshifts were described before (Cárcamo et al., 
1998; Goldman, Korus, & Mandecki, 2000; Hust et al., 2006) and were proposed to result 
from RNA secondary structures or a selection pressure against oligopeptides which may 
be toxic for the E. coli host. Therefore, an enrichment for 100 % ORFs may not be possible 
at all. 
For two out of the three selected immunogenic oligopeptides, consisting of 20 and 
56 amino acids, an identification by blast analysis was not possible. The third selected 
oligopeptide comprised 40 amino acids of a phosphoribosylaminoimidazole-
succinocarboxamide synthase (SAICAR synthase) of Blautia sp. and is very similar to 
SAICAR synthases from other highly abundant members of the mammalian gut (e.g. 
Dorea sp. and Clostridium sp.) but the exact origin of the DNA sequence was not 
identified. The closest similarity was to the Roseburia hominis SAICAR gene. SAICAR 
synthase is an enzyme involved in the de novo biosynthesis of purine nucleotides (Lukens 
& Buchanan, 1959) and is essential for all living organisms. Due to structural and 
functional differences between microbial and vertebrate SAICAR synthase, selective 
inhibitors have been proposed as antimicrobial agents (Ginder, Binkowski, Fromm, & 
Honzatko, 2006) and structural differences may confer immunogenicity to bacterial 
SAICAR synthase. 
The antibody response against the selected oligopeptides was not only specific for mice 
suffering from ileal inflammation but there was also a trend towards a correlation between 
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ileal inflammation and antibody response. Additionally, mice kept under specific pathogen 
free conditions that developed less inflammation (and were lacking colonic inflammation) 
also showed decreased serum response against the selected peptides if present at all. 
Lacking immune response against the oligopeptide JOZ158-G8 may indicate the absence 
of the originating species in SPF housing suggesting not only an influence of gut 
inflammation but also of the gut microbiome composition on the humoral immune 
response. 
The successful identification of immunogenic oligopeptides specific for the TNFARE/+ 
mouse model of Crohn’s disease using ORFeome phage display motivated to apply the 
technology also to human IBD samples to identify novel biomarker candidates for IBD. 
Following two different panning strategies, candidate oligopeptides were selected from 
gut microbiome-derived metaproteome phage display libraries of IBD patients. However, 
neither a panning approach that used a pool of IBD sera for selection nor combining library 
and serum derived from the same donor individual for selection resulted in oligopeptides 
highly reactive with the majority of samples in the tested IBD cohort. Lacking sensitivity of 
the selected biomarker candidates suggest that strong individual-specific antibody 
responses were driving the oligopeptide selection and universal markers may not even be 
existent with high antibody titers. Nevertheless, the absence of reactive sera in the 
preliminary control group suggested that antibody responses against gut microbiome-
derived antigens are more diverse in humans and a combination of these markers may 
confer some diagnostic accuracy. Increased diagnostic performance by combining 
different serologic, genetic and fecal markers has been described before (Plevy et al., 
2013). However, the further validation of the selected panel of biomarker candidates was 
not possible as a larger control group demonstrated the selected oligopeptides were not 
specific to IBD and even healthy individuals can have high antibody titers against proteins 
of the gut microbiome. 
Despite the transgenic model spontaneously develops gut inflammation and has many 
shared features with human Crohn’s disease such as the involvement of TNF and the gut 
microbiome as inflammation trigger (Schaubeck et al., 2015), there are certain limitations 
for the translation to human IBD. The mice used in this study most likely represented a 
more homogenous cohort regarding the gut microbiome composition than a human IBD 
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cohort and this might have been reflected in a more homogenous immune response. First 
of all, host genetics is a determinant of gut microbiome composition. Twin studies in 
humans revealed the gut microbiome composition in monozygotic twins is more similar 
than in dizygotic twins (Goodrich et al., 2014). In a study conducted by Turnbaugh and 
colleagues the trend of less dissimilar microbiomes in monozygotic twins was not 
significant but the microbiome between twins (di- and monozygotic) was more similar than 
to their mothers’ (Turnbaugh et al., 2009) suggesting that the gut microbiome is shared 
among family members and the closer host genetics are the more similar the gut 
microbiota compositions becomes. The transgenic animals used in the present study have 
a common genetic offspring and partially originated from the same parental animals. Thus, 
the genetic homogeneity of experimental mice did not reflect the true situation in a human 
cohort. Further, the maternal transmission of the microbiota in mammals was reported to 
influence the gut microbiome in mouse studies (Benson et al., 2010; Friswell et al., 2010) 
and the influence of a common maternal animal has to be considered not only with respect 
to host genetics. Although some of the mouse cohorts were not housed under strictly 
controlled SPF conditions, the housing might still have influenced the gut microbiome as 
cage mates interact with each other. Multiple studies have reported a homogenization of 
the gut microbiome between co-housed mice (Elinav et al., 2011; Zenewicz et al., 2013) 
which might result from repeated inoculation of cage mates by coprophagy. Another 
environmental influence on the gut microbiome is the diet. All mice were fed the same 
standardized diet and diet was shown to have an impact on gut microbiome composition 
as it was able to shift the enterotype of wild mice housed under laboratory conditions on 
chow diet (Wang et al., 2014). 
Although all animals in the study had a common genetic background, were fed the same 
diet and were at the same age there were still inter-individual differences in gut 
microbiome composition as well as in the reactivity of sera towards the selected 
oligopeptides. With respect to genetic variability, age and individual lifestyle the gut 
microbiome may be even more individual-specific in humans. A recent population-level 
microbiome study has identified 69 factors associated with gut microbiome composition 
(Falony et al., 2016). Thus, great heterogeneity and relatively small number of human 
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samples in the cohort may have hampered the selection of universal biomarker 
candidates. 
IBD has been associated with shifts in microbiome composition rather than a single 
pathogen signature (Gevers et al., 2014). Antibody serum markers with highest 
prevalence are directed against autoantigens or microbial structures that seem not very 
specific to single species. ASCAs are antibodies against yeast carbohydrate structures 
(Sendid et al., 1996) and antibodies against bacterial proteins are directed against flagellin 
of gram-positive bacteria (Lodes et al., 2004), protein I2 from Pseudomonas fluorescens, 
which is a homologue of bacterial transcription factor tetR (Sutton, Kim, et al., 2000; Wei 
et al., 2002) as well as E. coli OmpC that may be a cross-reaction with autoantigens 
(Cohavy et al., 2000). Additionally, antibody responses against common gut bacteria were 
shown to have higher diagnostic accuracy than single antigens (Adams et al., 2008). 
Consequently, antibodies found in IBD patients potentially result from an increased 
exposure of gut microbial antigens as a consequence of epithelial leakiness. This might 
be reflected by the specific antibody response against bacterial SAICAR synthase as a 
rather universal antigen found in the TNFARE/+ mouse model. Whether inflammation is 
causative for barrier breakdown alone still has to be elucidated as findings that affected 
and unaffected first-degree relatives have increased antibody titers against bacterial 
antigens suggesting a genetic influence rather than a consequence of inflammation (Mei 
et al., 2006; Michielan et al., 2013; Sutton, Yang, et al., 2000; Török et al., 2005).  
Gut inflammation in TNFARE/+ mice develops gradually over age (Baur et al., 2011; 
Kontoyiannis et al., 1999) whereas human IBD is characterized by periodically occurring 
intestinal inflammation. The samples used for the selection of biomarker candidates were 
from patients in disease remission. Antibody titers specific for IBD were reported to be 
stable over the disease (Müller et al., 2005; Seibold, 2005). However, this seems to be 
controversial as other studies reported a correlation between antibody titers and disease 
activity (Canani et al., 2004; El-Matary, Dupuis, & Sokoro, 2015) which was supported by 
the findings that serum response in TNFARE/+ mice tended to correlate with gut 
inflammation. Moreover, the successful identification of bacterial flagellin as serologic 
marker for Crohn’s disease (Lodes et al., 2004) was based on a colitogenic mouse model 
that develops strong IgG responses against antigens of the enteric flora (Brandwein et al., 
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1997). The ASCA/ANCA status as surrogate for antibody titers against microbiota-derived 
antigens was unknown for the human IBD samples and information about anti-TNF 
treatment was not available. Anti-TNF treatment was previously reported to impact ASCA 
levels (Frehn et al., 2014). Therefore, from a technological perspective the relevant 
antibody titers might not have been high enough to allow the selection of disease-specific 
biomarkers. Heterogeneity of the human IBD cohorts together with phenotypic differences 
in disease course compared to the mouse model added another level of complexity to the 
selection of biomarker candidates. Consequently, as long as the complex pathogenic 
mechanisms underlying IBD are not completely understood, it might be difficult to develop 
a rational strategy for the selection of novel biomarker candidates. 
In conclusion, despite the ORFeome phage display technology has demonstrated 
promising features for the identification of microbiome-derived biomarkers in a mouse 
model of Crohn’s disease it was not possible to eventually identify such markers using 
human IBD samples. Heterogeneity of the human IBD cohorts as well as unclear antibody 
levels in the IBD samples may have hampered biomarker candidate selection. 
Nevertheless, the technology was proven for its applicability to metagenomic samples and 
libraries may be constructed from any type of genomic or metagenomic DNA. Thus, 
ORFeome phage display may also facilitate the use of environmental metagenomes to 
identify protein interaction partners of microbial communities with potential further interest 
for biotechnological or industrial processes.  
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5 Outlook 
The present study described the first successful application of ORFeome phage display 
in a metagenomic context and prove the technology to be applicable to study host-
microbiome interactions. Metagenomes provide a rich source for novel protein functions 
and the technology may not only be used to identify disease related biomarkers but also 
protein interaction partners from environmental samples that are of biotechnological 
interest. 
Further technological development of ORFeome phage display may still be possible 
considering library design. Using a more homogenous insert size distribution in initial 
libraries may decrease bias towards smaller fragments during ORF enrichment and phage 
packaging. With respect to the increased complexity when using whole metagenomes for 
library construction, the ELISA-based screening approach of 92 clones may limit the 
panning output especially considering the heterogeneity of human cohorts in a disease 
context like IBD. Future studies may include NGS analysis to provide a more 
comprehensive analysis of panning output and array-based screening methods may 
identify profiles of antibody responses rather than single immunogenic proteins. Using 
newly developed array copier and in vitro translation technologies, array-based screening 
might be implemented into the workflow and make the ORFeome phage display 
technology even more powerful.  
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6 Summary 
Pathogen infections, autoimmune diseases, and chronic inflammatory disorders are 
associated with systemic antibody responses from the host immune system. Disease-
specific antibodies can be important serum biomarkers, but the identification of antigens 
associated with specific immune reactions is challenging, in particular if complex 
communities of microorganisms are responsible for the disease. Despite promising new 
diagnostic opportunities, the discovery of these serological markers is difficult and 
becomes even more challenging with increasing complexity of the microbial communities.  
In the present work, a metagenomic M13 phage display approach (ORFeome phage 
display) was used to identify novel gut microbiome-derived biomarker candidates in the 
disease context of inflammatory bowel disease (IBD). As a proof-of-concept, TNFΔARE/+ 
mice of Crohn’s-like experimental ileitis were used. Three individual metaproteome phage 
display libraries with a library size of approximately 107 clones each were constructed 
from the caecum of ileal inflamed mice. The libraries were analyzed by next generation 
sequencing revealing a substantial degree of diversity for oligopeptide selection. Using 
serum antibodies, three oligopeptides that induced specific antibody responses in 
inflamed mice were selected and validated.  
Translating the technology to human IBD, metaproteome phage display libraries were 
constructed from the gut microbiome of patients suffering from Crohn’s disease and 
ulcerative colitis. Several candidate oligopeptides were selected using patient sera and 
were initially validated on oligopeptide phage level with a small control cohort. But using 
a larger control cohort, it was not possible to confirm the selected immunogenic proteins 
being IBD-specific. Broader cohort heterogeneity of humans compared to a mouse model 
may have hampered the selection of specific biomarker candidates for human IBD. 
Nevertheless, the present work provides the first successful application of ORFeome 
phage display using a metaproteome approach for the study of protein-protein interactions 
and the discovery of potential disease biomarkers.  
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11 Supplemental Information 
11.1 Supplementary tables 
Suppl. Table 1: Summary of selected clones and heat map of reactivity with different IBD pools. Clones marked 
with asterisk were further analyzed. (S = single serum used for selection; 1-4 CD serum pools; 5-6 UC serum 
pools; 7 = healthy control serum pool) 
 Insert 
size (bp) Copies 
IBD serum 
Clone S 1 2 3 4 5 6 7 
JOZ240-B11 172 1 1 0 0 0 0 0 0 0 
JOZ240-B7 100 1 2 0 0 0 0 0 0 0 
JOZ240-D12 34 1 3 0 0 0 0 0 0 0 
JOZ240-D7* 181 1 1 0 1 0 0 0 1 0 
JOZ240-D9 74 1 1 0 1 0 0 0 0 0 
JOZ240-E3 178 2 2 0 0 0 0 0 0 0 
JOZ240-E4 115 1 0 0 0 0 0 0 0 0 
JOZ240-G3 199 1 2 0 1 0 1 0 1 1 
JOZ240-G4 409 1 3 3 3 3 3 3 3 3 
JOZ240-G5 280 1 2 0 1 0 0 0 0 0 
JOZ240-H2* 121 1 2 0 0 0 0 0 0 0 
JOZ241-A4* 229 1 1 0 1 0 2 0 1 0 
JOZ241-C4* 349 1 2 0 1 0 1 0 0 0 
JOZ241-E1 490 5 3 3 3 3 3 3 3 3 
JOZ241-F4 94 1 1 1 1 0 1 0 0 1 
JOZ241-F8 94 3 1 0 1 0 0 0 0 0 
JOZ242-B2 163 1 0 0 1 0 0 0 0 1 
JOZ242-C1 157 1 0 0 1 0 0 0 0 0 
JOZ242-C11 277 1 1 1 0 0 0 0 0 0 
JOZ242-C9* 328 1 2 1 1 0 1 0 0 0 
JOZ242-G4* 217 1 1 2 0 0 1 1 1 0 
JOZ242-H4 76 1 2 0 0 0 0 0 1 0 
JOZ243-B9 118 1 2 0 1 0 0 0 0 0 
JOZ243-F12* 31 3 3 1 0 0 2 0 2 0 
JOZ243-C7 280 1 2 0 0 0 0 0 0 0 
JOZ243-E11 181 1 2 1 0 0 0 0 0 0 
JOZ243-E9* 208 1 2 1 1 0 2 1 1 0 
JOZ243-F1 115 1 0 1 0 0 0 0 0 0 
JOZ243-F11 196 1 1 0 0 0 1 0 0 0 
JOZ243-F9* 296 1 1 0 1 1 1 0 0 0 
JOZ243-G3 277 1 2 0 1 0 0 0 0 0 
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Suppl. Table 2: Summary of PCR amplified and cloned full-length genes 
Full length 
protein 
GenBank 
Accession 
Identity DNA 
level (%) 
Identity protein 
level (%) 
Identity selected 
and amplified 
sequence (DNA 
level) (%) 
JOZ191-G8 ALY14458.1 97.0 98.7 93 
JOZ241-A4 AJE06446.1 99.1 98.9 100 
JOZ241-C4 AAO81020.1 99.2 98.9 100 
JOZ242-C9 ALE13104.1 99.1 99.8 100 
JOZ243-F9 AII76920.1 - - - 
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11.2 Supplementary figures 
 
Suppl. Figure 1: Illustration of the cloning site in the ORFeome phage display vector pHORF3. Only insert with 
3n+1 nucleotides result in open reading frames with pelB leader sequence, hexahistidine tag and M13 minor 
coat protein III gene (gIII). 
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Suppl. Figure 2: Enrichment of binding oligopeptide phage in the unmatched panning approach. Enrichment in 
second panning round by more than two orders of magnitude and in third round by only about one order of 
magnitude. Phage titers were determined by infecting E. coli with dilution series of phage and spotting on 
ampicillin supplemented medium. 
  
Supplemental Information 
 
100 
 
11.3 Sequences 
11.3.1 Mouse approach 
>JOZ156-H5 
GGGACTTCATGGGGAACTTTTGGAATTTTAATTCCTATCGCGACTTCGATTTTCCCCG 
 
>JOZ158-E11 
TCTGGCCTGCTGACGGATATGAACCGGGACACGGTCAGCCTTCCTTTGACAAGCAGTTTGCCCGCGACTGGCTGAAAG
AAAATGACGGTCATGACTGGACTCTTCCTCAGGAGATCGTTGA 
 
>JOZ158-G8 
CAAACGACCTGAACGCGCTGCTTGAGACAAACATATCCGCGGGAACCAGAACTACCCAGGTATCTATGAGCTATTTCG
GGGAAATGCTTATGAGCCATATCGCGGACAATGAATTCTTAAGCGGCTCGGAAGATGAAAAGGCGGCTCACGCAAATG
CGCTTGC 
 
11.3.2 Human approach 
 
11.4 Sequence alignments 
11.4.1 JOZ191-G8 
11.4.1.1 DNA alignment 
                              1                                     40 
           ALY14458.1     (1) ATGGTTAAATTACCGCCGCTGAGTCTCTACATTCACATCC 
JOZ191-G8 full-length     (1) ATGGTTAAATTACCGCCGCTGAGTCTCTACATTCACATCC 
            JOZ191-G8     (1) ---------------------------------------- 
                              41                                    80 
           ALY14458.1    (41) CGTGGTGCGTGCAGAAATGCCCGTACTGCGATTTCAACTC 
JOZ191-G8 full-length    (41) CGTGGTGCGTGCAGAAATGCCCGTACTGCGATTTCAACTC 
            JOZ191-G8     (1) ---------------------------------------- 
                              81                                   120 
           ALY14458.1    (81) TCACGCGTTGAAAGGAGAAGTGCCGCACGACGATTACGTT 
JOZ191-G8 full-length    (81) TCACGCGTTGAAAGGAGAAGTGCCGCACGACGATTATGTT 
            JOZ191-G8     (1) ---------------------------------------- 
                              121                                  160 
           ALY14458.1   (121) CAGCATCTGCTTTGCGATCTGGACAATGATGTGGCTTACG 
JOZ191-G8 full-length   (121) CAGCATCTGCTTAACGATCTGGACAACGATGTGGCTTACG 
            JOZ191-G8     (1) ---------------------------------------- 
                              161                                  200 
           ALY14458.1   (161) CTCAGGGCCGTGAAGTAAAGACAATCTTTATTGGCGGTGG 
JOZ191-G8 full-length   (161) CTCAGGGCCGTGAAGTAAAGACAATCTTTATTGGCGGTGG 
            JOZ191-G8     (1) ---------------------------------------- 
                              201                                  240 
           ALY14458.1   (201) TACGCCGAGCCTGCTTTCCGGCCCGGCGATGCAAACGCTG 
JOZ191-G8 full-length   (201) TACGCCGAGCCTGCTTTCCGGCCCGGCGATGCAAACGCTG 
            JOZ191-G8     (1) ---------------------------------------- 
                              241                                  280 
           ALY14458.1   (241) CTGGACGGCGTGCGTGCGCGTTTGCCGCTGGCAGCGGATG 
JOZ191-G8 full-length   (241) CTGGACGGCGTGCGTGCGCGTTTGCCGCTGGCAGCGGATG 
            JOZ191-G8     (1) ---------------------------------------- 
                              281                                  320 
           ALY14458.1   (281) CAGAAATTACTATGGAAGCGAACCCTGGTACGGTAGAAGC 
JOZ191-G8 full-length   (281) CAGAAATTACTATGGAAGCGAACCCTGGCACGGTAGAAGC 
            JOZ191-G8     (1) ---------------------------------------- 
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                              321                                  360 
           ALY14458.1   (321) CGATCGCTTTGTCGATTATCAGCGTGCTGGTGTGAACCGC 
JOZ191-G8 full-length   (321) CGATCGCTTTGTCGATTATCAGCGTGCTGGTGTGAACCGC 
            JOZ191-G8     (1) ---------------------------------------- 
                              361                                  400 
           ALY14458.1   (361) ATCTCTATTGGTGTGCAGAGTTTTAGCGAAGAAAAGCTGA 
JOZ191-G8 full-length   (361) ATCTCTATTGGTGTGCAGAGTTTTAGCGAAGAAAAGCTGA 
            JOZ191-G8     (1) ---------------------------------------- 
                              401                                  440 
           ALY14458.1   (401) AACGACTTGGGCGTATTCATGGCCCGCAAGAAGCGAAACG 
JOZ191-G8 full-length   (401) AACGACTTGGGCGTATTCATGGCCCGCAAGAAGCGAAACG 
            JOZ191-G8     (1) ---------------------------------------- 
                              441                                  480 
           ALY14458.1   (441) CGCGGCAAAGCTGGCGAGCGGGCTGGGGCTGCGTAGCTTT 
JOZ191-G8 full-length   (441) CGCGGCGAAGCTGGCGAGCGGTTTAGGGTTACGTAGCTTT 
            JOZ191-G8     (1) ---------------------------------------- 
                              481                                  520 
           ALY14458.1   (481) AACCTCGATTTGATGCATGGACTACCGGATCAATCACTGG 
JOZ191-G8 full-length   (481) AACCTTGATTTGATGCATGGGCTGCCGGATCAATCACTGG 
            JOZ191-G8     (1) ---------------------------------------- 
                              521                                  560 
           ALY14458.1   (521) AAGAGGCGCTTGGCGATCTACGCCAGGCCATTGAACTGAA 
JOZ191-G8 full-length   (521) AAGAGGCGCTTGGCGATCTACGCCAGGCCATTGAACTGAA 
            JOZ191-G8     (1) ---------------------------------------- 
                              561                                  600 
           ALY14458.1   (561) TCCGCCGCATCTTTCCTGGTATCAACTGACCATCGAACCT 
JOZ191-G8 full-length   (561) TCCGCCGCATCTTTCCTGGTATCAACTGACCATCGAACCC 
            JOZ191-G8     (1) -----------------------------CCATCGAACCT 
                              601                                  640 
           ALY14458.1   (601) AATACGCTGTTTGGTTCACGCCCGCCGGTACTGCCGGACG 
JOZ191-G8 full-length   (601) AATACGCTGTTTGGTTCGCGACCACCGGTGCTGCCGGACG 
            JOZ191-G8    (12) AATACGCTGTTTGGTTCACGCCCGCCGGTACTGCCGGACG 
                              641                                  680 
           ALY14458.1   (641) ACGACGCGCTGTGGGATATATTCGAACAGGGGCATCAGTT 
JOZ191-G8 full-length   (641) ATGACGCGTTGTGGGATATATTCGAACAGGGGCATCAGTT 
            JOZ191-G8    (52) ACGACGCGCTGTGGGATATATTCGAACAGGGGCATCAGTT 
                              681                                  720 
           ALY14458.1   (681) ATTAACCGCAGCGGGTTATCAGCAATATGAAACTTCCGCT 
JOZ191-G8 full-length   (681) ATTAACCGCAGCGGGTTATCAGCAATATGAAACTTCCGCT 
            JOZ191-G8    (92) ATTAACCGC------------------------------- 
                              721                                  760 
           ALY14458.1   (721) TACGCCAAACCCAGTTATCAGTGCCAGCACAATCTCAACT 
JOZ191-G8 full-length   (721) TACGCCAAACCCGGTTATCAGTGCCAGCACAATCTCAACT 
            JOZ191-G8   (101) ---------------------------------------- 
                              761                                  800 
           ALY14458.1   (761) ACTGGCGCTTTGGCGACTACATCGGTATTGGCTGCGGCGC 
JOZ191-G8 full-length   (761) ACTGGCGCTTTGGTGACTACATCGGTATTGGCTGCGGCGC 
            JOZ191-G8   (101) ---------------------------------------- 
                              801                                  840 
           ALY14458.1   (801) GCACGGCAAAGTGACCTTCCCGGATGGGCGCATTCTGCGT 
JOZ191-G8 full-length   (801) ACACGGCAAAGTGACCTTCCCGGATGGGCGCATTCTGCGT 
            JOZ191-G8   (101) ---------------------------------------- 
                              841                                  880 
           ALY14458.1   (841) ACCACTAAAACGCGTCATCCGCGTGGTTTTATGCAAGGAA 
JOZ191-G8 full-length   (841) ACCACCAAAACGCGTCATCCGCGTGGTTTTATGCAAGGAA 
            JOZ191-G8   (101) ---------------------------------------- 
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                              881                                  920 
           ALY14458.1   (881) GGTATCTGGAAAGCCAGCGTGATGTCGAAGCCGCAGATAA 
JOZ191-G8 full-length   (881) GGTATCTGGAAAGCCAGCGTGATGTCGAAGCCACAGATAA 
            JOZ191-G8   (101) ---------------------------------------- 
                              921                                  960 
           ALY14458.1   (921) GCCGTTTGAGTTCTTTATGAACCGCTTTCGCTTGCTGGAG 
JOZ191-G8 full-length   (921) GCCGTTTGAGTTCTTTATGAATCGCTTCCGTCTGCTGGAG 
            JOZ191-G8   (101) ---------------------------------------- 
                              961                                 1000 
           ALY14458.1   (961) GCCGCGCCACGCGCAGAGTTTAGTGCGTATACCGGGCTTT 
JOZ191-G8 full-length   (961) GCCGCGCCGCGCGTGGAGTTTATTGCGTATACCGGGCTTT 
            JOZ191-G8   (101) ---------------------------------------- 
                              1001                                1040 
           ALY14458.1  (1001) GCGAAGATGTGATTCGCCCACAGTTAGACGAGGCGATTGC 
JOZ191-G8 full-length  (1001) GCGAAGATGTGATTCGCCCACAGTTAGACGAGGCGATTGC 
            JOZ191-G8   (101) ---------------------------------------- 
                              1041                                1080 
           ALY14458.1  (1041) CCAGGGTTATCTCACCGAATGTGCGGATTACTGGCAGATA 
JOZ191-G8 full-length  (1041) CCAGGGTTATCTCACCGAATGTGCGGATTACTGGCAGATA 
            JOZ191-G8   (101) ---------------------------------------- 
                              1081                                1120 
           ALY14458.1  (1081) ACGGAACATGGGAAGCTGTTTTTAAATTCGCTGCTGGAGC 
JOZ191-G8 full-length  (1081) ACGGAACATGGGAAGCTGTTTTTAAATTCGCTGCTGGAGC 
            JOZ191-G8   (101) ---------------------------------------- 
                              1121                                1160 
           ALY14458.1  (1121) TTTTTCTGGCTGAG-------------------------- 
JOZ191-G8 full-length  (1121) TTTTTCTGGCTGAGGCGGCCGCACTCGAGCACCACCACCA 
            JOZ191-G8   (101) ---------------------------------------- 
                              1161 
           ALY14458.1  (1135) ---------- 
JOZ191-G8 full-length  (1161) CCACCACTGA 
            JOZ191-G8   (101) ---------- 
 
 
11.4.1.2 Protein alignment 
                             1                                     40 
           ALY14458.1    (1) MVKLPPLSLYIHIPWCVQKCPYCDFNSHALKGEVPHDDYV 
JOZ191-G8 full-length    (1) MVKLPPLSLYIHIPWCVQKCPYCDFNSHALKGEVPHDDYV 
            JOZ191-G8    (1) ---------------------------------------- 
                             41                                    80 
           ALY14458.1   (41) QHLLCDLDNDVAYAQGREVKTIFIGGGTPSLLSGPAMQTL 
JOZ191-G8 full-length   (41) QHLLNDLDNDVAYAQGREVKTIFIGGGTPSLLSGPAMQTL 
            JOZ191-G8    (1) ---------------------------------------- 
                             81                                   120 
           ALY14458.1   (81) LDGVRARLPLAADAEITMEANPGTVEADRFVDYQRAGVNR 
JOZ191-G8 full-length   (81) LDGVRARLPLAADAEITMEANPGTVEADRFVDYQRAGVNR 
            JOZ191-G8    (1) ---------------------------------------- 
                             121                                  160 
           ALY14458.1  (121) ISIGVQSFSEEKLKRLGRIHGPQEAKRAAKLASGLGLRSF 
JOZ191-G8 full-length  (121) ISIGVQSFSEEKLKRLGRIHGPQEAKRAAKLASGLGLRSF 
            JOZ191-G8    (1) ---------------------------------------- 
                             161                                  200 
           ALY14458.1  (161) NLDLMHGLPDQSLEEALGDLRQAIELNPPHLSWYQLTIEP 
JOZ191-G8 full-length  (161) NLDLMHGLPDQSLEEALGDLRQAIELNPPHLSWYQLTIEP 
            JOZ191-G8    (1) -------------------------------------IEP 
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                             201                                  240 
           ALY14458.1  (201) NTLFGSRPPVLPDDDALWDIFEQGHQLLTAAGYQQYETSA 
JOZ191-G8 full-length  (201) NTLFGSRPPVLPDDDALWDIFEQGHQLLTAAGYQQYETSA 
            JOZ191-G8    (4) NTLFGSRPPVLPDDDALWDIFEQGHQLLT----------- 
                             241                                  280 
           ALY14458.1  (241) YAKPSYQCQHNLNYWRFGDYIGIGCGAHGKVTFPDGRILR 
JOZ191-G8 full-length  (241) YAKPGYQCQHNLNYWRFGDYIGIGCGAHGKVTFPDGRILR 
            JOZ191-G8   (33) ---------------------------------------- 
                             281                                  320 
           ALY14458.1  (281) TTKTRHPRGFMQGRYLESQRDVEAADKPFEFFMNRFRLLE 
JOZ191-G8 full-length  (281) TTKTRHPRGFMQGRYLESQRDVEATDKPFEFFMNRFRLLE 
            JOZ191-G8   (33) ---------------------------------------- 
                             321                                  360 
           ALY14458.1  (321) AAPRAEFSAYTGLCEDVIRPQLDEAIAQGYLTECADYWQI 
JOZ191-G8 full-length  (321) AAPRVEFIAYTGLCEDVIRPQLDEAIAQGYLTECADYWQI 
            JOZ191-G8   (33) ---------------------------------------- 
                             361                       389 
           ALY14458.1  (361) TEHGKLFLNSLLELFLAE----------- 
JOZ191-G8 full-length  (361) TEHGKLFLNSLLELFLAEAAALEHHHHHH 
            JOZ191-G8   (33) ----------------------------- 
 
 
11.4.2 JOZ241-A4 
11.4.2.1 DNA alignment 
                              1                                     40 
           AJE06446.1     (1) ATGGCAACTGAGAACGATGATTCCCAGTCTATGAACGGTA 
JOZ241-A4 full-length     (1) ATGGCAACTGAGAACGATGATTCCCAGTCTATGAACGGTA 
            JOZ241-A4     (1) ----------------ATGATTCCCAGTCTATGAACGGTA 
                              41                                    80 
           AJE06446.1    (41) TTCTGTCCAATATATCTCGGGATGTGGTGGACACCAGCTG 
JOZ241-A4 full-length    (41) TTTTGTCCAACATATCTCGGGATGTGGTGGACACCAGCTG 
            JOZ241-A4    (25) TTTTGTCCAACATATCTCGGGATGTGGTGGACACCAGCTG 
                              81                                   120 
           AJE06446.1    (81) GGATATTCCTCCGCTGACCTTCCCCAAATTGCAGCCTACC 
JOZ241-A4 full-length    (81) GGATATTCCTCCGCTGACCTTCCCCAAATTGCAGCCTACC 
            JOZ241-A4    (65) GGATATTCCTCCGCTGACCTTCCCCAAATTGCAGCCTACC 
                              121                                  160 
           AJE06446.1   (121) GATTCGGAAGAAGCCGATGGTGCGGATGAGGCTTCGCTTG 
JOZ241-A4 full-length   (121) GATTCGGAAGAAGCCGATGGTGCGGATGAGGCTTCGCTTG 
            JOZ241-A4   (105) GATTCGGAAGAAGCCGATGGTGCGGATGAGGCTTCGCTTG 
                              161                                  200 
           AJE06446.1   (161) CTGAGCCCCGCACCATCGCTTCCTCCGTGCCTGCGCAAAC 
JOZ241-A4 full-length   (161) CTGAGCCCCGCACCATCGCTTCCTCCGTGCCTGCGCAAAC 
            JOZ241-A4   (145) CTGAGCCCCGCACCATCGCTTCCTCCGTGCCTGCGCAAAC 
                              201                                  240 
           AJE06446.1   (201) GGAACAGCCGGTTTCGGCTGCGCCAACAATCGCGGATATT 
JOZ241-A4 full-length   (201) GGAACAGCCGGTTTCGGCTGCGCCAACAATCGCGGATATT 
            JOZ241-A4   (185) GGAACAGCCGGTTTCGGCTGCGCCAACAATCGCGGATATT 
                              241                                  280 
           AJE06446.1   (241) CCCAGTATGCCGCTCGATACCGTCGATTTCGATGATGCGG 
JOZ241-A4 full-length   (241) CCCAGTATGCCGCTCGACACCATCGATTTCGATGATGCGG 
            JOZ241-A4   (225) CCCAG----------------------------------- 
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                              281                                  320 
           AJE06446.1   (281) TTGCACCAGCCGATGCCGAGGAAACCGCCACTTTGCCACC 
JOZ241-A4 full-length   (281) TTGCACCAGCCGATGCCGAGGAAACCGCCACTTTGCCACC 
            JOZ241-A4   (230) ---------------------------------------- 
                              321                                  360 
           AJE06446.1   (321) CCTCGTCTCTTCGACAGATGAACAGGACGTCGAAGCGACT 
JOZ241-A4 full-length   (321) CCTCGTCTCTTCGACAGATGAACAGGACGCCGAAGCGACT 
            JOZ241-A4   (230) ---------------------------------------- 
                              361                                  400 
           AJE06446.1   (361) CAGGCCTTTGATACATCAGGTGGCATAACCGACCTAGAGG 
JOZ241-A4 full-length   (361) CAGGCCTTTGACACTTCGGATGGCATAACCGACCTAGAGG 
            JOZ241-A4   (230) ---------------------------------------- 
                              401                                  440 
           AJE06446.1   (401) AGCTGGCCGCGGAAGATCCGGAACATGATCCGCTGAAAAC 
JOZ241-A4 full-length   (401) AACTTGCCGCGGAAGATCCGGAACATGATCCGCTGAAAAC 
            JOZ241-A4   (230) ---------------------------------------- 
                              441                                  480 
           AJE06446.1   (441) CATTCCGGTCGCACCGAAAGAGCCGTCTGCGGACAAGCGA 
JOZ241-A4 full-length   (441) CATTCCGGTCGCACCGAAAGAGCCGTCTGCGGACAAGCGA 
            JOZ241-A4   (230) ---------------------------------------- 
                              481                                  520 
           AJE06446.1   (481) AAGATTATTGCCATTGTCGCTGCGATTGCGGCAGTGGCGG 
JOZ241-A4 full-length   (481) AAGATTATTGCCATTGTCGCTGCGATTGCGGCAGTGGCGG 
            JOZ241-A4   (230) ---------------------------------------- 
                              521                                  560 
           AJE06446.1   (521) TTGCTATTGCCGGTGTCATCGTGGTACGCAATCGTATCAA 
JOZ241-A4 full-length   (521) TTGCTATTGCCGGTGTCATCGTGGTACGCAATCGTATCAA 
            JOZ241-A4   (230) ---------------------------------------- 
                              561                                  600 
           AJE06446.1   (561) TTCGAAAGAACAGCGTGCGGCAGTGGTGGTATGTGAGAAG 
JOZ241-A4 full-length   (561) TTCGAAAGAACAGCGTGCGGCAGTGGTGGTATGTGAGAAG 
            JOZ241-A4   (230) ---------------------------------------- 
                              601                                  640 
           AJE06446.1   (601) GCGAAATCCAAATACTCCAAAGCCAACGAAAAACTGCAAA 
JOZ241-A4 full-length   (601) GCGAAATCCAAATACTCCAAAGCCAACGAAAAACTGCAAA 
            JOZ241-A4   (230) ---------------------------------------- 
                              641                                  680 
           AJE06446.1   (641) ACGCCATCGAACAGGCAACTAGTCTGCAGGGCACTGCGGC 
JOZ241-A4 full-length   (641) ACGCCATCGAACAGGCAACTAGTCTGCAGGGCACTGCGGC 
            JOZ241-A4   (230) ---------------------------------------- 
                              681                                  720 
           AJE06446.1   (681) AAACCAGGTGGCGGATGCCGCCACAATCGACCAGCTCACT 
JOZ241-A4 full-length   (681) AAACCAGGTGGCGGATGCCGCCACAATCGACCAGCTCACT 
            JOZ241-A4   (230) ---------------------------------------- 
                              721                                  760 
           AJE06446.1   (721) CAGGCCGTGACCAAGGCGCAAAACCTCAAGACGGTCGGCG 
JOZ241-A4 full-length   (721) CAGGCCGTGACCAAGGCGCAAAACCTCAAGACGGTCGGCG 
            JOZ241-A4   (230) ---------------------------------------- 
                              761                                  800 
           AJE06446.1   (761) GATGTTCGGTGCTGCTGTCCGAAACCACACTGCGTGCGCA 
JOZ241-A4 full-length   (761) GATGTTCGGTGCTGCTGTCCGAAACCACACTGCGTGCGCA 
            JOZ241-A4   (230) ---------------------------------------- 
                              801                                  840 
           AJE06446.1   (801) CGCCCGTAGCATGAGCAAGCAGATCAGCAATATCAAAGAA 
JOZ241-A4 full-length   (801) CGCCCGTAGCATGAGCAAGCAGATCAGCAATATCAAAGAA 
            JOZ241-A4   (230) ---------------------------------------- 
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                              841                                  880 
           AJE06446.1   (841) CAGACCAAGGCCGTTACCGCAGCAGCCACAGCTGTGGACG 
JOZ241-A4 full-length   (841) CAGACCAAGGCCGTTACCGCAGCAGCCACAGCTGTGGACG 
            JOZ241-A4   (230) ---------------------------------------- 
                              881                                  920 
           AJE06446.1   (881) CCAGCAAGCGAGCTTTGGAAGTGAATAAGACGACTGCCGC 
JOZ241-A4 full-length   (881) CCAGCAAGCGAGCTTTGGAAGTGAATAAGACGACTGCCGC 
            JOZ241-A4   (230) ---------------------------------------- 
                              921                                  960 
           AJE06446.1   (921) ATTGCAGAAGGCCATTGCCGACGCAAAGACGTTGCTTGAC 
JOZ241-A4 full-length   (921) ATTGCAGAAGGCCATTGCCGACGCAAAGACGTTGCTTGAC 
            JOZ241-A4   (230) ---------------------------------------- 
                              961                                 1000 
           AJE06446.1   (961) GGTTCTGCAGGCCAGGTTGCGGACGAGTCGACACGTGACG 
JOZ241-A4 full-length   (961) GGTTCTGCAGGCCAGGTTGCGGACGAGTCGACACGTGACG 
            JOZ241-A4   (230) ---------------------------------------- 
                              1001                                1040 
           AJE06446.1  (1001) CGCTTGCCAAGGCGATTGACGCTGCCCAGAAACTCCTCGA 
JOZ241-A4 full-length  (1001) CGCTTGCCAAGGCGATTGACGCTGCCCAGAAACTCCTCGA 
            JOZ241-A4   (230) ---------------------------------------- 
                              1041                                1080 
           AJE06446.1  (1041) TGGCAAAAGCACCGATGTTGCGGCCATGCAGAACGCTTCG 
JOZ241-A4 full-length  (1041) TGGCAAAAGCACCGATGTTGCGGCCATGCAGAACGCTTCG 
            JOZ241-A4   (230) ---------------------------------------- 
                              1081                                1120 
           AJE06446.1  (1081) AAGGTGATTTCCTCGACTTCTGACGGCGTAAACAAGTCTG 
JOZ241-A4 full-length  (1081) AAGGTGATTTCCTCGACTTCTGACGGCGTAAACAAGTCTG 
            JOZ241-A4   (230) ---------------------------------------- 
                              1121                                1160 
           AJE06446.1  (1121) TGGCGGAGCAAACTGCGGCCAATGCCCAGTCGAATACCAA 
JOZ241-A4 full-length  (1121) TGGCGGAGCAAACTGCGGCCAATGCCCAGTCGAATACCAA 
            JOZ241-A4   (230) ---------------------------------------- 
                              1161                                1200 
           AJE06446.1  (1161) TTCGAATACCAATAACGGCACTACGAACCGGCGTTACACA 
JOZ241-A4 full-length  (1161) TTCGAATACCAATAACGGCACTACGAACCGGCGTTACACA 
            JOZ241-A4   (230) ---------------------------------------- 
                              1201                                1240 
           AJE06446.1  (1201) TATACGTGGCAATTTGGTCCGGGCTCTGGAAACGGTGTGA 
JOZ241-A4 full-length  (1201) TATACGTGGCAATTTGGTCCGGGCTCTGGAAACGGTGTGA 
            JOZ241-A4   (230) ---------------------------------------- 
                              1241                                1280 
           AJE06446.1  (1241) ACGGTGGTGGTTCGACCGGTGGCAATAACAATGGTGGCTC 
JOZ241-A4 full-length  (1241) ACGGTGGTGGTTCGACCGGTGGCAATAACAATGGTGGCTC 
            JOZ241-A4   (230) ---------------------------------------- 
                              1281                                1320 
           AJE06446.1  (1281) AACCGGTGGTAATGGCGATTCGACCGGCAACGGCAACGGC 
JOZ241-A4 full-length  (1281) AACCGGTGGTAATGGCGATTCGACCGGCAACGGCAACGGC 
            JOZ241-A4   (230) ---------------------------------------- 
                              1321                                1360 
           AJE06446.1  (1321) GATTCAAACGGCGGCGGTAACGGCGATTCGAATGACGGTA 
JOZ241-A4 full-length  (1321) GATTCAAACGGCGGCGGTAACGGCGATTCGAATGACGGTA 
            JOZ241-A4   (230) ---------------------------------------- 
                              1361                                1400 
           AJE06446.1  (1361) ATGGTGGTTCGACCGGCAACGGCAACGGCGATTCAAACGG 
JOZ241-A4 full-length  (1361) ATGGCGATTCGACCGGCAACGGCAACGGCGATTCAAACGG 
            JOZ241-A4   (230) ---------------------------------------- 
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                              1401                                1440 
           AJE06446.1  (1401) CGGCGGTAACGGCGATTCGAATGACGGTAATGGTGGTTCG 
JOZ241-A4 full-length  (1401) CGGCGGTAACGGCGATTCGAATGACGGTAATGGTGGTTCG 
            JOZ241-A4   (230) ---------------------------------------- 
                              1441                                1480 
           AJE06446.1  (1441) ACCGGCAACGGCAACGGCGATTCAGATACAGGTACTGCTG 
JOZ241-A4 full-length  (1441) ACCGGCAACGGCAACGGCGATTCAGATACAGGTACTGCTG 
            JOZ241-A4   (230) ---------------------------------------- 
                              1481                                1520 
           AJE06446.1  (1481) GCGAA----------------------------------- 
JOZ241-A4 full-length  (1481) GCGAAGCGGCCGCACTCGAGCACCACCACCACCACCACTG 
            JOZ241-A4   (230) ---------------------------------------- 
                              1521 
           AJE06446.1  (1486) - 
JOZ241-A4 full-length  (1521) A 
            JOZ241-A4   (230) - 
 
 
11.4.2.2 Protein alignment 
                             1                                     40 
           AJE06446.1    (1) MATENDDSQSMNGILSNISRDVVDTSWDIPPLTFPKLQPT 
JOZ241-A4 full-length    (1) MATENDDSQSMNGILSNISRDVVDTSWDIPPLTFPKLQPT 
            JOZ241-A4    (1) ------DSQSMNGILSNISRDVVDTSWDIPPLTFPKLQPT 
                             41                                    80 
           AJE06446.1   (41) DSEEADGADEASLAEPRTIASSVPAQTEQPVSAAPTIADI 
JOZ241-A4 full-length   (41) DSEEADGADEASLAEPRTIASSVPAQTEQPVSAAPTIADI 
            JOZ241-A4   (35) DSEEADGADEASLAEPRTIASSVPAQTEQPVSAAPTIADI 
                             81                                   120 
           AJE06446.1   (81) PSMPLDTVDFDDAVAPADAEETATLPPLVSSTDEQDVEAT 
JOZ241-A4 full-length   (81) PSMPLDTIDFDDAVAPADAEETATLPPLVSSTDEQDAEAT 
            JOZ241-A4   (75) P--------------------------------------- 
                             121                                  160 
           AJE06446.1  (121) QAFDTSGGITDLEELAAEDPEHDPLKTIPVAPKEPSADKR 
JOZ241-A4 full-length  (121) QAFDTSDGITDLEELAAEDPEHDPLKTIPVAPKEPSADKR 
            JOZ241-A4   (76) ---------------------------------------- 
                             161                                  200 
           AJE06446.1  (161) KIIAIVAAIAAVAVAIAGVIVVRNRINSKEQRAAVVVCEK 
JOZ241-A4 full-length  (161) KIIAIVAAIAAVAVAIAGVIVVRNRINSKEQRAAVVVCEK 
            JOZ241-A4   (76) ---------------------------------------- 
                             201                                  240 
           AJE06446.1  (201) AKSKYSKANEKLQNAIEQATSLQGTAANQVADAATIDQLT 
JOZ241-A4 full-length  (201) AKSKYSKANEKLQNAIEQATSLQGTAANQVADAATIDQLT 
            JOZ241-A4   (76) ---------------------------------------- 
                             241                                  280 
           AJE06446.1  (241) QAVTKAQNLKTVGGCSVLLSETTLRAHARSMSKQISNIKE 
JOZ241-A4 full-length  (241) QAVTKAQNLKTVGGCSVLLSETTLRAHARSMSKQISNIKE 
            JOZ241-A4   (76) ---------------------------------------- 
                             281                                  320 
           AJE06446.1  (281) QTKAVTAAATAVDASKRALEVNKTTAALQKAIADAKTLLD 
JOZ241-A4 full-length  (281) QTKAVTAAATAVDASKRALEVNKTTAALQKAIADAKTLLD 
            JOZ241-A4   (76) ---------------------------------------- 
                             321                                  360 
           AJE06446.1  (321) GSAGQVADESTRDALAKAIDAAQKLLDGKSTDVAAMQNAS 
JOZ241-A4 full-length  (321) GSAGQVADESTRDALAKAIDAAQKLLDGKSTDVAAMQNAS 
            JOZ241-A4   (76) ---------------------------------------- 
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                             361                                  400 
           AJE06446.1  (361) KVISSTSDGVNKSVAEQTAANAQSNTNSNTNNGTTNRRYT 
JOZ241-A4 full-length  (361) KVISSTSDGVNKSVAEQTAANAQSNTNSNTNNGTTNRRYT 
            JOZ241-A4   (76) ---------------------------------------- 
                             401                                  440 
           AJE06446.1  (401) YTWQFGPGSGNGVNGGGSTGGNNNGGSTGGNGDSTGNGNG 
JOZ241-A4 full-length  (401) YTWQFGPGSGNGVNGGGSTGGNNNGGSTGGNGDSTGNGNG 
            JOZ241-A4   (76) ---------------------------------------- 
                             441                                  480 
           AJE06446.1  (441) DSNGGGNGDSNDGNGGSTGNGNGDSNGGGNGDSNDGNGGS 
JOZ241-A4 full-length  (441) DSNGGGNGDSNDGNGDSTGNGNGDSNGGGNGDSNDGNGGS 
            JOZ241-A4   (76) ---------------------------------------- 
                             481                     507 
           AJE06446.1  (481) TGNGNGDSDTGTAGE------------ 
JOZ241-A4 full-length  (481) TGNGNGDSDTGTAGEAAALEHHHHHH- 
            JOZ241-A4   (76) --------------------------- 
 
 
11.4.3 JOZ241-C4 
11.4.3.1 DNA alignment 
                              1                                     40 
           AAO81020.1     (1) ATGAAAACACTCATTAAAAATGTGCATATACTAACAATGG 
JOZ241-C4 full-length     (1) ATGAAAACACTCATTAAAAATGTGCATATACTAACAATGG 
            JOZ241-C4     (1) ---------------------------------------- 
                              41                                    80 
           AAO81020.1    (41) ATGAGCAATTTTCAGAAATCAAAGCCGGCTATTTAGTGAT 
JOZ241-C4 full-length    (41) ATGAGCAATTTTCAGAAATCAAAGCCGGCTATTTAGTGAT 
            JOZ241-C4     (1) ---------------------------------------- 
                              81                                   120 
           AAO81020.1    (81) TGAAGAAGACACAATTGTGGAATTAGCACCAATGACCACA 
JOZ241-C4 full-length    (81) TGAAGAAGATACAATTGTGGAATTAGCACCAATGACCACA 
            JOZ241-C4     (1) ---------------------------------------- 
                              121                                  160 
           AAO81020.1   (121) CTTGATGAAAAGCGAATGGCTGCAAATCAAGTAATCGATG 
JOZ241-C4 full-length   (121) CTTGATGAAAAGCGAATGGCTGTAAATCAAGTAATCGATG 
            JOZ241-C4     (1) ---------------------------------------- 
                              161                                  200 
           AAO81020.1   (161) GTCAAAATGGAATTTTAATGCCTGGGATGATTAACACCCA 
JOZ241-C4 full-length   (161) GTCAAAATGGAATTTTAATGCCTGGGATGATTAACACCCA 
            JOZ241-C4     (1) ---------------------------------------- 
                              201                                  240 
           AAO81020.1   (201) TACCCATGTAGGCATGATTCCGTTTCGTTCGTTAGGAGAC 
JOZ241-C4 full-length   (201) TACCCATGTAGGCATGATTCCGTTTCGTTCGTTAGGAGAC 
            JOZ241-C4     (1) ---------------------------------------- 
                              241                                  280 
           AAO81020.1   (241) GATGTGCCAGATCGACTCCGGCGTTTTCTTTTTCCATTAG 
JOZ241-C4 full-length   (241) GATGTGCCAGATCGACTCCGGCGTTTTCTTTTTCCATTAG 
            JOZ241-C4     (1) ---------------------------------------- 
                              281                                  320 
           AAO81020.1   (281) AACAATTCATGACAAAAGAATTAGTAGGATGCAGTAGTGA 
JOZ241-C4 full-length   (281) AACAATTCATGACAAAAGAATTAGTAGGATGCAGTAGTGA 
            JOZ241-C4     (1) ---------------------------------------- 
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                              321                                  360 
           AAO81020.1   (321) TTATGCAATTGCCGAAATGTTACTGAGTGGTATTACGAGC 
JOZ241-C4 full-length   (321) TTATGCAATTGCTGAAATGTTACTGAGTGGTATTACGAGC 
            JOZ241-C4     (1) ---------------------------------------- 
                              361                                  400 
           AAO81020.1   (361) TTTTGTGATATGTATTATTTTGAAGATGAAATTGCTAAAA 
JOZ241-C4 full-length   (361) TTTTGTGATATGTATTATTTTGAAGATGAAATTGCTAAAA 
            JOZ241-C4     (1) ---------------------------------------- 
                              401                                  440 
           AAO81020.1   (401) GTTGTGAAAAAATGAGTGTTCGTGCTTTGCTCGGAGAGAC 
JOZ241-C4 full-length   (401) GTTGTAAAAAAATGAGTGTTCGTGCTTTGCTCGGAGAGAC 
            JOZ241-C4     (1) ---------------------------------------- 
                              441                                  480 
           AAO81020.1   (441) GATCATTGATATGCCCACTTGTGATAGTCCGGAGCCTTCA 
JOZ241-C4 full-length   (441) GATCATTGATATGCCCACTTGTGATAGTCCGGAGCCTTCA 
            JOZ241-C4     (1) ---------------------------------------- 
                              481                                  520 
           AAO81020.1   (481) GGCGGTCTTTTTTACGCGGAAACCTTTATTCGCAAGTGGC 
JOZ241-C4 full-length   (481) GGCGGTCTTTTTTACGCGGAAACCTTTATTCGCAAGTGGC 
            JOZ241-C4     (1) ---------------------------------------- 
                              521                                  560 
           AAO81020.1   (521) AAGGCCATCCGTTGATTACGCCTATGCTTGCGCCACATGC 
JOZ241-C4 full-length   (521) AAGGCCATCCGTTGATTACGCCTATACTTGCGCCACATGC 
            JOZ241-C4     (1) ---------------------------------------- 
                              561                                  600 
           AAO81020.1   (561) ACCGAATACCAATTCACCAGAAGTGTTGGCGAAAATTATT 
JOZ241-C4 full-length   (561) ACCGAATACCAATTCACCAGAAGTGTTGGCGAAAATTATT 
            JOZ241-C4     (1) ---------------------------------------- 
                              601                                  640 
           AAO81020.1   (601) GAACTTAGTCGGCAATACCAAGTTCCTGTGACCATGCACG 
JOZ241-C4 full-length   (601) GAACTTAGTCGGCGATACCAAGTTCCTGTGACCATGCACG 
            JOZ241-C4     (1) ---------------------------------------- 
                              641                                  680 
           AAO81020.1   (641) TTGCTGAAATGACTTATGAAATGGCTGAGTTTGAAAAAGC 
JOZ241-C4 full-length   (641) TTGCTGAAATGACTTATGAAATGGCTGAGTTTGAAAAAGC 
            JOZ241-C4     (1) ---------------------------------------- 
                              681                                  720 
           AAO81020.1   (681) CTATCAAAAAACACCAATTGCTTTCTTAGAAGAACTGGGT 
JOZ241-C4 full-length   (681) CTATCAAAAAACACCAATTGCTTTCTTAGAAGAACTGGGT 
            JOZ241-C4     (1) ---------------------------------------- 
                              721                                  760 
           AAO81020.1   (721) TATTTGAGCGAGCCGTTTATTTTAGCGCATTGTATTTTGG 
JOZ241-C4 full-length   (721) TATTTGAGCGAGCCGTTTATTTTAGCTCATTGTATTTTGG 
            JOZ241-C4     (1) -------------------------------GTATTTTGG 
                              761                                  800 
           AAO81020.1   (761) CAACAGATGAAGATCTTGCGAGTTTAGCTGCTACTAATGG 
JOZ241-C4 full-length   (761) CAACAGATGAAGATCTTGCGAGTTTAGCTGCTACTAATGG 
            JOZ241-C4    (10) CAACAGATGAAGATCTTGCGAGTTTAGCTGCTACTAATGG 
                              801                                  840 
           AAO81020.1   (801) AAAAGCGCGTGTCGCTCATTGTATCGGTGCGAATACTAAA 
JOZ241-C4 full-length   (801) AAAAGCGCGTGTCGCTCATTGTATCGGTGCGAATACTAAA 
            JOZ241-C4    (50) AAAAGCGCGTGTCGCTCATTGTATCGGTGCGAATACTAAA 
                              841                                  880 
           AAO81020.1   (841) TCAGCCAAAGGCGTAGCGCCGATTAAGCAAATGCTTGATC 
JOZ241-C4 full-length   (841) TCAGCCAAAGGCGTAGCGCCGATTAAGCAAATGCTTGATC 
            JOZ241-C4    (90) TCAGCCAAAGGCGTAGCGCCGATTAAGCAAATGCTTGATC 
 
 
Supplemental Information 
 
109 
 
                              881                                  920 
           AAO81020.1   (881) AAGGGATTATTGTCGGTTTAGGCACGGATGGACCTAGTAG 
JOZ241-C4 full-length   (881) AAGGGATTATTGTCGGTTTAGGAACGGATGGACCTAGTAG 
            JOZ241-C4   (130) AAGGGATTATTGTCGGTTTAGGAACGGATGGACCTAGTAG 
                              921                                  960 
           AAO81020.1   (921) TGGGAATACATTAGATTTATTCACCCAAATGCGCATGGTT 
JOZ241-C4 full-length   (921) TGGGAATACATTAGATTTATTCACCCAAATGCGCATGGTT 
            JOZ241-C4   (170) TGGGAATACATTAGATTTATTCACCCAAATGCGCATGGTT 
                              961                                 1000 
           AAO81020.1   (961) GCGAATTTTCATAAGACAGCACACCAAGATCGCTCCTTGT 
JOZ241-C4 full-length   (961) GCGAATTTTCATAAGACAGCACACCAAGATCGCTCCTTGT 
            JOZ241-C4   (210) GCGAATTTTCATAAGACAGCACACCAAGATCGCTCCTTGT 
                              1001                                1040 
           AAO81020.1  (1001) TTCCTGCTAAAGAAATTGTTTATCTGGCAACGATGGGGGG 
JOZ241-C4 full-length  (1001) TTCCTGCTAAAGAAATTGTTTATCTGGCAACGATGGGGGG 
            JOZ241-C4   (250) TTCCTGCTAAAGAAATTGTTTATCTGGCAACGATGGGGGG 
                              1041                                1080 
           AAO81020.1  (1041) CGCTAAAACGTTAGGCTTGGCGGAGCAAGTCGGCTCATTG 
JOZ241-C4 full-length  (1041) CGCTAAAACGTTAGGCTTGGCGGAGCAAGTCGGTTCATTG 
            JOZ241-C4   (290) CGCTAAAACGTTAGGCTTGGCGGAGCAAGTCGGTTCATTG 
                              1081                                1120 
           AAO81020.1  (1081) GAAGTGGACAAAAAAGCGGATATAACATTAATTGAAACGC 
JOZ241-C4 full-length  (1081) GAAGTGGGCAAAAAAGCGGATATAACATTAATTGAAACGC 
            JOZ241-C4   (330) GAAGTGGGCAAAAAAGCGGA-------------------- 
                              1121                                1160 
           AAO81020.1  (1121) AATCAGTTAATATGTTTCCGATTTTTGATGCCTATTCAGC 
JOZ241-C4 full-length  (1121) AATCAGTTAATATGTTTCCGATTTTTGATGCCTATTCAGC 
            JOZ241-C4   (350) ---------------------------------------- 
                              1161                                1200 
           AAO81020.1  (1161) GTTGGTTTATTCAGCAAATGCTAGCAATGTTGAAGCCGTT 
JOZ241-C4 full-length  (1161) ATTGGTTTATTCAGCAAATGCTAGCAATGTTGAAGCCGTT 
            JOZ241-C4   (350) ---------------------------------------- 
                              1201                                1240 
           AAO81020.1  (1201) TGGGTGAACGGTCAACAGTTAGTTGCCAATAAAGAATTAC 
JOZ241-C4 full-length  (1201) TGGGTGAACGGTCAACAGTTAGTTGCCAATAAAGAATTAC 
            JOZ241-C4   (350) ---------------------------------------- 
                              1241                                1280 
           AAO81020.1  (1241) AACAAGCTAATCTCAAAGAAATCAAGGAAAAATTATATCA 
JOZ241-C4 full-length  (1241) AACAAGCTAATCTCAAAGAAATCAAGGAAAAATTATATCA 
            JOZ241-C4   (350) ---------------------------------------- 
                              1281                                1320 
           AAO81020.1  (1281) GGCCATGAATACGTTTGTGAAAGAAGCTAAAAAAAGAGCT 
JOZ241-C4 full-length  (1281) GGCCATGAATACGTTTGTGAAAGAAGCTAAAAAAAGAGCT 
            JOZ241-C4   (350) ---------------------------------------- 
                              1321                                1360 
           AAO81020.1  (1321) GCTCTC---------------------------------- 
JOZ241-C4 full-length  (1321) GCTCTCGCGGCCGCACTCGAGCACCACCACCACCACCACT 
            JOZ241-C4   (350) ---------------------------------------- 
                              1361 
           AAO81020.1  (1327) -- 
JOZ241-C4 full-length  (1361) GA 
            JOZ241-C4   (350) -- 
 
 
Supplemental Information 
 
110 
 
11.4.3.2 Protein alignment 
                             1                                     40 
           AAO81020.1    (1) MKTLIKNVHILTMDEQFSEIKAGYLVIEEDTIVELAPMTT 
JOZ241-C4 full-length    (1) MKTLIKNVHILTMDEQFSEIKAGYLVIEEDTIVELAPMTT 
            JOZ241-C4    (1) ---------------------------------------- 
                             41                                    80 
           AAO81020.1   (41) LDEKRMAANQVIDGQNGILMPGMINTHTHVGMIPFRSLGD 
JOZ241-C4 full-length   (41) LDEKRMAVNQVIDGQNGILMPGMINTHTHVGMIPFRSLGD 
            JOZ241-C4    (1) ---------------------------------------- 
                             81                                   120 
           AAO81020.1   (81) DVPDRLRRFLFPLEQFMTKELVGCSSDYAIAEMLLSGITS 
JOZ241-C4 full-length   (81) DVPDRLRRFLFPLEQFMTKELVGCSSDYAIAEMLLSGITS 
            JOZ241-C4    (1) ---------------------------------------- 
                             121                                  160 
           AAO81020.1  (121) FCDMYYFEDEIAKSCEKMSVRALLGETIIDMPTCDSPEPS 
JOZ241-C4 full-length  (121) FCDMYYFEDEIAKSCKKMSVRALLGETIIDMPTCDSPEPS 
            JOZ241-C4    (1) ---------------------------------------- 
                             161                                  200 
           AAO81020.1  (161) GGLFYAETFIRKWQGHPLITPMLAPHAPNTNSPEVLAKII 
JOZ241-C4 full-length  (161) GGLFYAETFIRKWQGHPLITPILAPHAPNTNSPEVLAKII 
            JOZ241-C4    (1) ---------------------------------------- 
                             201                                  240 
           AAO81020.1  (201) ELSRQYQVPVTMHVAEMTYEMAEFEKAYQKTPIAFLEELG 
JOZ241-C4 full-length  (201) ELSRRYQVPVTMHVAEMTYEMAEFEKAYQKTPIAFLEELG 
            JOZ241-C4    (1) ---------------------------------------- 
                             241                                  280 
           AAO81020.1  (241) YLSEPFILAHCILATDEDLASLAATNGKARVAHCIGANTK 
JOZ241-C4 full-length  (241) YLSEPFILAHCILATDEDLASLAATNGKARVAHCIGANTK 
            JOZ241-C4    (1) -----------ILATDEDLASLAATNGKARVAHCIGANTK 
                             281                                  320 
           AAO81020.1  (281) SAKGVAPIKQMLDQGIIVGLGTDGPSSGNTLDLFTQMRMV 
JOZ241-C4 full-length  (281) SAKGVAPIKQMLDQGIIVGLGTDGPSSGNTLDLFTQMRMV 
            JOZ241-C4   (30) SAKGVAPIKQMLDQGIIVGLGTDGPSSGNTLDLFTQMRMV 
                             321                                  360 
           AAO81020.1  (321) ANFHKTAHQDRSLFPAKEIVYLATMGGAKTLGLAEQVGSL 
JOZ241-C4 full-length  (321) ANFHKTAHQDRSLFPAKEIVYLATMGGAKTLGLAEQVGSL 
            JOZ241-C4   (70) ANFHKTAHQDRSLFPAKEIVYLATMGGAKTLGLAEQVGSL 
                             361                                  400 
           AAO81020.1  (361) EVDKKADITLIETQSVNMFPIFDAYSALVYSANASNVEAV 
JOZ241-C4 full-length  (361) EVGKKADITLIETQSVNMFPIFDAYSALVYSANASNVEAV 
            JOZ241-C4  (110) EVGKKA---------------------------------- 
                             401                                  440 
           AAO81020.1  (401) WVNGQQLVANKELQQANLKEIKEKLYQAMNTFVKEAKKRA 
JOZ241-C4 full-length  (401) WVNGQQLVANKELQQANLKEIKEKLYQAMNTFVKEAKKRA 
            JOZ241-C4  (116) ---------------------------------------- 
                             441       453 
           AAO81020.1  (441) AL----------- 
JOZ241-C4 full-length  (441) ALAAALEHHHHHH 
            JOZ241-C4  (116) ------------- 
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11.4.4 JOZ242-C9 
11.4.4.1 DNA alignment 
                             1                                     40 
           ALE13104.1    (1) ATGTGCAGGAGATTCGCGCTCGATTTGGATTGGGATGCCG 
JOZ242-C9 full-length    (1) ATGTGCAGGAGATTCGCGCTCGACTTGGATTGGGATGCCG 
            JOZ242-C9    (1) ----------------------------ATTGGGATGCCG 
                             41                                    80 
           ALE13104.1   (41) TGGCCTCACAGTTCGCGGTAGACGAGGATGACGTGCGCGT 
JOZ242-C9 full-length   (41) TGGCCTCACAGTTCGCGGTAGACGAGGATGACGTGCGCGT 
            JOZ242-C9   (13) TGGCCTCACAGTTCGCGGTAGACGAGGATGACGTGCGCGT 
                             81                                   120 
           ALE13104.1   (81) TGACACTCTGCCACAGCCTTCCTACAACATCGCACCCACG 
JOZ242-C9 full-length   (81) TGACACTCTGCCACAGCCTTCCTACAACATCGCACCCACG 
            JOZ242-C9   (53) TGACACTCTGCCACAGCCTTCCTACAACATCGCACCCACG 
                             121                                  160 
           ALE13104.1  (121) CAGAACATTGGCGTGGTGGCACAGGGCAAGGATGGCCGCC 
JOZ242-C9 full-length  (121) CAGAACATTGGCGTGGTGGCACAGGGCAAGGATGGCCGCC 
            JOZ242-C9   (93) CAGAACATTGGCGTGGTGGCACAGGGCAAGGATGGCCGCC 
                             161                                  200 
           ALE13104.1  (161) GTCATCTGACCGGTGCCTATTGGTCGCTGGTGCCGCGATG 
JOZ242-C9 full-length  (161) GTCATCTGACCGGTGCCTATTGGTCGCTGGTGCCGCGATG 
            JOZ242-C9  (133) GTCATCTGACCGGTGCCTATTGGTCGCTGGTGCCGCGATG 
                             201                                  240 
           ALE13104.1  (201) GAGCGCCAGCAAAGTGCTGAGCTACCCCACATATAATGCG 
JOZ242-C9 full-length  (201) GAGCGCCAGCAAAGTGCTGAGCTACCCCACATATAATGCG 
            JOZ242-C9  (173) GAGCGCCAGCAAAGTGCTGAGCTACCCCACATATAATGCG 
                             241                                  280 
           ALE13104.1  (241) CGTGTGGAGTCTGCGCATGTCAAGCCGGCGTTCGCCGAAT 
JOZ242-C9 full-length  (241) CGTGTGGAGTCTGCGCATGTCAAGCCGGCGTTCGCCGAAT 
            JOZ242-C9  (213) CGTGTGGAGTCTGCGCATGTCAAGCCGGCGTTCGCCGAAT 
                             281                                  320 
           ALE13104.1  (281) CCACAAAATCCATGCGAGCCATCATCCCCGCTTCCGGCTA 
JOZ242-C9 full-length  (281) CCACAAAATCCATGCGAGCCATCATCCCCGCTTCCGGCTA 
            JOZ242-C9  (253) CCACAAAATCCATGCGAGCCATCATCCCCGCTTCCGGCTA 
                             321                                  360 
           ALE13104.1  (321) CTACGAATGGAAAGGTCGCAGGCCGTTCTATTTTCACGCA 
JOZ242-C9 full-length  (321) CTACGAATGGAAAGGTCGCAGGCCGTTCTATTTTCACGCA 
            JOZ242-C9  (293) CTACGAATGGAAAGGTCGCAGGCCGTTCTATTTTCA---- 
                             361                                  400 
           ALE13104.1  (361) CCACATGATGAACTATTGTCTTTGGCCGGCCTGTACTCAT 
JOZ242-C9 full-length  (361) CCACATGATGAACTATTGTCTTTGGCCGGCCTGTACTCAT 
            JOZ242-C9  (329) ---------------------------------------- 
                             401                                  440 
           ALE13104.1  (401) GGTGGAGGCCGTCTCCCGCATCGCCATGGCAGCTGACCGC 
JOZ242-C9 full-length  (401) GGTGGAGGCCGTCTCCCGCATCGCCATGGCAGCTGACCGC 
            JOZ242-C9  (329) ---------------------------------------- 
                             441                                  480 
           ALE13104.1  (441) AACCATCATCACCTGCCCTGCCGCGGACGAGTTCGTCAAG 
JOZ242-C9 full-length  (441) AACCATCATCACCTGCCCTGCCGCGGACGAGTTCGTCAAG 
            JOZ242-C9  (329) ---------------------------------------- 
                             481                                  520 
           ALE13104.1  (481) GTGCATGATCGCATGCCCCTGCTGGCTCCTCGGAATATGG 
JOZ242-C9 full-length  (481) GTGCATGATCGCATGCCCCTGCTGGCTCCTCGGAACATGG 
            JOZ242-C9  (329) ---------------------------------------- 
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                             521                                  560 
           ALE13104.1  (521) TTGCCTCATGGCTGGACCGCTCCGTTGACGGGGCCGCACT 
JOZ242-C9 full-length  (521) TTGCCTCATGGCTGGACCGCTCCGTTGACGGAGCCGCACT 
            JOZ242-C9  (329) ---------------------------------------- 
                             561                                  600 
           ALE13104.1  (561) GTTAGATTCCATGCGGGAAGCGGGTACCATGCTTTCCCGG 
JOZ242-C9 full-length  (561) GTTAGATTCCATGCGGGAAGCGGGTACCATGCTTTCCCGG 
            JOZ242-C9  (329) ---------------------------------------- 
                             601                                  640 
           ALE13104.1  (601) CGTCTGCAATTTCACGAAGTCGCGCCACTGAACAGCGACG 
JOZ242-C9 full-length  (601) CATCTGCAATTTCACGAAGTCGCGCCACTGAACAGCGACG 
            JOZ242-C9  (329) ---------------------------------------- 
                             641                                  680 
           ALE13104.1  (641) GCAAACGTCTTATTCAGCCATTGGATTCCACCGAACCCAT 
JOZ242-C9 full-length  (641) GCAAACGTCTTATTCAGCCATTGGATTCCACCGAACCCAT 
            JOZ242-C9  (329) ---------------------------------------- 
                             681                                  720 
           ALE13104.1  (681) GCGTCTGTTT------------------------------ 
JOZ242-C9 full-length  (681) GCGTCTGTTTGCGGCCGCACTCGAGCACCACCACCACCAC 
            JOZ242-C9  (329) ---------------------------------------- 
                             721 
           ALE13104.1  (691) ------ 
JOZ242-C9 full-length  (721) CACTGA 
            JOZ242-C9  (329) ------ 
 
 
11.4.4.2 Protein alignment 
                             1                                     40 
           ALE13104.1    (1) MCRRFALDLDWDAVASQFAVDEDDVRVDTLPQPSYNIAPT 
JOZ242-C9 full-length    (1) MCRRFALDLDWDAVASQFAVDEDDVRVDTLPQPSYNIAPT 
            JOZ242-C4    (1) ----------WDAVASQFAVDEDDVRVDTLPQPSYNIAPT 
                             41                                    80 
           ALE13104.1   (41) QNIGVVAQGKDGRRHLTGAYWSLVPRWSASKVLSYPTYNA 
JOZ242-C9 full-length   (41) QNIGVVAQGKDGRRHLTGAYWSLVPRWSASKVLSYPTYNA 
            JOZ242-C4   (31) QNIGVVAQGKDGRRHLTGAYWSLVPRWSASKVLSYPTYNA 
                             81                                   120 
           ALE13104.1   (81) RVESAHVKPAFAESTKSMRAIIPASGYYEWKGRRPFYFHA 
JOZ242-C9 full-length   (81) RVESAHVKPAFAESTKSMRAIIPASGYYEWKGRRPFYFHA 
            JOZ242-C4   (71) RVESAHVKPAFAESTKSMRAIIPASGYYEWKGRRPFYF-- 
                             121                                  160 
           ALE13104.1  (121) PHDELLSLAGLYSWWRPSPASPWQLTATIITCPAADEFVK 
JOZ242-C9 full-length  (121) PHDELLSLAGLYSWWRPSPASPWQLTATIITCPAADEFVK 
            JOZ242-C4  (109) ---------------------------------------- 
                             161                                  200 
           ALE13104.1  (161) VHDRMPLLAPRNMVASWLDRSVDGAALLDSMREAGTMLSR 
JOZ242-C9 full-length  (161) VHDRMPLLAPRNMVASWLDRSVDGAALLDSMREAGTMLSR 
            JOZ242-C4  (109) ---------------------------------------- 
                             201                                  240 
           ALE13104.1  (201) RLQFHEVAPLNSDGKRLIQPLDSTEPMRLF---------- 
JOZ242-C9 full-length  (201) HLQFHEVAPLNSDGKRLIQPLDSTEPMRLFAAALEHHHHH 
            JOZ242-C4  (109) ---------------------------------------- 
                             241 
           ALE13104.1  (231) - 
JOZ242-C9 full-length  (241) H 
            JOZ242-C4  (109) -
  
 
